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Chapter 1 
Introduction 
For years sympathetic act!Vlty in man and experimental animals has been 
assessed by measuring circulating catecholamines. As their plasma 
concentration is not only determined by sympathetic activity but also by 
spillover and clearance, it is only useful as a screening tool for gross 
disturbances in general sympathetic tone. The isotope dilution method uses 
tritiated norepinephrine to differentiate between norepinephrine release into 
and its removal from the circulation. This technique is not only more precise 
but can also be applied for the assessment of regional sympathetic tone. 
Alternatively, local sympathetic activity can be monitored by 
microneurography, i.e. measuring the electrical activity of postganglionic 
sympathetic efferents. However, due to its invasive nature, microneurography 
in humans is restricted to monitoring sympathetic control of skin and muscle 
vasculature. Microdialysis is a new technique that can monitor local 
sympathetic act!Vlty almost continuously by measuring interstitial 
norepinephrine concentrations. The technique is based on the diffusion of 
norepinephrine from the intercellular space through a semi-permeable 
membrane mounted in a small catheter into a suitable perfusion fluid like 
Ringer's or Ringer's lactate, which can be collected continuously for later 
analysis. In conclusion, none of the mentioned techniques for monitoring 
sympathetic activity is superior to another as each has its own strengths and 
limitations. The choice for one or more of these methods strongly depends on 
the question that has to be answered; a combination of the various techniques 
may provide the investigator with a more powerful tool to monitor the 
sympathetic nervous system. 
Lameris TW, Boomsma F, van den Meiracker AH. Monitoring 
sympathetic activity; tools of the trade. Submitted. 
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Introduction 
For years, sympathetic actiVIty in man and experimental animals has been 
assessed by measuring circulating catecholamines. As their concentration is not 
only a reflection of release but is also determined by clearance, other more 
precise methods for assessing sympathetic activity have been developed. The 
aim of this review is to discuss the merits and limitations of three established 
techniques for studying sympathetic tone, i.e. measurement of plasma 
catecholamine concentrations, the isotope dilution method and 
microneurography, and of a recently introduced fourth technique, 
microdialysis. 
Plasma Catecholamines 
One of the simplest and -therefore- the most widely used techniques for the 
assessment of sympathetic activity is the measurement of circulating 
catecholamines and in particular plasma norepinephrine (Table 1, Figure 1). 
While it is a helpful screening tool for gross disturbances in overall sympathetic 
tone, e.g. pheochromocytoma and autonomic dysfunction, its value as a 
measure of sympathetic activity is limited. The plasma norepinephrine 
concentration is not only determined by (i) sympathetic activity, but also by (ii) 
spillover, i.e. the amount of norepinephrine that is released from the 
sympathetic nerve terminals and ultimately reaches the circulation, and (ill) 
plasma clearance, i.e. the rate of removal of norepinephrine from the 
circulation. 
(i) Sympathetic activity 
Sympathetic actiVIty is characterized by a considerable regional 
differentiationY At rest, the bulk of norepinephrine in plasma originates from 
sympathetic nerve terminals; the nerve terminals of the kidney, skeletal muscles 
and the lungs provide the largest contribution, whereas approximately 30 
percent is derived from the sympathetic neurons of the liver, the 
gastrointestinal tract, the heart and the skin. In contrast, epinephrine is largely 
produced in and released from the adrenal medulla as a systemically active 
hormone. During heavy physical exercise and heart failure a minute amount of 
epinephrine is co-released with norepinephrine from sympathetic nerve 
terminals, and contributes in these circumstances to circulating epinephrine 
concentrations.'·' As a precursor of norepinephrine, dopamine is only sparingly 
released from the nerve terminals and the adrenal medulla. In the kidney, 
dopamine is synthesized from DOPA that is extracted from the circulation by 
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the renal tubules. A small proportion of this renal dopamine may reenter the 
circulation while most is excreted in urine.'·' 
Upon stimulation, sympathetic nervous system (SNS) responses 
typically show regional patterns of activation or inhibition depending on the 
type of the stimulus. For example, mental sttess induces a preferential increase 
in cardiac and renal sympathetic outflow, whereas cardiac failure and 
ventricular arrhythmias show a preferential cardiac SNS response. Submaximal 
exercise, however, is one of the very few stimuli resulting in a generalized 
increase in SNS activity.' 
Table 1. Strengths and Limitations of Four Different Techniques for Monitoring 
Sympathetic Activity. 
Method Strengths limiutions 
Plas11Ja norepinephrine +Sim-ple, 'Widely used - Only assesses ove.rall sympatheticacrivity 
concentration 
Isotopc Dilution 
Mdhod 
Micronmrography 
Microdiafysi.r 
(ii) Spillover 
+ Good screening tool for gross S~S 
disturbances 
+Barely invasive 
+ Monitors regional SNS activity 
+ Distin~ishes release :rnd removal 
+ Monitors regional S::\JS acr:ivity 
+ Distinguishes betWeen central and loc:U 
neuronal responses 
+ Relatively simple 
+No withdmval of blood samples 
+ Online, real-rime assessment ofSNS activity 
+Measures interstitial roncentrations 
- Indirect measure of activity. ronfounded by 
clearance and spillover 
- Assumes negligibleg:cadients between the 
sites of release and plasma, hence 
underestimates :.JE release 
- Requires arterio-venous s=pling 
- Uses radioactive rom pounds 
- In humans, it Cll1 only be used for 
monitoring skin and m us de sympathetic 
nerve activity 
- Only measures nerve firing rnte., does not 
ao::ount for &ctors that affect the proportioml 
relation between nerve firing and 
norepinephrine release 
- Requires sensitive analysis tedlniques 
+Monitors regional SNS activity - In humans, it Cll1 only be used for 
+Distinguishes rclcase and removal monitoring skin and muscle SNS activity 
+ Semi-rontinuous assesment ofSNS activity - Only measures mon interstitial 
ronccntrations 
+ Ko withdrawal of blood samples - When investigating other rom pounds, the 
+ Can be used in 'stop-flow' experiments size of the analyteis limited by the rot-off 
+Allows for the simultaneous measurement value of the membr:.me 
of othc:rrompounds 
+Allows for locll phannarologicll 
m:mipulation without systemic effects 
In humans, only 10-20 percent of the norepinephrine that is released from the 
sympathetic nerve terminals eventually enters the circulation. This spillover is 
determined by sympathetic act!Vlty, neuronal reuptake (Ul), and local 
metabolism, and amounts to 200-600 ng/ min in resting healthy individuals. 
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During strenuous exercise, the spillover rate can increase enormously to 1500-
4000 ng/ min.' 
(iii) Clearance 
Catecholanrines are cleared from the plasma by neuronal uptake, extra-
neuronal uptake by various cell types, and local intra- and extra-cellular 
metabolic processes, e.g. 0-methylation (COMT), oxidative deanrination, and 
sulfoconjugation. Under normal conditions, catecholanrines are cleared very 
rapidly from the circulation; norepinephrine, for instance, is cleared at a rate of 
1.5 to 4 liters per minute.' Like sympathetic activity, the plasma clearance of 
catecholanrines is tissue-dependent. Not only the rate of removal, but also the 
relative contribution of the processes that comprise this removal, is different 
for the various tissues and depends on the density of the sympathetic 
innervation of that particular tissue. For instance, in the densely 
sympathetically innervated heart, 80 percent of circulating norepinephrine is 
removed in a single pass, of which 69 percent is cleared by neuronal uptake. In 
the forearm, with a less dense sympathetic innervation, only 54 percent of 
norepinephrine that passes through is removed, with neuronal uptake 
constituting only 14 percent of local clearance.8J 
Figure 1. Four techniques to assess sympathetic nerve activity. 
MSNA: Muscle Sympathetic Nerve Activity 
Micro dialysis 
PLASMA: measurement of plasma NE concentrations 
IDM: Isotope Dilution Method. 
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Isotope Dilution Method 
The use of tritiated norepinephrine as applied in the isotope dilution method 
provides a useful estimation of the relative contribution of release and removal 
to the norepinephrine plasma level (Table 1, Figure 1 ). The technique is based 
on a one-compartment model, which assumes that all de novo sources of 
norepinephrine enter the circulation and all losses are irreversible, i.e. any 
recirculation is negligible. However, only very little norepinephrine that is 
released from the sympathetic nerve terminals into the synaptic cleft and 
intercellular space spills over into the circulation. The bulk of norepinephrine is 
taken up by the neurons and adjoining cells, or is metabolized locally. Thus, the 
use of a two-compartment model seems more appropriate.10 Esler et al 11 
introduced 'spillover' (SO) which aims to reflect the rate of norepinephrine 
entering the circulation rather than true production as a more adequate 
parameter of sympathetic activity. Later, this parameter was refined to account 
for regional differentiation with the use of arterio-venous organ sampling 
according to the following formula. 12 
Regional norepinephrine Spillover = Q.(V- A + FxNE.A) 
Q = organ plasma flow 
V = venous norepinephrine concentration 
A = arterial norepinephrine concentration 
Fx.:..'~"E =fractional extraction of tritiated norepinephrine 
One example of the merits of spillover is the assoc1at1on of elevated 
norepinephrine plasma levels with age. At first glance, elevated norepinephrine 
plasma levels would suggest an increased sympathetic activity. However, 
several studies have shown a marked decrease in norepinephrine clearance in 
relation to age, while there is barely any evidence for such age-related 
differences in total norepinephrine spillover, either at rest or during exercise. 
Thus, the elevation of norepinephrine plasma levels with advancing age 
appears to be primarily due to a diminished ability to remove norepinephrine 
1' from the body. ' 
Chang et al 14 agree with the application of the two-compartment 
model but the investigators introduce an alternative parameter, the plasma 
appearance rate (P A), which is defined as the total amount of norepmephrine 
that enters the sampled plasma compartment. 
PA 
spillover 
l-FxNE 
12 
In contrast to spillover, P A should account for norepinephrine that 
spills over into the circulation and subsequently is taken up before it leaves the 
organ. Additionally, it should be less sensitive to changes in organ flow and 
local clearance. 
The compartmental kinetic model for catecholamines is based on the 
fundamental assumption that transport or diffusion of catecholamines from 
the circulation to the sites of metabolism in the target organ do not differ for 
locally released catecholamines, i.e. the existence of an endothelial barrier is 
ruled out14.t5 Several studies, however, have provided evidence for such a 
barrier.16.20 Accordingly, previous studies from our department 521 as a well as 
others 22"23 showed a marked difference in hemodynamic response to 
exogenously administered norepinephrine through an intravenous infusion and 
endogenously released norepinephrine. For instance, an infusion of 30 
ng/kg/ min norepinephrine increased the norepinephrine plasma level about 
five fold without any sigcificant pressor response, whereas 20 >'gkg/ min of 
tyramine increased norepinephrine plasma levels only two fold while diastolic 
blood pressure rose by 20 mmHg.5 Tyramine forces norepinephrine out of the 
nerve terminals because of its higher affinity for the storage proteins, thus 
acting as an endogenous source of norepinephrine.35 
To account for these diffusion barriers Cousineau eta! 17 and Rose eta! 
24 developed the "distributed" model for interstitial-capillary exchange. Based 
on the same multiple indicator technique, Johnson 25 devised the tissue 
homogeneity model that, in contrast to the distributed model, assumes a 
random distribution of capillary entrances and exits throughout the tissue thus 
providing for a 'well-mi..'<:ed' interstitium. While accounting for a possible 
endothelial barrier, both models do underestimate norepinephrine release 
because of the assumption that the concentration gradients between the 
neuroeffector junctions and the interstitial-capillary barrier are negligible. In 
fact, several clinical and e'--perimental studies have demonstrated a considerable 
interstitial gradient of about threefold between the sites of release and 
plasma.15.26.27 
Microneurography 
An alternative method for monitoring local sympathetic activity is measuring 
the electrical activity of the postganglionic sympathetic efferents that innervate 
the organ of interest (Figure 1).20 Due to the invasive nature of this technique, 
microneurography in humans is mainly targeted to monitor sympathetic 
control of the vasculature of skeletal muscle or skin with small percutaneous 
tungsten electrodes (Table 1). While skin sympathetic nerve activity (SSNA) is 
Chapter 1 Introduction 13 
primarily modulated by thermal, respiratory and emotional responses, muscle 
sympathetic nerve activity (MSNA) is mainly under baroreflex control and as 
such is a more appropriate tool for assessing cardiovascular sympathetic 
activity. Indeed, in several conditions associated with increased sympathetic 
tone like the early phase of essential hypertension, obesity and congestive heart 
failure, MSNA is increased whereas SSNA remains unchanged.29•30 
One of the major benefits of this elegant technique is that it allows for 
an online, real-time assessment of sympathetic activity. Additional benefits are 
its relative simplicity, no withdrawal of blood samples, no use of radioactive 
compounds and its ability to distin,ouish central from local neuronal responses, 
like those elicited by mechano- and metabo-receptors.30J 1 On the downside, 
however, this technique also has some important limitations. Firstly, while its 
ability to investigate local sympathetic activity is one of its stren,oths, it is also 
one of its weaknesses since the alteration of sympathetic tone in some disease 
states or conditions is limited to a single organ, like salt depletion (kidney), mild 
to moderate heart failure (heart), coronary insufficiency (heart), and mental 
stress (heart)! Secondly, although sympathetic nerve firing rate is the principle 
force behind norepinephrine release, it is certainly not the only factor 
determining norepinephrine concentration at the neuroeffector junction. 
Other factors that will affect the relation between nerve firing and 
norepinephrine release have to be considered, like changes in norepinephrine 
clearance, e.g. alterations in regional blood flow and impaired neuronal 
reuptake (heart failure, use of tricyclic antidepressants), modification of the 
amount of norepinephrine released per nerve impulse by pre-synaptic 
inhibition or facilitation, the use of sympathetic nerve-blocking drugs like 
guanethidine (firing without release), and events or drugs that give rise to non-
exocytotic release (release without firing), e.g. myocardial ischemia and 
tyramine 4'32• Subsequently, microneurography by itself does not allow for the 
investigation of processes that occur at the fingertips of the SNS, the 
neuroeffector junction. 
Microdialysis 
Until recently, the extra-vascular compartment could only be monitored either 
by estimation through application of mathematic kinetic modeling, or by using 
in-vitro or semi-in-vivo preparations. Microdialysis is a technique that allows 
for a semi-continuous measurement of interstitial concentrations in vivo (Table 
1). It is based on diffusion of analytes from the intercellular space through a 
semi-permeable membrane into a suitable perfusion fluid like Ringer's or 
Ringer's lactate (Figure 2). The microdialysis catheter can be inserted in the 
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organ of interest, clinically in skin or muscle, and experimentally for example in 
the heart, the brain, or the kidney, like one would insert a simple percutaneous 
venous catheter. The perfusion fluid is pumped through the microdialysis 
catheter via the inlet tube using a microinjection pump at a set perfusion rate. 
The dialysate is collected at the end of the outlet tube in microvials and stored 
for later analysis. 
membrane-length: 
~-~~~~=:LJ----~1~0~m~m~------~~---:~ 1. membrane cut-off: 
20kD 
Figure 2. The microdialysis probe, dimensions and principles. IN: Inlet tube; OUT: Outlet 
tube. Derived from pictures on the .internet site of Carnegie Medicine AB 
(http:/ /'W-ww.microdialysis.se). 
The procedure is relatively simple and the technique is now in 
experimental and clinical use in a number of medical disciplines.33·37 It should 
be noted, however, that sample volumes are small (f.tL's) requiring sensitive 
analytical techniques. The technique does not involve the withdrawal of 
circulatory volume so it is possible to take an almost endless amount of 
"samples", only limited by the length of the experiment and the laboratory's 
capacity to process these samples. Furthermore, it allows for the measurement 
of concentrations in stop-flow conditions like myocardial norepinephrine 
concentrations in the flow area of a clipped coronary artery. The size of the 
analyte is limited by the cut-off of the membrane. Most probes that are 
available commercially have a cut-off of 20 kDa, which in reality limits the size 
of the substance of interest that can be analyzed to a MW of about 2000 Da. In 
general, this technique cannot be used for measuring the interstitial 
concentration of larger peptides, proteins or smaller conjugated substances. 
Fortunately, catecholamines are quite small (MW < 200 Da) and readily 
diffuse through the microdialysis membrane, making microdialysis well suited 
for measuring local SJ\:S activity; dialysate catecholamine concentrations are 
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about 50 % of actual interstitial catecholamine concentrations when the 
perfusion of the microdialysis catheter is set at a rate of 2 1-1L/ min.38•39 
Microdialysis can be particularly useful for monitoring sympathetic tone since 
it allows for the measurement of norepinephrine in the intercellular space, i.e. 
close to the sites of release and reuptake (Figure 1). In fact interstitial 
norepinephrine levels are reported to correlate much more closely with 
regional sympathetic activity and it's subsequent physiologic response than 
plasma norepinephrine concentrations.4D 
Another advantage of this technique is the possibility of modification 
of local processes such as norepinephrine reuptake without provoking an 
undesired systemic response, by adding a reuptake blocker like desipramine to 
the perfusion fluid39"41•43 Thus, the amount of norepinephrine that is removed 
by neuronal reuptake can be measured. In addition, microdialysis has revealed 
that the aforementioned concentration gradient of norepinephrine between the 
interstitial and intra-vascular compartments in the heart is not due to an 
endothelial barrier but is the result of neuronal as well as extra-neuronal 
norepinephrine uptake.14.1;·39 
Finally, it is important to realize that while it is a more direct technique 
to measure interstitial norepinephrine concentrations than the estimates based 
on the isotope dilution technique, it will only provide information about the 
mean interstitial norepinephrine concentration and not about the 
concentration at sites of release. 
Summary 
None of the described techniques for monitoring sympathetic activity is strictly 
superior to another as each has its own strengths and limitations (fable 1). The 
choice for one or more of these methods strongly depends on the question 
that has to be answered. A large-scale patient study in which overall 
sympathetic tone is only monitored to rule out gross SNS disturbances at 
baseline or during the intervention, requires another approach than a smaller 
scale study in which the assessment of regional sympathetic tone is the 
principal objective. Whereas measuring plasma catecholamine concentrations is 
most suited for the former study, a more specific technique like the isotope 
dilution method would the better option in the latter situation. 
In many instances a combination of various techniques would provide 
the investigator with a more powerful tool to monitor the SNS. For instance, 
the combination of MSNA with microdialysis would allow for investigating the 
relationship between nerve-firing and interstitial norepinephrine 
concentrations. This would be of particular interest in heart failure as the 
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mechanism underlying the associated increase in sympathetic tone is still 
unclear.44•45 Such an approach could distinguish whether the activation of the 
SNS is due to augmented sympathetic nerve traffic or an increase in interstitial 
norepinephrine concentrations as a result of diminished clearance, e.g. due to a 
failing neuronal reuptake. 
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Chapter 2 
Aim and outline of the thesis 
Introduction 
This thesis comprises sL'< studies concerning the pharmacokinetics, modulation 
and pathophysiological role of norepinephrine in the porcine heart. When 
investigating norepinephrine kinetics, the heart is of particular interest. 
Although the human and porcine hearts are both para-sympathetically 
dominant and the contribution to total body norepinephrine levels is rather 
small, only 3 percent, 1 regional spillover is distinctively high because of the 
heart's e>.-tensive sympathetic innervation. Indeed the sympathetic nervous 
system plays a major role in maintaining cardiac output and adjusting 
cardiovascular function to the bodf s demand. 
arterial sampling 
-17--+-~ coronary venous 
3 MD- probes 
LAD- region 
sampling 
MD-probe in 
LCx- region 
+/- DMl +/- PHA 
Figure 1. EA-perimental setup and instrUmentation. :MD: rnicrodialysis; 
DMI: desipramine, neuronal reuptake -blocker; PHA: phentolamine, 
non-selective cx:-adrenergic receptor-antagonist. 
After describing the technical aspects of the measurement of 
norepinephrine and other catecholamines in chapter 3, we will explore the 
pharmacokinetics of norepinephrine in chapter 4. In chapters 5 and 6 the 
modulation of norepinephrine by the vaso-active hormones angiotensine II 
and epinephrine will be discussed. Finally, the fate and potential role of 
norepinephrine in pathophysiological processes like ischemia will be described 
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in chapters 7 and 8. In all studies we use the aforementioned rnicrodialysis 
technique to measute catecholarnines in the myocardial interstitial fluid. To this 
end, fout rnicrodialysis probes are inserted into the left ventricular wall (figure 
1), three of which in the region perfused by the left anterior descending 
coronary artery (LAD) and one in the region perfused by the left circumflex 
coronary artery (LCx). 
As over 80% of neutonally released norepinephrine is taken up by 
sympathetic nerves through the neutonal reuptake (Ul) mechanism (figure 2, 
the Ul-inhibitor desipramine is added to the perfusate of one the rnicrodialysis 
probes to provide local Ul-blockade. In addition, the non-selective ()(-
adrenergic receptor antagonist phentolamine is added to the perfusate of 
another probe in combination with desipramine (figure 1) to account for a 
possible inhibition of norepinephrine release through stimulation of 
presynaptic O<o-adrenergic receptors (f\,oure 2). 
Figure 2. Cardiac sympathetic nerve terminals: presynaptic facilitation and 
inhibition. Shown are the varicosities of sympathetic nerve terminals containing 
the norepillephrine (NE) storage vesicles, the neuronal reuptake mechanism (Cl ), 
facilitatory presynaptic receptors (+), e.g. ~2-adrenergic receptor (~2), 
thromboxane type 2 receptor (IXA2) and angiotensin II type 1 receptor (AT 1), 
and inhibitory pre-synaptic receptors (-), e.g. adenosine Al-receptor (Al), X2-
adrenerg:ic receptor (a2) and prosta$.?:landin PGE2-receptor (PGE2). 
Chapter 3. Determination of catecho!amines in microdia/:ysis samples 
This chapter concerns the technical aspects of the measutement of 
catecholamines in rnicrodialysis samples. The slow perfusion rate with 
rnicrodialysis (in the order of 0.5 to 5 JJL/rnin) on the one hand and the need 
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for a reasonable time-resolution (1 0 minutes) on the other, result in small 
sample volumes (20 f!L), and thus call for a highly sensitive assay method with 
a large through-put. Furthermore, the studies in this thesis require the 
simultaneous measurement of not only the natural catecholamines 
(norepinephrine, epinephrine and dopamine), but also some synthetic 
catecholamines (e.g. isoproterenol, 1-erythro-<X-methyl-norepinephrine and 
epinine, see also chapter 4). In addition, the in vitro and in vivo recovery, i.e. the 
quotient of dialysate catecholamine concentration and the actual catecholamine 
concentration in the medium that is dialyzed, is assessed for all natural as well 
as a few synthetic catecholamines. 
Chapter 4. Catecholamine handling in the porcine heart 
This chapter will focus on the pharmacokinetics of norepinephrine in the heart 
and its modulation by the U1-mechanism. Several e':perimental findings 
suggest that in the heart a pronounced concentration gradient for 
norepinephrine exists between the interstitial and intra-vascular compartments. 
For instance, Silverberg et al.2 showed that the coronary sinus norepinephrine 
concentration induced by a norepinephrine infusion that led to only a small 
increase in the heart rate was eight times higher than with stellate ganglion 
stimulation causing a similar increase in heart rate. Cousineau et al.3 estimated 
from tracer dilution experiments a ratio between the interstitial and arterial 
compartments of 15 % in canine hearts. Because of the dense sympathetic 
innervation, especially in the heart, neuronal reuptake of norepinephrine could 
be an important determinant for maintaining such a gradient.1.4 However, other 
investigators have suggested that the concentration gradient is caused by a 
physical barrier of the blood vessel wall as well.3~-9 
In a series of experiments, in which either the circulatory or the 
interstitial norepinephrine concentration is increased, we investigate how the 
norepinephrine concentration in the myocardial interstitial fluid relates to its 
concentration in the arterial and coronary venous circulation. The importance 
of the neuronal and extra-neuronal uptake to this relationship is e:>.-plored by 
adding desipramine (U1-inhibitor) to the dialysate of one of the microdialysis 
probes (figure 1) and by performing experiments with isoproterenol, a 
catecholamine known not to be handled by the U1-mechanism (figure 2). 
Furthermore, the cardiac spillover, uptake and release of norepinephrine are 
estimated with the use of the norepinephrine concentrations in myocardial 
interstitial fluid, arterial plasma and the coronary effluent at baseline and during 
intravenous norepinephrine infusions. 
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Chapter 5. Epinephrine in the heart 
This chapter describes to which e..xtent epinephrine is taken up by and released 
from cardiac sympathetic nerves and whether it can increase myocardial 
interstitial norepinephrine concentrations under basal conditions and during 
sympathetic activation. Several studies have shown that cardiac epinephrine is 
released into the coronary circulation of the human heart during exercise, at 
rest with advancing age and in conditions like hypertension, heart failure and 
panic disorders.10.12 Whether cardiac epinephrine is released from sympathetic 
nerve terminals after it has been taken up from the circulation or whether it is 
released from extraneuronal stores remains unclear.13•14 
Another point of debate relates to the role of locally released 
epinephrine. Several in vitro as well as in vivo studies have suggested that 
epinephrine enhances neuronal norepinephrine release through stimulation of 
presynaptic ~2-receptors located at the sympathetic nerve terminals (figure 2).15. 
18 This presynaptic facilitation of norepinephrine release by epinephrine is 
essential to the "epinephrine hypothesis", which proposes that excessive 
adrenomedullary activation leads to the development of hypertension through 
increasing sympathoneural norepinephrine release.18 Other studies, however, 
have failed to confirm this mechanism.19.21 
To unravel the source of cardiac epinephrine, the effect of 
intracoronary tyramine infusions on epinephrine concentrations in myocardial 
interstitial fluid is investigated before and after loading the heart with 
epinephrine by means of intracoronary epinephrine infusions. Finally, we 
explore whether intracoronary infusions of epinephrine can increase 
myocardial interstitial norepinephrine concentrations under basal conditions 
and during sympathetic activation induced by electrical stimulation of the left 
stellate ganglion. 
Chapter 6. Angiotensin II and norepinephrine release 
In this chapter, we determine whether physiological (p:M) to pathophysiological 
(n:M) concentrations of angiotensin II modulate interstitial norepinephrine 
concentrations in the porcine heart under various conditions. Activation of the 
sympathetic nervous system simultaneously leads to activation of the renin-
angiotensin-system via stimulation of ~-adrenergic receptors within the kidney 
resulting in an increased renin release. There is also, albeit conflicting, evidence 
that the sympathetic nervous system is activated by the renin-angiotensin-
system.22.34 This activation supposedly occurs through stimulation of 
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angiotensin II receptors within the central nervous system and/ or stimulation 
of presynaptic angiotensin II receptors located at sympathetic nerve terminals. 
In those studies that demonstrated interaction between angiotensin II 
and the sympathetic nervous system, most evidence points towards direct 
facilitation mediated by presynaptic angiotensin II type 1 (AT1) receptors 
(figure 2) resulting in either a 'classic' calcium-dependent augmentation of 
exocytotic norepinephrine release,22.24 or in enhanced nonexocytotic release via 
activation of the Na+ /H+ exchanger.35•36 Therefore, the modulation of 
interstitial norepinephrine concentrations by angiotensin II is not only 
investigated under basal conditions but also during enhanced exocytotic 
norepinephrine release evoked by stimulation of the left stellate ganglion as 
well as during nonexocytotic norepinephrine release induced by ischemia. 
Chapter 7. Cardiac ischemia and local catecholamine release 
In this chapter, we explore the fate and potential role of catecholamines and in 
particular of norepinephrine in myocardial ischemia. Myocardial ischemia is 
associated with a marked accumulation of norepinephrine in ischemic tissue. 37. 
40 Interestingly, in vitro studies in the sympathetically dominant rat heart suggest 
that the ischemia-induced norepinephrine release can be attenuated by 
blocking neuronal reuptake, indicating that under ischemic conditions the U1-
mechanism is reversed, and can operate as a cactier for outward instead of 
inward norepinephrine transport. 41.42 However, it is not known whether this 
mechanism is also operative in parasympathetically dominant human and 
porcine hearts. 
Furthermore, there is little information about myocardial release of 
epinephrine and dopamine in the ischemic heart in vivo. Hence, in this chapter 
we investigate time course and ma,onitude of changes in myocardial interstitial 
fluid concentrations of catecholamines during severe myocardial ischemia and 
reperfusion, as well as the contribution of reversal of the U1-mechanism to 
ischemia-induced norepinephrine release. 
Finally, the functional integrity of the cardiac sympathetic nerve 
endings is assessed by comparing local norepinephrine response to an 
intracoronary infusion of tyramine in the post-ischemic myocardium to the 
response observed in the non-ischemic porcine myocardium of control 
animals. As tyramine is taken up via U1 into the sympathetic nerve endings 
where it releases norepinephrine, it provides information on the 
norepinephrine content as well as U1-function of sympathetic nerve endings. 
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Chapter 8. Cerebral ischemia, norepinephrine and cardioprotection 
This chapter describes the role of norepinephrine in local and remote 
preconditioning. Ischemic preconditioning, originally described for the 
myocardium,43 also occurs in kidney,44 skeletal muscle:' lung46 and brain.47 
Przyklenk et al.48 showed that brief regional myocardial ischemia protects not 
only the jeopardized myocardium during a subsequent coronary artery 
occlusion, but also the adjacent "virgin" myocardium. Furthermore, it has been 
shown that brief ischemia in remote organs is also capable of limiting 
myocardial infarct size produced by a prolonged coronary artery occlusion.49•50 
As norepinephrine is one of the mediators involved in the signaling 
pathway leading to ischemic preconditioning,51~2 and because cerebral ischemia 
causes a profound release of norepinephrine from sympathetic nerve endings 
in normal myocardium,53 this raises the question whether transient cerebral 
ischemia prior to a coronary artery occlusion may also be cardioprotective. 
Therefore, we inves~o-ate the effect of cerebral ischemia on myocardial 
infarct size produced by a coronary artery occlusion. Because the 
cardioprotective effect of norepinephrine has not been established in pigs, we 
first explore whether intracoronary infusions of norepinephrine are capable of 
limiting myocardial infarct size. Finally, we quantitate myocardial 
norepinephrine concentrations during cerebral ischemia and exogenous 
norepinephrine infusions, and determine whether limitation of infarct size is 
mediated by attenuation of myocardial interstitial norepinephrine levels during 
coronary artery occlusion. 
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Chapter 3 
Sensitive and specific method for the 
simultaneous determination of natural and 
synthetic catecholamines and 3,4-
dihydro:xyphenylglycol in microdialysis 
samples 
The relatively new technique of microclialysis provides new possibilities for 
investigating in vivo the functioning of the sympathetic nervous system. The 
small sample volumes obtained, however, are a great challenge for analytical 
chemists. We report here a HPLC method for measuring in one run both 
natural and synthetic catecholamines (dopamine, (nor)epinephrine, 1-erythro-o:-
methyl-norepinephrine, isoproterenol and epinine) and the intraneuronal 
metabolite 3,4-clihydrm,-yphenylglycol in small microclialysis samples after 
derivatization with the fluorogenic agent 1,2-cliphenylethylenecliamine. No 
prior clean-up step is necessary. N-Ethylmaleimide is necessary for preventing 
an inhibitory action on derivatization occurring in in vivo microclialysis samples. 
The method can handle large numbers of samples, is sensitive (on-column 
detection limits 30 to 200 fg) and reproducible (RSD 1 - 7%). Recovery 
characteristics of the commercial microclialysis probe used (CMA/20) were 
extensively investigated both in vitro and in vivo at various perfusion rates; for 
practical purposes a rate of 2 f.!L/ min and sampling at 1 0-min intervals was 
found to be workable and to give good and reproducible recoveries (50 - 70%). 
Alberts G, Lameris T, van den Meiracker AH, Man in 't Veld AJ, 
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Introduction 
The availability of sensrtlve methods for measuring the catecholamines 
norepinephrine (NE), epinephrine (EPI) and dopanrine (DA) in plasma has 
increased our understanding of the sympathetic nervous system. The 
development of the isotope dilution method made it possible to uoravel the 
contributions from spillover and clearance to a measured concentration, both 
overall and in various organs and tissuesY The method, however, also has its 
drawbacks, both from a theoretical and from a practical viewpoint.3 With the 
introduction of the microdialysis technique, in which a small catheter with a 
semipermeable membrane at its end is introduced into the interstitial space of 
an organ or tissue, it has become possible to actually measure as well as to 
influence the concentration of compounds in the interstitial space! The slow 
perfusion rate with microdialysis (in the order of 0.5 to 5 f-LL/min) means 
however that the amount of dialysate which can be collected in a reasonable 
time is very small, thus leading to a need for highly sensitive assay methods 
with a large through-put. 
It would be advantageous to be able to measure at the same time not 
only the natural catecholanrines NE, EPI and DA, but also some synthetic 
catecholamines, which are used sometimes in the study of the sympathetic 
nervous system (e.g., isoproterenol, ISO) or used as internal standards (e.g., 1-
erythro-tx-methyl-norepinephrine, fu\fN, and ep1n1ne, EPl\<'). Likewise, 
simultaneous measurement of 3,4-dihydrm:yphenylglycol (DHPG), an 
important intra-neuronal metabolite of NE, would be desirable.' Since 
dialysates are relatively clean samples, it may be possible to avoid the time-
consuming extraction procedures necessary for plasma and urine samples. 
So far, catecholanrine measurements of microdialysis samples are, apart 
from some radio-enzymatic methods,'·' mostly based on high-performance 
liquid chromatography (HPLC) with electrochemical detection;9·13 in most 
reports a prior clean-up procedure was deemed necessary. An alternative, more 
specific method based on derivatization with the selective fluorogenic agent 
1,2-diphenylethylenedianrine (DPE) has been used successfully for 
measurement of both natural and synthetic catecholanrines in plasma and 
urine_14- 17 Its sensitivity and selectivity would make it ideally suitable for 
measurements in microdialysis samples, as has already been proposed.18 In one 
report, such a method has already been used.19 For the measurement ofDHPG 
in microdialysis samples, one separate method has been reported employing 
HPLC with electrochemical detection.20 
In this study we describe a sensitive and selective method in which 
natural and synthetic catecholamines as well as DHPG in microdialysate 
samples are simultaneously measured after direct derivatization, without an 
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extraction step, with the fluorogenic agent DPE followed by HPLC separation 
and fluorimetric detection. The method has been optimized and some 
unexpected and hitherto unnoticed problems have been solved. The simple 
derivatization procedure and the short chromatographic runs (15 min) allow 
for a high throughput. We also report here an extensive evaluation of in vitro 
and in vivo recovery experiments using the new method. 
Methods 
Reagents 
Bicine, NE, EPI, DA, A.J.\1N, ISO, EPN and DHPG were obtained from 
Sigma (St. Louis, MO, USA), ethylenediaminetetraacetic acid (EDTA), N-
ethylmaleimide (NEM) and hydrochloric acid from Merck (Darmstadt, 
Germany), potassium ferricyanide (PFC) from Aldrich (Bomem, Belgium), -
glutathione from Fluka (Buchs, S"''itzerland), acetic acid and acetonitrile from 
Baker (Deventer, The Netherlands), Ringer's solution from Braun (Melsungen, 
Germany) and Ringer's lactate from Ba.xter (Uden, The Netherlands). DPE 
was prepared as reported previously.16 All water used had been purified by a 
:Milli Q-Plus system (:Millipore, Bedford, MA, USA). 
Apparatus 
The instrumentation for chromatography consisted of a Spectra System P4000 
pump (Thermo Separation, San Jose, CA, USA), a Kontron 460 autosampler 
(Kontron, Milan, Italy) and an FP920 fluorescence detector Gasco, Toh.-yo, 
Japan) operated at excitation and emission wavelengths of 350 and 480 nm, 
respectively. Data acquisition was performed using an SP4500 Labnet interface 
and a PC1 000 system v3.0.1 from Thermo Separation. Separations were 
performed on a 3 m Allsphere ODS-2 (100 mmx2.1 mm I.D.) column 
(Alltech, Deerfield, IL, USA) at ambient temperature. For some preliminary 
experiments, an electrochemical detector (Antec, Leiden, The Netherhnds; 
operated at 600 m V) was used. 
Microdia!ysis samples 
CMA/20 microdialysis catheters (Carnegie Medicine AB, Stockholm, Sweden; 
membrane 10 mmxO.S mm, cut-off: 20 kD) were inserted into left ventricular 
myocardium, coronary vein and carotid artery of pigs, and in freshly obtained 
blood samples from pigs and humans. CMA/ 60 catheters (membrane 30 
mmX0.6 mm, cut-off: 20 kD) were inserted into subcutaneous fat and muscle 
of humans. Catheters were perfused with Ringer's lactate solution at a rate of 2 
!JL/rnin using a CMA/100 microperfusion pump; 10-rnin fractions (20 !JL) 
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were collected into microvials contauung 20 JiL of 0.08 M acetic acid 
containing 2% (w/v) of disodium-EDTA (HAc/EDTA) which usually also 
contained 100 pg of internal standard AMN. Samples were stored at -80°C 
until assay. 
Assqy method 
To the samples or standards were added subsequently 40 JiL of acetonitrile, 10 
JiL of 20 ffi.L\1 NEM in 1. 7 5 M bicine buffer containing 1% (w /v) of disodium-
EDTA (pH 7.50), 20 JiL of 0.1 M DPE in 0.1 M HCl, and 4 JiL of 20 mM PFC 
in water. Samples were then incubated for 2 h at 37°C in the dark. After 
cooling to ambient temperature 6 JiL of an 80 mM solution of glutathione in 
water was added, and the sample was put into the storage compartment of the 
auto sampler, which was kept at 4 °C. The auto sampler injected 20 JiL into the 
chromatographic system. For elution, 0.05 M sodium acetate buffer (pH 
7.0)/methanol/acetonitrile was used in the proportions (60:20:20, v/v/v) 
(mobile phase A) and (30:1 0:60, v /v /v) (mobile phase B). A linear gradient was 
used starting with A/B (70:30) at time 0 to 100% B at 14 min; flow-rate was 
200 JiLl min. 
All assays also contained blank samples and three different standard 
concentrations in triplicate. Standard mixtures containing (per mL) 5 ng of 
NE, .&\1N and EPI each, 10 ng of DA, ISO and DHPG each, and 25 ng of 
EPN were prepared in HAc/EDT A. Derivatizations of 5 (1 0,20) )J.L of 
standard mi.xture to which were added 15 (10,0) JiL of HAc/EDTA and 20 JiL 
of Ringer's solution were used for constructing a standard line. 
Results and discussion 
Electrochemical method 
Preliminary experiments showed that measurement of catecholarnines by ditect 
injection of microdialysis samples into a chromatographic system equipped 
with an electrochemical detector leads to a large number of peaks completely 
obscuring the peaks of interest. Thus e..xtensive clean up of microdialysis 
samples will be necessary in order to reliably measure catecholarnines using an 
electrochemical detector. 
Derivatization with DPE 
The alternative method of derivatizing samples with the fluorogenic agent 
DPE without prior clean-up procedures was carried out essentially as described 
previously for extracts of plasma and urine, except for smaller volumes and a 
different optimal pH of the bicine buffer.14. 17 To 20 J.lL of a mi.xture of 
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catecholamines and DHPG in HAc/EDT A and 20 J1L of Ringer's solution 
were added subsequently 40 J1L of acetonitrile, 20 J1L of 0.1 M DPE in 0.1 M 
HCl, 10 J1L of 1.75 M bicine buffer containing 1% (w/v) of disodium-EDTA 
(pH 7.50), and 4 J1L of 20 nu\1 PFC in water. The order of addition of the 
various reagents has to be strictly adhered to, as has been described 
previously.18 
After 1 h at 37°C in the dark the vials were placed into the 
autosampler, and 20 J1L was injected into the chromatographic system. 
Fluorescence observed was equal to the fluorescence observed when samples 
were first extracted as described previously and then derivatized, except for 
DHPG.16 DHPG can be derivatized with DPE but is lost to a great extent 
during the extraction procedure necessary for plasma and urine samples.21 A 
longer period of derivatization did not result in any difference in fluorescence 
of the catecholamines, but did increase the fluorescence of DHPG. The 
optimal incubation time for catecholamines and DHPG was found to be 2 h. 
When the thus established derivatization procedure was executed on 
catecholamines and DHPG standards dissolved not in Ringer's solution or 
HAc/EDTA, but in real microdialysis samples, we noticed that the 
fluorescence of DA, NE, AMN and DHPG was greatly inhibited. The 
fluorescence of EPI, ISO and EPN on the other hand was much more as 
expected (Table 1). This phenomenon occurred in microdialysis samples from 
pigs and humans as well as in microdialysis samples from freshly obtained 
blood, albeit to different extents. Apparently, real microdialysis samples 
contain (an) unknown compound(s), which inhibit(s) the derivatization 
reaction. Longer incubation, incubation at higher temperatures or the addition 
of extra amounts of PFC did not solve the problem. 
Table 1. Relative fluorescence of compounds in in vivo microdialysis 
samples, as a percentage of the fluorescence of the same amount of the 
compounds in Ringer's solution. 
-NEM +O:EM .,. !-.'EM 
Compound 
-GLUT ·GLUT + GLl:T 
3,4-Dih ydro,')phen jlgl )<Dl 8±5 120 ± 10 102 ± 5 
Norepinephrine 12 ± 2 lOS ± 7 103 ± 4 
1 -erythro-ct-meth yl-norepinephrine 47 ± 3 102 ± 5 100 ± 7 
Epinephrine 96 ± 3 102 ± 3 103 ± 4 
Dopamine 6±1 102 ± 5 102 ± 5 
Isoproterenol 84 ± 3 102 ± 1 99 ± 2 
Ep.inine 74 ± 9 95 ± 4 96 ± 6 
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The apparent inhibition of the DPE derivatization reaction for some, 
but not all, catecholamines is reminiscent of the report by Nohta et al.22 who 
noticed that in erythrocytes and platelets samples compounds are present 
which interfere with the fluorescence derivatization reaction of NE and DA, 
but not EPI. They concluded that the sulfhydryl-reagent NEM can prevent this 
interference, and we found that the same applies for rnicrodialysis samples: 
including 20 m...\1 of NEM in the bicine buffer was sufficient to overcome the 
inhibitory action of the unknown compound(s) on the derivatization reaction 
(Table 1). During rnicrodialysis, these compounds apparently cross the 
membrane and enter the dialysate. 
As can be seen in Table 1 the fluorescence peak of DHPG was now 
higher than ecxpected. This was caused by a small peak arising from the added 
NEM, which had nearly the same retention time as DHPG. Adding 6 J.1L of a 
80 !Il.J.\1 solution of glutathione in water at the end of the derivatization 
procedure got rid of this interfering peak, and resulted in optimal and complete 
fluorescence for all catecholamines and DHPG as compared to derivatization 
in Ringer's solution or HAc/EDTA (Table 1). 
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Figure 1. Chromatograms of microdialysis samples. (A) Standard mi:,ture. On -column 
amounts: 8.3 pg for NB(2), BPI(4) and AMN(3), 16.7 pg for DHPG(1), DA(S) and IS0(6), 
and 41.7 pg for BPN(7). (B) Porcine myocardium sample. On-column amounts: DHPG 1.7 
pg; NB 2.8 pg; BPI 0.2 pg; DA 0.2 pg. (C) Porcine myocardium sample (after occlusion of 
coronary artery). On-column amounts: DHPG 2.6 pg; NB 33.6 pg; BPI 1.4 pg; DA 2.1 pg. 
All peaks of interest are clearly separated in the chromatograms (Figure 
1). Although it is possible to change the elution conditions in such a way that 
the DHPG and NE peaks, which ride on the descending part of the front 
peak, come completely clear from the front, this will lengthen the runs 
considerably, with great loss of sensitivity for the later-eluting peaks. At low 
concentrations of DHPG and NE, automatic quantification of the 
chromatographic peaks by a computer program is not good enough, and 
careful delineation by hand is necessary. This can however be done 
reproducibly, certainly if performed by the same person. Since the 
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superposition thus does not appreciably interfere with reliable quantification of 
DHPG and NE, we have left the elution conditions as stated. With small 
variations in the percentage of acetonitrile, however, the elution times of the 
peaks can be easily influenced. 
Table 2. Intra- and inter-assay variabilities at tw"o different concentrations (C t-Cz)* 
Compound DHPG NE EPI DA ISO A..~ EPK 
C1Intr:a-assay, 1673 ± 2.3 325 ± 3.3 969 ± 1.3 1891 ± 3.1 1818 ± 0.8 978 ± 2.5 5019 ± 2.5 
mean±RSD (%) 
C1 Inter-assay, 1699 ± 4.7 361 ± 6.1 959 ± 2.9 1918 ± 1.3 1830 ± 2.1 976 ± 1.6 5168 ± 2.3 
mean±RSD (%) 
Czinrr:a-assay, 175 ± 7.6 57± 3.3 169 ± 0.9 381 ± 1.8 345 ± 2.4 212 ± 2.5 1025 ± 3.3 
mcan::::RSD (%) 
Czinter-assay, 159 ± 7.3 58 ± 1.5 172 ± 6.3 378 ± 1.6 336 ± 6.5 221 ± 5.8 1036 ± 5.1 
mean±RSD (%) 
*Intra-assay: n=6; inter-assay: n=6. Concentrations: pg/mL. 
Reproducibility and detection lincit 
Two mi..xtures of microdialysis samples enriched with different amounts of 
catecholamines and DHPG were used for determining the intra- and inter-
assay variabilities (Table 2). Taking an S/N ratio of 3 as the detection limits, 
the minimal on-column detectable amounts were 30 fg for NE, EPI and A.i\iN, 
50 fg for ISO, 80 fg for DHPG and DA, and 200 fg for EPN. With standard 
assay conditions, this amounts to 10 pg for NE, EPI and fu\1N, 15 pg for ISO, 
25 pg for DHPG and DA, and 60 pg for EPN per mL of dialysate. 
In vitro and in vivo recoveries 
For relating measured dialysate concentrations to actual interstitial 
concentrations, one must know the relative recovery, i.e., the ratio between 
concentrations in dialysate and surrounding medium. Furthermore, from a 
practical point of view, it is important to know the absolute recovery, i.e., the 
amount of a compound entering the dialysate in a defined period of time11 We 
have determined relative and absolute recoveries of NE, EPI, DA, ISO, A.\1N 
and DHPG in vitro with CMA/20 microc!ialysis probes in triplicate by 
inserting them in standard mi..'<:tures of the above-mentioned compounds 
(concentrations 4 to 12 ng/mL) in Ringer's solution and perfusing the probes 
with Ringer's solution at flow-rates of 0.5, 1, 2, 4 and 8 f.LL/min. The standard 
mi..'<:tures were kept at 37°C and 1 h after starting perfusion four consecutive 20 
fLL samples were collected and assayed. 
The results (Figure 2) show that both relative and absolute recoveries 
of all compounds are similar and reproducible. The absolute recoveries are 
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represented here as a percentage of the amount found in the dialysate per min 
at the highest flow-rate of 8 f!L/ min. It can be concluded that a flow-rate of 2 
f!L/min, which gives good relative (53-66%) and absolute (69-77%) recoveries 
and allows for sampling at 10 min intervals, is appropriate for experiments. 
The inter-probe variability is quite small: on average 3±2% (NE, EPI and 
A.\1N 2±1 %, DA 4±2%, ISO 3±1 %, DHPG 7±5%). 
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Figure 2. Relative (closed symbols) 
and absolute (open symbols) 
recoveries of the compounds using 
the CMA/20 microdialysis probe at 
various perfusion flow rates. 
DHPG(III); NE(e); E(n); DA(*); 
IS0(+);&\1N(e). 
In vivo recovery was determined in two different ways. First, since 
characteristics of AMN are quite similar to those of the other catecholamines, 
we perfused the microdialysis probes inserted in the porcine heart with 
Ringer's lactate solution containing a known concentration of AMN and 
measured the concentration of A.\1N in the collected dialysate samples. This 
retrodialysis method, employed in four pig e::-.-periments, gave a recovery for 
A.tYIN of 52±8% (n=286), in close agreement with the results of the in vitro 
recovery determination. Second, with probes inserted into the carotid artery, 
we compared the concentrations of NE and EPI in these dialysate samples 
with the concentrations in the plasma samples obtained at the same time from 
the same artery (midway between the 1 0-min microdialysis period) during 
periods of elevated NE and EPI concentrations. Results showed a recovery of 
51±4% for NE (n=19) and somewhat higher recoveries for EPI (68±3%, 
n=17). 
The recovery experiments show that catecholamines and DHPG can 
reliably be measured in this way and that they can reproducibly give a good 
indication of the interstitial concentrations. The recovery compares favorably 
with the scarce results (on NE only) given in the literature with different, 
laboratory-made microdialysis probes (23-41 %).6"1123 As a compromise 
between high relative but low absolute recovery at a perfusion rate of 0.5 
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)JL/ min, and low relative but high absolute recovery at 8 )JL/ min, a perfusion 
rate of 2 ).!L/ min is satisfactory, with a sufficiently rapid sampling period of 10 
rrun. 
Conclusions 
The method described is sensrnve, simple and rapid. With the use of an 
autosampler a large number of samples can be processed. For our hospital 
setting, it was not practical to develop an automated on-line method; we 
preferred a manual derivatization procedure, which is time-consuming but not 
labor-intensive. If desired, our method can be adapted to an on-line method, as 
has been described previously,18.19 provided NEM is also included in the 
derivatization mixture. The addition of NEM is essential for obtaining good 
and reproducible derivatizations, and thus reliable measurements, of the 
compounds in question. The inbibition of the derivatization seen in the 
absence of NEM was never seen with plasma and urine samples, probably 
because the extraction procedures always used with such samples also remove 
these inbibitory substances. 
The fact that the intra-neuronal metabolite DHPG can also be 
quantitated at the same time is a great advantage, as is the possibility of 
measuring various unnatural catecholanrines which provides flexibility both in 
choosing internal standards and in determining concentrations of infused 
synthetic substances like isoproterenol. The 0-methylated metabolites cannot 
be measured with the present method. For measurement of these compounds, 
HPLC with electrochemical detection is the method of choice, which does not 
need derivatization, but is not selective enough to be used without extensive 
pre-purification of microdialysis samples. 
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Chapter4 
Catecholamine handling in the porcine 
heart 
Introduction - Experimental findings suggest a pronounced concentration 
gradient of norepinephrine (NE) between the intra-vascular and interstitial 
compartments of the heart, compatible with an active neuronal reuptake (U1) 
and/ or an endothelial barrier. 
Methods and &suits - Using the microdialysis technique in 8 anesthetized pigs, 
we investigated this NE gradient, both under baseline conditions and during 
increments in either systemic or myocardial interstitial fluid NE concentration 
(NEYITF)· At steady state, baseline NEYITF (0.9±0.1 nmol/L) was higher than 
arterial NE (0.3±0.1 nmol/L), but not different from coronary venous NE 
(1.5±0.3 nmol/L). Local U1-inhibition raised NEMIF concentration to 6.5±0.9 
nmol/L. During intravenous NE infusions (0.6 & 1.8 nmol·kg·1·min.1), the 
fractional removal of NE by the myocardium was 79±4% - 69±3% depending 
on infusion rate. Despite this extensive removal, the change in MIF /arterial 
concentration ratios (L'u\1IF/M) for NE were only 0.10±0.02 for the lower 
and 0.11±0.01 for the higher infusion rate, whereas U1-blockade caused the 
&.1IF / M ratio to rise to respectively 0.21±0.03 and 0.36±0.05. From the 
differences in L'u\1IF / M ratios with and without U1-inhibition it could be 
calculated that 67±5 % of NEMIF is removed by U1. Intracoronary infusion of 
tyramine (154 nmol·kg·1·min.1) caused a 15-fold increase in NEMIF 
concentration. This pronounced increase was paralleled by a comparable 
increase of NE in the coronary vein. 
Conclusion- We conclude that U1 as well as extra-neuronal uptake and not an 
endothelial barrier are the principal mechanisms underlying the concentration 
gradient of NE between the interstitial and intra-vascular compartments in the 
porcine heart. 
Lameris TW, van den Meiracker AH, Boomsma F,Alberts G, de Zeeuw 
S, Duncker DJ, Verdouw PD, Man in 't Veld AJ. Catecholamine handling 
in the porcine heart: a microdialysis approach. Am J Physiol 1999;277:H1562-
H1569. 
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Introduction 
Several experimental findings suggest that in the heart a pronounced 
concentration gradient for norepinephrine exists between the interstitial and 
intra-vascular compartments. Silverberg et al.1 showed that the coronary sinus 
norepinephrine concentration induced by a norepinephrine infusion that led to 
only a small increase in the heart rate was eight times higher than with stellate 
ganglion stimulation causing a similar increase in heart rate. Cousineau et al? 
estimated from tracer dilution experiments a ratio between the interstitial and 
arterial compartments of 15 % in canine hearts. More recently, Obst et al.O, 
using ultrafiltration of interstitial fluid from isolated perfused rat hearts, found 
ratios of interstitial transudate to arterial concentrations of norepinephrine of 
0.14 to 0.77 depending on the concentration of norepinephrine administered. 
These investigators interpreted these findings as to suggest that the neuronal 
uptake of norepinephrine is the most important determinant for maintaining a 
concentration gradient between the circulatory and interstitial compartment. 
Because of the dense sympathetic innervation, especially in the heart, neuronal 
reuptake (01) of norepinephrine could be an important determinant for 
maintaining such a gradient.4•5 However, other investigators have suggested 
that the concentration gradient is caused by a physical barrier of the blood 
vessel wall as well. 23•6•9 
A profound understanding of catecholamine kinetics is invaluable 
when interpreting catecholamine data and their representation of sympathetic 
activity. Using the isotope dilution method and arterio-venous sampling, Esler 
et al.10 introduced regional spillover (SO) as a kinetic parameter that aims to 
reflect the rate of norepinephrine entering the circulation rather than true 
production. In a recent study, Kopin et al.11 have modified this technique and 
introduced a new method to estimate neuronal release, which is based on the 
measurements of the specific activities of radiolabeled norepinephrine and its 
extra-neuronal metabolite normetanephrine in plasma. Neuronal release of 
norepinephrine into the interstitial space is estimated as the sum of the 
spillover (SO) of norepinephrine from the interstitium to the circulation and 
uptake of released norepinephrine (Ur) from the interstitium. Nonetheless, the 
interstitial compartment can only be monitored either by estimation through 
application of mathematic kinetic modeling, or by using in vitro or semi-in vivo 
preparations. The microdialysis technique, however, allows for the accurate 
estimation of the concentration of catecholamines in the myocardial interstitial 
fluid (MIF) in vivo. 12-15 The technique should allow for measuring the hitherto 
unquantifiable amount of norepinephrine that is released but taken up before 
reaching the vascular compartment, thus filling the gaps in existing kinetic 
models. 
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In a series of experiments, in which either the circulatory or the 
interstitial norepinephrine concentration was increased, it was investigated how 
the concentration of norepinephrine in the MIF relates to its concentration in 
the arterial and coronary venous circulation. The importance of U1 and extra-
neuronal uptake to this relationship was explored by adding desipramine 
(DMI), a well known U1-inhibitor, to the dialysate of one of the microdialysis 
probes and by performing experiments with isoproterenol, a catecholamine 
known not to be handled by Ul. Furthermore, norepinephrine concentrations 
in MIF (NEMIF), arterial plasma and the coronary effluent at baseline and 
during infusion of norepinephrine provided an estimate of spillover, uptake 
and release of norepinephrine. 
Methods 
Animal care 
All e'--periments were performed in accordance with the "Guiding Principles 
for Research Involving Animals and Human Beings" as approved by the 
Council of the American Physiological Society and under the regulations of the 
Animal Care Committee of the Erasmus University Rotterdam (The 
Netherlands). 
S urgica! procedure 
After an overnight fast, crossbred Landrace x Yorkshire pigs of either sex (30-
35 kg, n=8) were sedated with ketamine (20-25 mg/kg i.m., Ketalin") and 
anesthetized with sodium pentobarbital (20 mg/kg i.v., Narcovet"). The 
animals were intubated and connected to a respirator for intermittent positive 
pressure ventilation with a II!Lxture of oxygen and nitrogen. Respiratory rate 
and tidal volume were set to keep arterial blood gases within the normal range: 
pH between 7.35 and 7.45, pC02 between 35 and 45 mmHg, and p02 
between 100 and 150 mmHg. 
Catheters were positioned in the superior caval vein for continuous 
administration of sodium pentobarbital (10-15 mg/kg per hour) and 
Haemaccel® for replacing blood withdrawn during sampling. In the descending 
aorta, a fluid-filled catheter was placed for monitoring aortic blood pressure 
and for withdrawal of blood samples. Through the left carotid artery, a 
micromanometer-tipped catheter (B. Braun Medical BV, Uden, The 
Netherlands) was inserted into the left ventricle for measurement of left 
ventricular pressure and, by electrical differentiation, the ma.xi.mum of its first 
derivative (LV dP/dt,.~.J- After administration ofpancuronium bromide (4 mg, 
Pavulon"), a midstemal thoracotomy was performed, and the heart was 
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suspended in a pericardial cradle. An electroma,onetic flow-probe (Skalar, Delft, 
The Netherlands) was then placed around the ascending aorta for 
measurement of aortic blood flow (cardiac output). A proximal segment of the 
left anterior descending coronary artery (LAD) was dissected free for 
placement of a Doppler flow-probe. Distal to this site a small cannula (1.3 mm 
outer diameter) was inserted into the LAD for the administration of tyramine. 
The microdialysis catheters were implanted in the tissue with the help 
of a steel guiding needle and split plastic tubing. Three microdialysis probes 
were inserted in the left ventricular myocardium: one in the region of the left 
circumflex coronary artery (LCx) and two in the area perfused by the LAD. In 
order to achieve local Ul-inhibition, one of the LAD probes was co-perfused 
with DMI (1 00 fti\1:). 16 Additionally, microdialysis probes were placed in the 
right carotid artery and the anterior interventricular coronary vein that drains 
the territory perfused by the LAD. 
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Figure 1. Determination of in vivo recovery for isoproterenol (ISO) and norepinephrine (NE): 
arterial microdialysis vs. arterial sampling. 95 % confidence limits are indicated by the dotted 
lines. 7 animals, 17 data points 
Dialysis methodology 
For microdialysis CMA/20 probes (Carnegie Medicine AB, Sweden) were 
used. The polycarbonate dialysis membrane of these probes has a cut-off value 
of 20 kD, a length of 10 and a diameter of 0.5 mm. The probes were perfused 
with an isotonic Ringer's solution at a rate of 2 f.!L/min using a CMA/100 
microinjection pump. Dialysate volumes of 20 J.!L (sampling time 10 minutes) 
were collected in micro vials containing 20 fLL of a solution of 2 % \/ vl EDTA 
and 150 nM epinine as internal standard in 0.08 N acetic acid. Sampling was 
started immediately after inserting the catheters. The plasma samples were 
drawn into chilled heparinized tubes containing 12 mg glutathione, and, like 
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the microdialysis samples, stored at -80 °C, and analyzed within the next five 
17 days. 
Determination of in vivo probe recovery 
Probe recovery is defined as the quotient of dialysate catecholamine 
concentration and the actual catecholamine concentration in the medium that 
is dialyzed. In vivo probe recovery was determined separately for blood as well 
as myocardial intercellular fluid. Probe recovery for blood was estimated by 
comparing catecholamine concentrations in plasma to catecholamine 
concentrations in the corresponding dialysate of the microdialysis probe in the 
carotid artery (Figure 1). 
Recovery of norepinephrine for the probes in the myocardium was 
estimated by applying the retrodialysis method. This method relies on the 
assumptions that diffusion of a substance into the microdialysis probe equals 
outward diffusion and that the diffusion characteristics of the calibrator 
(substance A, Figure 2) match those of the analyte (substance B, Figure 2). 18•19 
Furthermore, this method will only provide an estimation of the concentration 
of the analyte at the outer membrane of the microdialysis probe rather than the 
mean interstitial concentration. Ideally, while the calibrator should not have 
any pharmacodynamic effects, both substances should have the same 
pharmacokinetic properties. Consequently, the concentration of the calibrator 
in the perfusate should be as low as possible to prevent any significant 
influence on the metabolism of the analyte, e.g. saturation of active uptake 
mechanisms like U 1. 
CAperfusate 
C A dialysate 
,...--------3>-
Cs dialysate 
A'"' 
Cs medium 
F B _C -.::.c''=ialysa="' X tn---:: 
Csmodtum 
Retrodialysis: Fx A'"'= Fx B'" 
=>Recovery B = Fx A'"' 
Figure 2. The retrodialysis method. C A: concentration of calibrator A; C B: concentration of 
analyte B; Fx Aout: Fraction of calibrator A that has diffused out of the perfusate; Fx Bin: 
Fraction of analyte B that has diffused out of the medium in to the dialysate, i.e. the recovery of 
aoalyte B 
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In this study 1-eryth:ro-IX-methyl-norepinephrine (At\1N) was chosen as 
the calibrator for probe recovery for norepinephrine. This AMN isomer is 
considered to be a "false transmitter"; it is handled like norepinephrine, while it 
does not share its pharmacodynamic effects. Retrodialysis was performed in 
four animals for the len,otb of the whole experiment. The average percentage 
of loss of A...\1N, i.e. in vivo probe recovery for norepinephrine in MIF, was 
based on the data derived from the LAD and LCx probes of all four animals. 
This method revealed a probe recovery of 52±1% (2 probes in 4 animals). 
Comparison of the concentration of norepinephrine in arterial plasma with the 
norepinephrine concentration in the dialysate obtained from the probe 
positioned in the carotid artery showed a similar value for probe recovery of 
norepinephrine, (52±4%, Figure 1). For isoproterenol, using a similar 
approach, the in vivo probe recovery was 37±3% (Figure 1). 
Protocol 
After 120-150 minutes, steady state conditions were reached at baseline. 
Thereafter, norepinephrine and isoproterenol were infused consecutively 
intravenously for 30 minutes for each dose, followed by a 30-min 
intracoronary infusion of tyramine. After each infusion, a 30-min stabilization 
period was introduced, allowing for a complete washout of the infused 
substances and return to baseline conditions. The infusion rates of 
isoproterenol (0.16 & 0.48 nmol/kg/min) and tyramine (154 nmol/kg/min) 
were chosen to correspond with the hemodynamic response of the 
norepinephrine infusions (0.6 & 1.8 nmol/kg/min)?0 At the end of the 
experiments, the pigs were killed with an overdose of pentobarbital. 
Analytical procedure 
Plasma catecholamines were determined by HPLC with fluorimetric detection 
after liquid-liquid extraction and derivatization with the fluorogenic agent 1,2-
diphenyl-ethylenediamine (DPE).21 For microdialysis samples, the 
catecholamines are not extracted prior to fluorimetric detection with HPLC, 
but directly derivatized according to the procedure described by Alberts et al?2 
This method suppresses the interference of in vivo factors on derivatization, 
thus improving sensitivity. 
Reagents and pharmaceuticals 
Ketalin" and )Jarcovet" were obtained from Apharmo BV (Arnhem, The 
Netherlands), Pavulon" from Organon Teknica BV (Boxtel, The Netherlands), 
Ringer's solution from Ba..'<:ter (Uden, The Netherlands), Haemaccel" from 
Behringwerke A.G. (Marburg, Germany), and epinine from Zambon (Milan, 
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Italy). Tyramine, norepinephrine and isoproterenol for infusions were obtained 
from tbe department of pharmacy of tbe University Hospital Rotterdam. DMJ, 
bicine, norepinephrine, and Ac\1N were purchased from Sigma (St. Louis, MO, 
USA), EDTA, N-etbylmaleimide and hydrochloric acid from Merck 
(Darmstadt, Germany), potassium ferricyanide from Aldrich (Bornem, 
Belgium), L-glutathione from Fluka (Buchs, Switzerland), and acetic acid and 
acetonitrile from Baker (Deventer, Tbe Netberlands). DPE was prepared as 
d . l Oj reporte preVIous y.-
Statistics and calculations 
Results are expressed as mean±SEM. Norepinephrine and isoproterenol 
concentrations obtained witb microdialysis were corrected for probe recovery 
to yield NEMIF and ISOMIF· Baseline values were determined by averaging tbe 
data of tbe steady state prior to tbe infusions. During tbe infusions of 
norepinephrine and isoproterenol, tbe cardiac extraction (E(%)) was calculated 
as 
E(%) = M-/',.V ·100% 
M 
(I) 
where M and /',. V are tbe change from baseline of respectively arterial and 
coronary venous concentrations. The ratio of interstitial norepinephrine to 
arterial plasma norepinephrine is presented as 
I . M1IF t:,.MIF M rat10 = --
M 
(II) 
where /',.MIF is tbe change from baseline of tbe myocardial interstitial fluid 
concentration. The percentage of norepinephrine tbat can be recovered from 
tbe MIF and tbat is taken up by U1 (FxU1 %) can be calculated from tbe 
difference between tbe /',.MIF I M ratio witb and witbout G1-inhibition 
(III) 
in which /',.MIF I MoMr is tbe /',.MIF I M ratio witb U1-inhibition. Tbe 
percentage of NEMIF tbat is originating from tbe circulation (MIF NEA%) at 
baseline can be estimated as follows 
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MIFNEA%= M1IF/Mratio-NEA _100% 
NE"" 
(IV) 
where NEA and NEMIF are the baseline norepinephrine concentration in arterial 
plasma and MIF. 
Although no radiolabeled material was used in the present study, the 
method introduced by Kopin and colleagues11 can still be applied to estimate 
neuronal release by replacing specific activity of radiolabeled norepinephrine 
with the ratio of change to baseline of the norepinephrine concentration in 
plasma (RA, Rv) and MIF (RMIF) during systemic infusion of norepinephrine. 
The use of this ratio is based on the assumptions that endogenous 
norepinephrine is reflected by the baseline norepinephrine concentration, and 
that the chauge in its release is negligible compared to the change in 
norepinephrine concentrations induced by infused norepinephrine. According 
to these revised equations, spillover (SO) can be calculated as 
SO= Q·NEA ·(1-E)·[(~)-1] (V) 
where Q is the coronary plasma flow (CPF) that is calculated from the 
coronary blood flow and the hematocrit which was estimated using the plasma 
hemoglobin concentration, NEA is the arterial plasma norepinephrine 
concentration at baseline, E is the extraction fraction, and RA and Rv are the 
ratios of change to baseline of the norepinephrine concentrations in arterial 
plasma and coronary effluent. The uptake of released norepinephrine (Ur) 
from the interstitium can be estimated using the ratio of change for MIF ~F) 
to baseline NEo.m. in an analogous equation 
(VI) 
As mentioned above, the sum of equations V and VI provides estimation of 
the neuronal release rate (Rr) 
Rr=SO+ Ur (VII) 
Subsequently, the ratio of uptake of released norepinephrine and neuronal 
release rate can be used as a measure for the efficiency of total uptake (Effu%) 
Ur Effc% =-·100% 
Rr 
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(VIII) 
For statistical analysis two-way analysis of variance, one-way analysis of 
variance for repeated measures with Dunner's multiple comparison test as 
post-hoc test, Smdent's t test and linear regress10n analysis were used as 
appropriate. 
Results 
Norepinephrine infusions 
Steady state concentrations of NEMIF were observed 120-150 minutes after 
placement of the probes and start of microdialysis. Baseline arterial plasma 
norepinephrine concentration was about three times lower than NEMIF 
(P<0.001, Figure 3). N~ concentrations in the LAD and LCx region were 
similar and values did not differ from those in the coronary vein. During U1-
blockade, NE,;aFincreased over six-fold (P<0.01, Figure 3). 
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Figure 3. Norepinephrine Oeft) and isoproterenol concentrations (right) during successive 
intravenous infusions of norepillephrine and isoproterenol. Data are sho'Vlll for JYO:F in LAD 
region in absence (•) and presence ofUl-blockade (o), MIF in LC.'< region in Ul blockade 
(x), and concentrations in arterial plasma (A) and in the coronary vein (p). Data presented as 
mean ± SEM, 8 animals. 
Circulatory and MIF norepinephrine concentrations at 20 and 30 
minutes after the start of both systemic norepinephrine infusions did not 
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differ, suggesting steady state was reached within 20 minutes (Figure 3). The 
extraction of arterially delivered norepinephrine was 79±4 % and 69±3 % for 
the low and high infusion rates respectively. Without U1-blockade, NEMIF 
(LAD and LCx region) remained considerably lower than arterial and coronary 
venous norepinephrine concentration. During U1-blockade however, NE,.nF 
was between arterial plasma and coronary venous concentration (Table 1, 
Figure 3). Without U1-blockade, the fu\1IF I M ratio (eq. If) was 0.10±0.01 for 
the lower and 0.11±0.01 for the higher norepinephrine infusion rate, whereas 
DMI caused the fu\1IF I M ratio to rise to respectively 0.21±0.02 and 
0.36±0.05 (P<O.OS). 
Table 1. Comparison of the increments of circulatory and interstitial concentrations of 
norepinephrlne and isoproterenol during systemic intravenous infusions of 
norepinephrine or isoproterenol 
Norepinephrine infusion Isoproterenol infusion 
Loation nmol/kg/ min nmol/kg/ min 
0.6 1.8 0.16 0.48 
Carotid artery, nmol/L 10.6 ± 0.8 28.2 ± 2.1 4.9 ± 0.8 9.2 ± 2.1 
Coronaxyvein, nmol/L 2.7 ± 0.8 9.6 ± 1.6 3.6 ± 0.6 6.9 ± 1.1 
E (%) 79 ± 4 69 ± 3 24 ± 5 23 ± 4 
"''JF LAD, nmol/L 1.1 ± 0.2 3.1 ± 0.3 1.8 ± 0.3 3.1 ± o.s 
"''JF LAD + DMI, nmol/L 2.1 ± 0.5 11.2±2.9t 1.8 ± 0.2 3.1 ± 0.4 
"''JF LCx, nmol/L 1.3 ± 0.2 3.6 ± 0.3 1.9 ± 0.3 3.4 ± o.s 
,6,MJF I M ratio -DMI 0.10 ± 0.01 0.11 ± 0.01 0.37 ± 0.02 0.34 ± 0.02 
+DJ\11 0.21 ± 0.03 * 0.36 ± 0.05t 0.37 ± 0.03 0.35 ± 0.02 
Values are mean±SE:\1, n=S. * P<0.05, t P<O.Ol DMI (-) vs. Dl\1I (+) 
Spillover (SO), rate of uptake (Ur), rate of neuronal release (Rr) and the 
efficiency of uptake (Effc%) at baseline were calculated from the data of both 
norepinephrine infusions using eqs. V-VIII. Despite the large increment in 
circulatory norepinephrine and NEMIF concentrations represented by the ratios 
of fu'\iE values to baseline between the lower and the higher norepinephrine 
dose, the kinetic parameters for norepinephrine remained unchanged (Table 2). 
Systemic infusions of norepinephrine caused a marked dose-dependent 
increase in heart rate, blood pressure, coronary blood flow and LV dP I dt,, 
(Table 3). The relationship between changes in LV dPidt,,_ and NE:.rrF was 
much steeper than the relationship between changes in LV dP I dt,,_ and 
arterial norepinephrine concentration (P<0.001, Figure 4). 
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Table 2. Spillover, uptake and release of norepinephrine 
at baseline derived from the data during systemic 
intravenous infusions of norepinephrine. 
Norepinephrine (nmol/kgl min) 
0.6 1.8 
RA 59.1 ± 8.2 155.3 ± 22 
Rv 1.8 ± 0.3 6.9 ± 0.6 
R:v.riF 1.3 ± 0.2 3.8 ± 0.5 
SO, pmol/ min 35.1 ± 5.6 38.8 ± 5.4 
Ur, pmol/ min 194.1 ± 33.4 204.0 ± 50.8 
Rr, pmol/ min ??9.3 ± 36.8 242.5 ± 53.4 
EffU% 84 ± 2 79 ± 2 
Values are mean±SEM, n=S 
Isoproterenol infnsions 
Systemic isoproterenol infusions caused dose-dependent increments in arterial 
and venous isoproterenol concentrations (Figure 3, Table 1). Circulatory and 
MIF isoproterenol concentrations at 20 and 30 minutes after the start of both 
systemic isoproterenol infusions did not differ significantly, suggesting steady 
state was reached within 20 minutes (Figure 3). The extraction of arterially 
delivered isoproterenol in the coronary circulation was 24±5%, with both the 
low and the high infusion rate. ISOo.rrF concentrations were lower than arterial 
and coronary venous concentrations and values did not alter in the presence of 
Ul-blockade. The ~F / M ratio for isoproterenol was 0.37±0.02 with the 
low and 0.34±0.02 with tl1e high infusion rate. 
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Isoproterenol infusions caused dose-dependent increments in heart 
rate, systolic blood pressure, coronary blood flow and LV dP I dt,"' and a dose-
dependent decrease in diastolic blood pressure (Table 3). The slope of the 
regression line of the relationship between LV dP I dt,., (%change) and 
isoproterenol concentration was 46±21 for ISOMIF and 13±8 for arterial 
isoproterenol concentrations. 
Table 3. Comparison of cardiac and systemic hemodynamics during systemic intravenous 
infusions of norepinephrine and isoproterenol 
!" orepincphrine infusion Isoproterenol infusion 
nmol/kg/min nmol/kg/min 
Baseline 0.6 1.8 Bas dine 0.16 0.48 
Heart rate., bpm 120 ± 8 127 ± 7 141 ± 5"' 125 ± 6 182 ± 4* 197 ± 7 * 
Systolic arterial pressure, 
103 ± 4 121 ± 4* 137 ± 5"' 97 ± 5 106 ± s * 112 ± 5 * 
mmHg 
Diastolic arterial 
pressure. mmHg 
72 ± 5 85 ± 4* 93 ± 5"' 66 ± 5 58± 3* 54± 4* 
LV dP/dtm."'.mmHg/s 1734±175 2991 ± 202 * 4832 ± 37i * 1621 ± 325 3810 ± 355"' 5327 ± 550 * 
LAD flow, mL/min 21 ± 3 25 ± 3* 28 ± 3* 20 ± 3 29 ± 3* 29 ± 4* 
Cardiac output. L/min 2.3 ± 0.1 2.6 ± 0.2 2.9 ± 0.3 * 2.2 ± 0.2 2.8 ± 0.2 3.3 ± 0.3* 
Values are mean±SEM. * P < 0.05 vs. Baseline 
Tyramine infUsion: 
Tyramine, like norepinephrine, is taken up by neurons through U1 and it 
subsequently displaces norepinephrine from the nerve terminals because of its 
higher affinity for the neuronal storage proteins than norepinephrine.15 
Consequently, the degree of attenuation of tyramine-induced norepinephrine 
release is a measure of the degree of U1-blockade. Without U1-blockade, 
infusion of tyramine in the LAD caused a 15-fold rise in N~in the LAD-
region, accompanied by a similar increase of the norepinephrine concentration 
in the coronary vein (Figure 5). Under U1-blockade, this response was almost 
completely abolished; indicating that with the dose of DMI used the blockade 
of U1 was virtually complete. 
Tyramine infusion in the LAD was also associated with a 5-fold 
increase of NEMIF in the LCx region. Because the systemic arterial 
norepinephrine concentration also slightly increased, this increase was most 
likely caused by overflow of tyramine from the coronary into the systemic 
circulation. The hemodynamic response to tyramine was mainly confined to 
the heart, LV dP I dt,,, increased almost three fold to 3933±465 mmHgl s, 
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comparable to the increase as seen during the infusions of norepinephrine and 
isoproterenol. 
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We investigated to what extent the concentration of norepinephrine in the 
myocardial intercellular space relates to its concentration in the arterial and 
coronary venous circulation at baseline and after increments in plasma or 
interstitial norepinephrine concentration induced either by systemic infusions 
of norepinephrine or by an intracoronary infusion of tyramine. In addition, the 
importance of the U1-mechanism for the NEw, concentration was assessed by 
perfusing one of the probes with the U1-inhibitor desipramine and by 
performing studies with isoproterenol, a catecholamine that is not handled by 
Ul. Finally, adaptation of the method introduced by Kopin et al. 11 provided an 
estimate of spillover, uptake and consequently, release of norepinephrine. 
In agreement with the results of other studies using the microdialysis 
technique, steady state NE,.rrF concentrations were observed 120-150 minutes 
after insertion of the probes and start of microdialysis. Basal NEMIF 
concentrations measured in this study were similar to those as reported by 
Akiyama et al. who performed microdialysis in feline hearts?3·24 At baseline, 
NEMIF concentrations in the LCx and LAD region were similar, suggesting no 
important regional differences in myocardial sympathetic activity. In contrast 
to various other microdialysis studies that reported arterial plasma levels at 
baseline to be similar to or even higher than interstitial norepinephrine 
1 el opso6 N"' . . th d thr . ev s; ·- - -'--"!IF concentrations ill e present stu y were ee tlmes 
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higher than arterial plasma concentrations. These results are in keeping with 
estimates made in other studies that report that the concentration of 
norepinephrine at sites of release is about 3 to 5-fold higher than in plasma.27-
29 This concentration gradient is the driving force behind the exchange of 
norepinephrine from the interstitial compartment to the circulation. 
Accordingly, one would expect this gradient to be reflected in somewhat 
higher norepinephrine concentrations in MIF than in the coronary vein. In 
contrast, norepinephrine concentrations in the coronary vein were similar to 
those in MIF, both under baseline conditions and during intracoronary 
infusion of tyramine, which induced a 15-fold increase in the NE'-1IF 
concentration. A possible explanation for this unexpected finding is that the 
norepinephrine concentration that is measured around the membrane of the 
microdialysis probe to some extent underestimated the concentration of 
norepinephrine at sites of release. 
The observed absence of a norepinephrine gradient between the MIF 
and coronary vein does not support previous suggestions of the existence of an 
endothelial barrier for the diffusion of norepinephrine from the interstitial to 
the intra-vascular compartment?·6·9 The presence of such an endothelial 
barrier could provide an explanation for the well-known difference in the 
relation of blood pressure response and plasma norepinephrine concentration 
observed for exogenously administered nor;f.}f'ephrine or for tyramine-
mduced endogenously released norepmephrine. · If an endothelial hamer for 
the diffusion of norepinephrine is present, NR.rrF and the norepinephrine 
concentration in the coronary vein, as a reflection of the norepinephrine 
concentration in the myocardial capillaries, should be different. However, both 
at baseline and during infusion of tyramine through the LAD, NEw, 
concentrations in the LAD region and coronary vein were similar, indicating an 
unhindered exchange of endogenous norepinephrine from the interstitial to the 
vascular compartments. The considerable gradient between norepinephrine 
concentrations in the coronary vein and MIF as seen during systemic infusion 
of norepinephrine was absent under U1-blockade and therefore is attributable 
to U1. Thus, no endothelial barrier to the diffusion of norepinephrine appears 
to be present in the porcine heart. 
Experimental studies and studies in man using labeled infusions of 
norepinephrine have shown that 60 to 80% of arterially delivered 
. hrin . d b th eli 43233 u. unlab 1 d norepmep e 1s remove y e myocar urn. · · smg e e 
norepinephrine in the present study the extraction of norepinephrine ranged 
from 79 to 69% depending on the infused dose (Table 1). Notwithstanding 
this high fractional removal, NEw, remained extremely low as reflected by 
~F/M ratio of about 0.10. This value is close to the MIF/ A ratio of 0.15 
reported for the canine myocardium by Cousineau et al.Z using the capillary-
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intersutmm concentration model developed by Ziegler and Goreski.34 The 
important role of U1 in the removal of norepinephrine from the MIF was 
confirmed by comparing the N~!IF concentrations in the microdialysis probes 
in the LAD region with and without the U1-inhibitor desipramine. Although 
the two probes were placed no more than 1 em apart, no inter-probe 
interference was observed. Basal N~ increased over sLx-fold during U1-
inhibition, while the increase of NEMIF due to infusion of norepinephrine was 
also markedly augmented. Local U1-inhibition in the LAD probe with 
desipramine increased the ili\1JF I M ratio to 0.21 - 0.36. Especially under U1-
blockade, the ili\1JF I M ratio for unlabeled norepinephrine is likely to be 
affected by norepinephrine that is released by or has leaked from the neurons. 
Considering this artifact, our results with DMI are quite comparable to the 
MIF I A ratio under U1-blockade as estimated by Cousineau.2 From the 
differences in ~FIM ratio measured in the probes with and without U1-
inhibition it can be calculated that 67±5% ofN~is removed by U1 (eq. III). 
This value is in close agreement with values reported for the rabbit 29 but lower 
than those observed in the human myocardium.4·35 
As expected, since isoproterenol is not taken up by Ul, similar ISOMIF 
concentrations were measured in the probes with and without the U1-inhibitor 
DMI. The ili\1JF I M ratios for isoproterenol were very similar to the &'v!IF I M 
ratio for norepinephrine during the high infusion rate of norepinephrine and 
local inhibition of Ul by DMI. As isoproterenol is not taken up by U1, the 
difference in removal of norepinephrine and isoproterenol over a certain vascular 
bed has been proposed to be a useful measure for U1 activity.4•36 Although there 
is some debate about the validity of the comparison of the pharmacokinetics of 
isoproterenol and norepinephrine during U1-blockade,237 the present findings 
suggest such an approach will indeed provide a reliable estimation of U1 activity. 
Despite similar extractions of norepinephrine, the extraction of isoproterenol in 
the porcine heart (24%) was considerably higher than that reported for the 
human heart (14%). This difference in extraction suggests that the cardiac extra-
neuronal uptake of norepinephrine is more important in the porcine than in the 
human heart. As proposed by Goldstein et al.4, the proportionate fractional tissue 
removal of norepinephrine by U1 can be calculated by subtracting the percent 
removal of isoproterenol from the percent removal of norepinephrine and 
dividing this by the percent removal of norepinephrine. Applying this equation in 
the present study, it appears that about 66% of norepinephrine in the porcine 
myocardium is removed by Ul. Although considerably lower than the value 
reported for the human heart (82%), this value agrees well with the proportionate 
fractional tissue removal of norepinephrine by U1 derived from the differences 
in the ili\1JF I M ratios with and without local U1 inhibition. 
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Because of the active U1 of norepinephrine in the myocardium, NE,ITF 
during systemic norepinephrine infusions remained relatively low as compared 
to the arterial norepinephrine concentration. This explains why the relationship 
between LV dP I dt,,, and changes in N~F was much steeper than the 
relationship between LV dP I dt=, and the changes in arterial norepinephrine 
concentration. Accordingly, since isoproterenol is not taken up by U1, the 
difference between relationships between LV dP I dt,"' and interstitial or 
arterial isoproterenol concentrations during isoproterenol infusions was less 
distinct. 
Studies performed in humans and dogs have shown that less than 5% 
of norepinephrine that is released in to the myocardial interstitium spills over 
to the circulation.11 In the present study, the calculated proportional spillover 
(about 15%) was considerably higher. As cardiac spillover in our e>.-periments is 
similar to the value measured in dogs, 38 it seems likely that proportional 
spillover was relatively high because the calculated uptake of norepinephrine 
was relatively low. As shown in eq. 1/1, the calculated uptake of norepinephrine 
strongly depends on the ratio of RA and RMIF. Although microdialysis is a more 
direct technique to measure interstitial norepinephrine concentrations than the 
estimates based on the isotope dilution technique, it will only provide 
information about the mean interstitial norepinephrine concentration and not 
about the concentration at sites of release. Because of the downward 
concentration gradient of norepinephrine from the site of entry in the 
interstitial fluid to the sites of uptake, the RMIF based on the mean interstitial 
norepinephrine concentration during systemic infusion of norepinephrine will 
be higher than RMIF at the sites where uptake of norepinephrine takes place. 
Considering eq. 1/1, overestimation of R:\ITF will lead to the underestimation of 
the calculated uptake of norepinephrine. 
In conclusion, microdialysis is a valuable tool for measuring as well as 
modifYing local sympathetic activity. The present in vivo experiments largely 
confirm the information about norepinephrine kinetics obtained by more 
indirect methods. We conclude that U1 as well as extra-neuronal uptake and 
not an endothelial barrier are the principal mechanisms underlying the 
concentration gradient of norepinephrine between the interstitial and intra-
vascular compartments in the porcine heart. 
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Chapter 5 
Epinephrine in the heart 
Introduction - Several studies have suggested that epinephrine au,oments the 
release of norepinephrine from sympathetic nerve terminals through 
stimulation of presynaptic receptors but evidence pertaining to this mechanism 
in the heart is scarce and conflicting. Using the microdialysis technique in the 
porcine heart, we investigated to which extent epinephrine is taken up by and 
released from cardiac sympathetic nerves and whether it can increase 
norepinephrine concentrations in myocardial interstitial fluid (NE,.rrFl under 
basal conditions and during sympathetic activation. 
Methods and Results - Before intracoronary epinephrine infusions, intracoronary 
infusion of tyramine increased NEMIF by 12.8±2.9 nmol/L, while the increase 
in epinephrine concentration in MIF (EPIMIF) was negligible. After infusion of 
epinephrine, however, tyramine induced an increase in EPIMIF of 9.5 nmol/L. 
While 68-78% of epinephrine was extracted over the heart during 
intracoronary epinephrine infusion of 10, 50 and 100 ng- kg-1· min·', the ratio of 
interstitial to arterial epinephrine concentrations was -20%. This ratio 
increased to 29% when neuronal reuptake was inhibited. Despite large 
increments in interstitial and coronary venous epinephrine concentrations, 
NEMIF did not change during the infusion of epinephrine. Finally, left stellate 
ganglion stimulation increased NEMIF from 3.4±0.5 to 8.2±1.5 nmol/L. Again, 
this increase was not enhanced by intracoronary epinephrine infusion. 
Conclusion - The present findings demonstrate that epinephrine is taken up by 
and released from cardiac sympathetic neurons. However, we did not find any 
evidence of a stimulatory effect of epinephrine on norepinephrine release from 
sympathetic nerves in the heart either under basal conditions or during 
sympathetic activation. 
Lameris TW, de Zeeuw S, Duncker DJ, Tietge W, Alberts G, Boomsma 
F, Verdouw PD, van den Meiracker AH. Epinephrine in the heart; uptake 
and release but no facilitation of norepinephrine release. Submitted. 
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Introduction 
Several studies have shown that cardiac epinephrine is released into the 
coronary circulation of the human heart during exercise, at rest with advancing 
age and in conditions like hypertension, heart failure and panic disorders.1·3 In 
accordance with these observations we recently have shown that occlusion of 
the left anterior descending coronary artery (LAD) for 60 minutes in the intact 
porcine heart is associated with a progressive increase of epinephrine 
concentrations (EPI) in the myocardial interstitial fluid (EPIMIF) 4 Whether 
cardiac epinephrine is released from sympathetic nerve terminals after it has 
been taken up from the circulation or whether it is released from extraneuronal 
stores remains uuclear.5·6 
Another point of debate relates to the role of this locally released 
epinephrine. Several in vitro as well as in vivo studies have suggested that 
epinephrine enhances sympathoneural norepinephrine release through 
stimulation of presynaptic ~2-adrenergic receptors located at the sympathetic 
nerve terminals.7.10 This presynaptic facilitation of norepinephrine release by 
epinephrine is essential to the "epinephrine hypothesis", which proposes that 
excessive adrenomedullary activation leads to the development of hypertension 
through increasing sympathoneural norepinephrine release.10 Other studies, 
however, have failed to confirm this mechanism.11.14 
In the present study we have used the microdialysis technique to 
measure interstitial epinephrine and norepinephrine concentrations in the 
intact porcine heart. To unravel the source of cardiac epinephrine, we 
investigated the effect of intracoronary tyramine infusions on interstitial 
epinephrine concentrations before and after loading the heart with epinephrine 
by means of intracoronary epinephrine infusions. As tyramine only displaces 
catecholamines from their storage vesicles in the sympathetic nerve terminals 
after it has been taken up by the neuronal reuptake (01) mechanism,15.1 6 
catecholamiues released by tyramine are exclusively from neuronal origin. In 
addition, we investigated to which extent epinephrine is taken up by and 
released from cardiac sympathetic nerves similarly to what we have shown for 
norepinephrine in a previous study.15 
Finally, as adrenomedullary activation in conditions like hypertension 
and heart failure would contribute to the deterioration of cardiac function 
through increasing sympathoneural norepinephrine release, and evidence 
pertaining to this mechanism in the heart is scarce and conflictiug,10•12 we 
explored whether intracoronary epinephrine infusions can increase myocardial 
interstitial norepinephrine (NEMIF) concentrations under basal conditions and 
during sympathetic activation induced by electrical stimulation of the left 
stellate ganglion. As over 80% of neuronally released norepinephrine is taken 
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up by sympathetic nerves of the porcine heart through the U1-mechanism,15 
the U1-inhibitor desipramine was added to the perfusate of one the 
microdialysis probes to provide local U1-blockade. In addition, we also 
accounted for a possible inhibition of norepinephrine release through 
stimulation of presynaptic 0<2-adrenergic receptors by adding the non-selective 
O<-adrenergic receptor antagonist phentolamine to the perfusate of another 
probe in combination with desipramine. 
Methods 
Anima/care 
All ec<:periments were performed in accordance with the "Guiding Principles 
for Research Involving Animals and Human Beings" as approved by the 
Council of the American Physiological Society and under the regulations of the 
Animal Care Committee of the Erasmus University Rotterdam (The 
Netherlands). 
Surgical procedure 
Crossbred Landrace x Yorkshire pigs of either sex (30-35 kg, n=15) were 
sedated with ketamine (20-25 mg/kg i.m., Apharma BV), anesthetized with 
sodium pentobarbital (20 mg/kg i.v., Apharma BV), intubated and ventilated 
with a mi.'<:ture of o>.-ygen and nitrogen. 
Catheters were positioned in the superior vena cava for infusion of 
sodium pentobarbital (10-15 mg/kgper hour) and physiological saline drip. A 
fluid-filled catheter was placed in the descending aorta for monitoring blood 
pressure and for blood sampling. A micromanometer-tipped catheter (B. Braun 
Medical BV) was inserted via the carotid artery into the left ventricle for 
measurement of left ventricular (LV) pressure and LV dP / dt. After a 
midsternal thoracotomy, an electromagnetic flow probe (Skalar) was placed 
around the ascending aorta and a Doppler flow probe (Triton) was placed on 
the proximal LAD segment, while a cannula (0: 1.3 mm) was inserted into the 
LAD distal to the flow probe for infusion of epinephrine and tyramine (Dept 
of Pharmacy). In animals subjected to sympathetic stimulation, the left stellate 
ganglion was dissected and an electrode was inserted into the ganglion as 
described previously by Gootman et al.17 and connected to a nerve stimulator 
(Grass S9; pulses of 12 V, 10Hz and 5 msec). 
:Microdialysis probes were implanted in LV myocardium: one in the 
region perfused by the left circumflex coronary artery (LCx) and three in the 
area perfused by the LAD. To achieve local U1-inhibition, one of the LAD 
probes was co-perfused with 100 fll\1: desipramine (DMI, Sigma),16 while one 
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LAD probe was co-perfused with DMI and the non-selective a-adrenergic 
receptor blocking agent 100 f.LM phentolamine (PHA, Dept of Pharmacy) to 
block presynaptic a-adrenergic receptor-mediated inhibition of norepinephrine 
release. The microdialysis technique, probe characteristics, probe recovery, 
handling and analysis of the microdialysis and plasma samples, have been 
described previously.15.1 8 
Experimental protocol 
After a 120-min stabilization period, baseline measurements were obtained 
over a 30-min period. Probes were perfused with Ringer's solution (Ba.""<ter) at a 
flow of 2 J.tL/ min; dialysate was collected at 1 0-min intervals, in which period 
blood was collected from the central aorta (Ao) and coronary vein (CV). In 9 
animals, tyramine was infused (26.7 f.l.g" kg·'·min-1) into the LAD before and 30 
minutes after intracoronary epinephrine at infusion rates of 10, 50 and 100 
ng· kg·'· min·', each for 20 min (group I). Finally, in 6 animals the left stellate 
ganglion was stimulated electrically before and during concomitant infusion of 
50- ng kg·'· min"1 epinephrine (group II). 
Data anajysis and calculations 
Dialysate epinephrine and norepinephrine concentrations were corrected for 
probe recovery to yield EPIMJF and NBwF!.l' Lower limits of detection were 
0.2 nmol/L in dialysate and 0.02 nmol/L plasma concentrations.18 Baseline 
values were determined by aver"z,o-ing the three measurements over the 30-min 
period prior to intervention. Epinephrine plasma concentrations in the LAD 
(EPICA) were calculated from epinephrine infusion rate, coronary plasma flow 
and EPIAo· The cardiac extraction of epinephrine (E) was calculated as 
E (%) = t.CA- t.CV ·100% 
t.CA 
(I) 
where t.CA and t.CV are the change from baseline of EPICA and EPicv during 
the intracoronary epinephrine infusions. The ratio of the absolute changes of 
interstitial to the absolute changes of arterial epinephrine concentrations is 
presented as 
t.MIF/t.CA 
where ili\1JF is the change from baseline of the myocardial interstitial fluid 
concentration. 
(II) 
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The percentage of epinephrine that can be recovered from the MIF and that is 
taken up by Ul (FxUl %) can be calculated from the difference between the 
LlMIF I !';.CA ratio with and without Ul-inhibition 
FxUl%= LlMIF/!';.CA DMI-/';.MIF/!';.CA _100% 
LlMIF/!';.CA DMI 
in which &WF I !';.CAmrr is the &WF I !';.CA ratio with Ul-inhibition. 
(III) 
In analogy to Kopin and colleagues 19 who used radiolabeled material 
to estimate neuronal release, we replaced the specific activity of radiolabeled 
catecholamines with the relative changes from baseline of epinephrine 
concentrations in the LAD CRcJ, in the interventricular coronary vein that 
drains the LAD region CRcvl and in MIF (RMIF) during intracoronary 
epinephrine infusions, similar to what we have shown for norepinephrine.". 
The use of these relative changes is based on the assumptions that baseline 
epinephrine concentrations reflect endogenous epinephrine, and that the 
change in epinephrine release is negligible compared to the change in 
epinephrine concentrations produced by infusion of epinephrine. Accordingly, 
spillover (SO) can be calculated as 
SO= Q · EPICA · (1- E)· [ ( ~:: )-1] (IV) 
where Q is the coronary plasma flow that is calculated from LAD flow and the 
hematocrit which was estimated using the plasma hemoglobin concentration. 
The uptake of released epinephrine (Ur) from the interstitium can then be 
estimated using RMIF· 
(V) 
The sum of equations IV and V provides an estimation of the neuronal release 
rate (Rr) 
Rr=SO+Ur (VI) 
Subsequently, the ratio of uptake of released epinephrine and neuronal release 
rate can be used as a measure for the efficiency of total uptake (Effu%) 
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Ur 
Effu%=-·100% 
Rr 
S tatistica! analysis 
(VII) 
All data are expressed as mean±SEM. For statistical analysis two-way analysis 
of variance, one-way analysis of variance for repeated measures with Dunnet's 
multiple comparison test as post-hoc test, Student's t test and linear regression 
analysis were used as appropriate. 
Results 
Intracoronary epinephrine infusion and tyramine-induced epinephrine and norepinephrine 
release 
lntracoronary infusion of tyramine caused increases in mean arterial pressure 
(J'v:[AP, 20%), heart rate (HR, 20%), LV dP/dt,,, (190%), LAD flow (40%) and 
NEMIF.LAD (12.8±2.9 nmol/L, P < 0.05). These responses were not affected by 
a preceding intracoronary epinephrine infusion (Figure 1, Table 1). In contrast, 
the change in EPIMIF.LAD during tyramine infusion was negligible before, but 
increased markedly after intracoronary infusion of epinephrine (9 .5±3.0 
nmol/L, P < 0.05). This was also reflected by the tyramine-induced increase in 
EPicv from 0.09±0.01 nmol/L before to 8.1±2.7 nmol/L after epinephrine 
infusion (P < 0.05). 
~--ns---
~--*--~ 
* 
before after 
epinephrine infusion 
Figure 1. Effect of intracoronary 
tyramine infusion on the concentrations 
of norepinephrine (NE) and epinephrine 
(EPI) in MIF before and after an 
intracoronary infusion of epinephrine. 
Data are mean ± SEM, n=9. * P<O.OS, 
*** P<0.001 
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Table 1. Cardiovascular function during intracoronary infusion of tyramine before 
and after intracoronary infusion of epinephrine 
EPI Baseline Tyramine 
~can arterial pressure, mmHg before 90 ±I 109 ± 4* 
aftcr 78 ± 3t 97 ± 4*t 
Cardiac output, L/min before 2.7 ± 0.3 3.2 ± 0.4* 
aftcr 2.5 ± 0.2 3.2±0.1* 
Heart rate, bpm before 128 ± 7 152 ± 9 * 
aftcr 128 ± 8 143 ± 9 * 
Systemicvasrularresisunre, mmHg.min ·1.L before 36 ± 4 37 ± 4 
after 32 ± 3 30 ± Zt 
Stroke volume, mL before 22 ± 2 21 ± 2 
aftcr 20 ± 2 24 ± 2 
LV dP/dtm:..x,mmHg/s before 1683 ± 89 4819 ± 433 * 
aftcr 1558 ± 213 4106 ± 333 *t 
LV end diastolicpressure, mmHg before 6 ± 1 6±3 
aftcr 7 ±I 7±2 
lAD flow, mL/min before 24 ± 2 34 ± 3 * 
after 24 ± 3 33 ± 4* 
EPI: three consecutive intracorona ry infusions of epinephrine, each for 20 minutes 
(10, 50 and 100 ng kg-1-min-1). The intracorona.ry infusion of tyramine was started 
30 minutes after the epinephrine infusions were discontinued. Values are 
mean±SEM, n=9. * P < 0.05 vs. Baseline; t P < 0.05 vs. before EPI 
Effect of intracoronary epinephrine infusions on norepinephrine and epinephrine 
concentrations 
The intracoronary epinephrine infusions caused dose-dependent increases in 
LV dP I dt;,,, (130%), HR (15%) and cardiac output (CO, 20%), while MAP (-
15%), systemic vascular resistance (SVR, -30%) and left ventricular end 
diastolic pressure (-20%) decreased (Table 2). In contrast, LAD flow increased 
45%, independent of the infused dose. 
Intracoronary infusion of epinephrine caused dose-dependent increases 
in EPicv from 0.16±0.08 nmol/L at baseline up to 228±39 nmol/L during 
infusion of 100 ng· kg-1-min-\ and EPI,IIF.LAD from 0.31±0.05 nmol/L up to 
140±30 nmol/L (Figure 2). U1-inhibition did not affect EPIMIF.LAD at baseline 
and the lowest infusion rate, but caused an increase in EPIMIF .LAD to similar 
values as EPicv at the two higher infusion rates (32-38%, P<0.001). Although 
the cardiac epinephrine extraction was 68 to 78%, there was a marked gradient 
between interstitial and circulatory concentrations. During the intracoronary 
epinephrine infusions, the &\1IF I LlCA ratio for epinephrine (equation II, 
Table 2) was 27±4%, 19±3% and 21±3% in the absence of U1-blockade, but 
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increased to 29±3% in the presence of U1-blockade, irrespective of the 
epinephrine infusion rate. 
Table 2. Cardiovascular Function during Intracoronary Epinephrine Infusion 
Baseline 
10 50 !00 
Mean arterial pressure, mmHg 89 ± 4 85 ± 4 77 ± 4* 76 ± 3 * 
Cardiac output, L/min 2.6 ± 0.2 2.8 ± 0.2 2.8 ± 0.2 3.1 ± 0.3* 
Heart rate, bpm 125 ± 7 130 ± 6 137 ± 6* 144 ± 7 * 
Systemicvasrularresistana; mmHg.min ·1.L 37 ± 4 32 ± 3* 29 ± 3* 26 ± 2* 
Stroke volume. mL 21 ± 3 22 ± 2 20 ± 3 27 ± 5 
LV dP/dtmao;, mmHg/s 1604 ± 136 2483 ± 191 * 3068 ± 222 * 3716 ± 186 * 
LV End Diastolic Pressure, mmHg 7±2 6±2 6 ± 2* 6 ± 2* 
lAD Flow, mL/ min 29 ± 4 41 ± 4* 41 ± 4* 43 ± 4* 
Values are mean±SEM, n=9. * P < 0.05 vs. Baseline 
Despite the large increments in circulatory and interstitial epinephrine 
concentrations, the pharmacokinetic parameters for epinephrine as spillover, 
rate of uptake, rate of neuronal release as well as the efficiency of uptake 
remained unchanged (Table 3). Notwithstanding the aforementioned large 
increments in EPicv and EPIMIF.LAD. norepinephrine concentrations in MIF, 
coronary vein and aortic plasma did not change (Figure 2). 
Table 3. Spillover, Uptake and Release of Epinephrine Compared to Norepinephrine 
Epinephrine (ng-kg.1·min.1) Norepinephrine (ng-kg -l·min"1) 
10 50 100 110 330 
ili\IIF/M,% 27 ± 4 19 ± 3 21 ± 3 10 ± 1 11 ±I 
ili\1IFnMIIM, % 29 ± 4 29 ± 3t 31 ± 3t 21 ± 3t 36 ± 5*t 
FxUl,% 17 ± 5 37 ± 6 * 33 ± 7* 51± 7 67 ± 5 
Extraction, % 78 ± 3 74 ± 5 68 ± 5* 79 ± 4 69 ± 3 
SO, pmol/min 2.4 ± 1.3 2.8 ± 1.4 3.7 ± 2.2 35 ± 6 39 ± 5 
Ur, pmol/min 46 ± 10 51± 14 36 ± 9 194 ± 33 204 ± 51 
Rr, pmol/min 49 ±II 54± 14 40 ± 10 229 ± 37 243 ±53 
EffU,% 95 ± 3 96 ± 2 94 ± 3 84 ± 2 79 ± 2 
Epinephrine values are derived from data during intracoronary infusions of epinephrine 
in the present study. )Jorepinephrine values are derived from historic data during 
systemic intravenous infusions of norepinephrine. 15 Abbreviations are explained in the 
text. Values are mean±SEM. * P < 0.05 vs. lowest dose, t P < 0.05 vs. without DMJ. 
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Figure 2. Effect ofintr:acoronary infusion of epinephrine (ngkg-!.min-1) on epinephrine (left 
panel) and norepinephrine (right panel) concentrations. Data are shown for EPIMIF.LAD 
(transparent) EPhiTF.LAD + DMI (light gray), EPicv(dark gray), EPICA (black bars), NEMIF.LAD 
(•), NE>IIF.LAD + DMI (o), NEMIF.LAD + DMI + PHA (A), NE>IIF.ccx (x), :\iEAo (solid bars) 
and NEcv (hatched bars). Data are mean± SEM, n=9. 
Intracoronary epinephrine irifusion and norepinephrine release during sympathetic activation 
Left stellate ganglion stimulation caused increases in MAP (21 %), LAD flow 
(36%) and in particular LV dP / dt,~, (184%, Table 4 and Figure 3) and caused a 
rise in NE"'F' particularly in the presence of U1- and ()(-adrenergic receptor 
blockade where NEMIF.LAD increased from 3.4±0.5 to 8.2±1.5 nmol/L (Figure 
3). Although intracoronary infusion of epinephrine decreased MAP (-25%) and 
SVR (-27%) and increased HR (22%), LV dP/d~, (93%) and LAD flow 
(32%),it did not alter the hemodynamic responses to stimulation. 
~ 
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Figure 3. Effect of intracoronary epinephrine infusion on LV dP / dt =' (left panel) and 
NEMIF.LAD + DMI + PHA (right panel) during left stellate ganglion srimnlation (LSG). EPI: 
.intracoronary infusion of 50 ng- kg-1• min·1epinephrine. Data are mean ± SEM, n=6. 
* p < 0.05; ** p < 0.01; *** p < 0.001. 
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Similarly, concomitant epinephrine infusion did not enhance the 
norepinephrine release upon stimulation of the left stellate ganglion (from 
2.6±0.3 to 6.9±1.5 nmol/L, Figure 3). In addition, stimulation did not increase 
EPI'-~~F.LAD (58±8 vs. 58±5 nmol/L), while EPicv even decreased (201 ±16 vs. 
158±6 nmol/L, P < 0.05). 
TABLE 4. Cardiovascular Function during Stellate Ganglion Stimulation before ( -) 
and dw:ing ( +) Intracoronaxy Infusion of Epinephrine 
EPI Baseline I.SG stimulation 
~ean arterial pressure, mmHg 87 ± 3 105 ± 5 * 
+ 67 ±II t 84±8*t 
Cardiac output, L/ min 2.6 ± 0.2 2.7 ± 0.3 
+ 2.8 ± 0.5 3.2 ± 0.5 
Heart rate, bpm 108 ± 6 115 ± 7 
+ 132 ± 4t 137 ± 5 t 
Systemicvasrula.r resistance, mmHg.min -1.L 34 ± 3 41 ± 4 
+ 25 ± Zt 28 ± 3t 
Stroke volume, mL 25 ± 1 24 ±I 
+ 22 ± 4 24 ± 4 
LV dP/dtm=•mmHg/s 1485 ± 36 4220 ± 374"' 
+ 2864 ± 507 t 5596 ± 980 *t 
LV end diastolic pressure, mmHg 12 ± 2 10 ± 2 
+ 8 ± 3 7 ± 3 
LAD flow, mL/ min 28 ± 5 38 ± 5 * 
+ 37 ± 3t 42 ± 8 
EPI: intracoronaxy infusion of epinephrine (SO ng- kg-Lmin-1). LSG: left stellate 
ganglion. Values are mean±SEM, n=6. * P < 0.05 vs. Baseline, t P < 0.05 vs. EPI-
Discussion 
This study shows that epinephrine is taken up from the circulation by the heart 
and that it can be released during infusion of tyramine after the heart has been 
loaded with epinephrine by means of intracoronary epinephrine infusions, 
indicating that cardiac epinephrine is stored in and released from sympathetic 
nerve terminals. Our results do not support the concept that myocardial 
norepinephrine release is facilitated by epinephrine either under basal 
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conditions or during activation of cardiac sympathetic tone induced by left 
stellate ganglion stimulation. 
Intracoronary epinephrine infusion and tyramine-induced epinephrine release 
As tyramine only displaces catecholamines from their storage vesicles in the 
sympathetic nerve terminals after it has been taken up by the neuronal 
reuptake (Ul) mechanism, 15·" catecholamines released by tyramine are 
exclusively from neuronal origin. Under basal conditions, the tyramine-induced 
epinephrine release was negligible, which is in agreement ·"1ith earlier results in 
the intact rabbit heart,20 and likely reflects the low intra-neuronal epinephrine 
content (1-2% of cardiac norepinephrine concentrations).21 After loading the 
heart with epinephrine by means of an intracoronary epinephrine infusion, 
tyramine caused substantial increases in EPIMJF and EPicv, which were 
comparable to the increases in NEMIF and NEcv. These findings unequivocally 
demonstrate that in the porcine heart epinephrine can be taken up from the 
circulation by and released from the sympathetic nerve terminals. This is in 
agreement with a previous study, in which we showed that myocardial ischemia 
caused cardiac epinephrine release and that this release is modulated by the 
Ul-mechanism as inhibition of Ul by DMI attenuated epinephrine release by 
more than 50%.4 In addition, the similar coronary venous and interstitial 
epinephrine concentrations during infusion of tyramine indicate an unhindered 
exchange of neuronally released epinephrine from the interstitial to the 
vascular compartments. 
Effect of intracoronary epinephrine infusions on epinephrine and norepinephrine 
concentrations 
Epinephrine concentrations. Experimental and human studies have reported that 
the extraction of arterially delivered epinephrine by the myocardium during a 
single pass (about 50%) is considerably lower than the cardiac extraction of 
norepinephrine (70-85 %)Y.15.22-ZS Because Ul is the major determinant of the 
cardiac clearance of catecholamines and the affinity of epinephrine for the Ul 
mechanism is lower than that of norepinephrine in the rabbit, 23 it is seems 
likely that the difference in extraction originates from this difference in affinity 
for Ul. This is also demonstrated by the effect of Ul-inhibition on 
ili\1JF / t.CA; depending on the infusion rate, only 17 to 37% of infused 
epinephrine is cleared by Ul, while we have previously shown that in the same 
e":perimental model Ul clears 51 to 67% of arterially delivered 
norepinephrine.15 
The gradient between coronary venous and interstitial epinephrine 
concentrations during intracoronary infusion of epinephrine decreased 
significantly under Ul-blockade and can therefore be attributed to Ul. 
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Together with the unhindered exchange of neuronally released epinephrine 
during intracoronary infusion of tyramine, these results indicate that no 
endothelial barrier to the diffusion of epinephrine is present in the porcine 
heart. 
Notwithstanding the relatively low clearance of epinephrine by U1, the 
70% cardiac epinephrine extraction was still considerably higher than the 50% 
reported for the human heart, 24 suggesting the presence of a more active extra-
neuronal clearance mechanism for epinephrine in the porcine heart, as was also 
reported for norepinephrine.15 The modest epinephrine spillover rate of 3.0 
pmol/ min is in close agreement with that estimated for the human heart and is 
about 10 times lower than the spillover rate of norepinephrine.1.3.23.24 Although 
the spillover rate of epinephrine is low, it should be kept in mind that the rate 
of neuronal release of epinephrine is more than ten times higher, since about 
9 5% of released epinephrine is already cleared by U1 and extra-neuronal 
uptake mechanisms before it reaches the circulation. 
Norepinephrine concentrations. Although intracoronary epinephrine infusions 
caused a 450-fold increase in EPI"lF,LAD and a 1400-fold increase in EPicv, we 
did not detect any changes in NE,F.LW or NEcv. Even under U1-inhibition 
and IX-adrenergic receptor-blockade to prevent respectively rapid clearance and 
presynaptic IX2-adrenergic receptor-mediated inhibition of norepinephrine 
release by epinephrine or norepinephrine itself, N~.LW did not increase 
during intracoronary infusion of epinephrine. These findings indicate that the 
potential facilitating effect of epinephrine on norepinephrine release was not 
masked by rapid clearance by U1 and local sympathoneural inhibition. Our 
findings agree with studies that also failed to demonstrate enhanced 
norepinephrine release by epinephrine in the human forearm1\ rabbit aorta,13 
rat mesentery, 14 and in particular with Thompson et al.12 who demonstrated 
that epinephrine did not increase norepinephrine spillover in the human heart. 
Conversely, other studies did show au,omentation of pressor responses,7"9 
increased plasma norepinephrine concentrations 26 and forearm norepinephrine 
spillover in humans,827 as well as increased norepinephrine outflow in rat 
atria.10 One may wonder whether the facilitation of norepinephrine release by 
epinephrine was obscured by an increase in norepinephrine clearance as a 
result of the epinephrine-induced increase in LAD flow. Indeed, LAD flow 
increased by 45% during the lowest dose of the intracoronary epinephrine 
infusion, which might explain the decrease in N~.LW in the presence of IX2-
adrenergic receptor blockade and U1-inhibition (Figure 2). However, there 
were no further changes in LAD flow and N~.LW when epinephrine 
infusion rate was further increased 5- to 10-fold (Table 1 a..ld Figure 2). 
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Intracoronary epinephrine infusion and norepinephrine release during sympathetic stimulation 
It could be argued that in anesthetized animals, facilitation of norepinephrine 
release by epinephrine is difficult to demonstrate because of the low basal 
norepinephrine concentrations as compared to awake swine.28 Hence, we 
investigated the effects of epinephrine on norepinephrine release during 
sympathetic activation, which was induced by electrical stimulation of the left 
stellate ganglion. Left stellate ganglion stimulation resulted in a marked increase 
in LV dP I dt," LAD flow and MAP. Although LV dP I dt,, was increased by 
epinephrine prior to stimulation, the hemodynamic response was not enhanced 
by an intra-coronary infusion of epinephrine (Table 3 and Figure 3). During 
stimulation of the left stellate ganglion NEMIF increased up to five-fold. The 
absolute increase in NEMIF.LAD was the most substantial in the presence of Ul-
and a-adrenergic receptor blockade, underscoring the importance of the a2-
adrenergic receptor-mediated feedback mechanism that inhibits neuronal 
release of norepinephrine. Similar to the hemodynamic response, concomitant 
infusion of epinephrine did not augment the response of norepinephrine to left 
stellate ganglion stimulation, irrespective of the presence of U1- and a-
adrenergic receptor blockade (Figure 3). 
Conclusions 
In summary, the present study shows that epinephrine is taken up by and 
released from cardiac sympathetic nerves. However, our findings in the porcine 
heart do not support the concept that myocardial norepinephrine release is 
facilitated by epinephrine either under basal conditions or during activation of 
cardiac sympathetic tone induced by left stellate ganglion stimulation. Hence, 
we hypothesize that the uptake of epinephrine by the heart is principally a 
mechanism for rapid clearance of circulatory epinephrine, and that the small 
amount of locally released epinephrine does not modulate left ventricular 
function. 
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Chapter 6 
Angiotensin II does not facilitate basal or 
stimulated norepinephrine release in the 
porcine heart. 
Background - Studies on the effect of angiotensin II on norepinephrine release 
from sympathetic nerve terminals through stimulation of presynaptic 
angiotensin II type 1-receptors are equivocal. Furthermore, evidence that 
angiotensin II activates the cardiac sympathetic nervous system in vivo is 
scarce or indirect. We investigated whether Angii increases myocardial 
interstitial norepinephrine concentrations (NE;.up) under basal conditions and 
during sympathetic activation, and whether it enhances exocytotic and 
nonexocytotic ischemia-induced norepinephrine release. 
Methods and &suits - In 27 anesthetized pigs, NEMIF was measured in the 
perfusion areas of the left anterior descending coronary artery (LAD). Local 
infusion of angiotensin II into the LAD at consecutive rates of 0.05, 0.5 and 5 
ng· kg·'· min.\ respectively did not affect NEMIF' LAD flow, LV dP / dt,~, and 
arterial pressure despite large increments in coronary arterial and venous 
angiotensin II concentrations. In the presence of uptake-1 inhibition and ()(-
adrenergic receptor blockade, left stellate ganglion stimulation increased NEMIF 
from 2.7±0.3 to 7.3±1.2 before and from 2.3±0.4 to 6.9±1.3 nmol/L during 
infusion of 0.5 ng· kg·'· min·' angiotensin II. 60 min of 70% LAD flow 
reduction caused a progressive increase in NEMIF from 0.9±0.1 to 16±6 
nmol/L, which was not enhanced by concomitant infusion of 0.5 ng· kg·'· min·' 
angiotensin II. 
Conclusions - In conclusion, we did not observe any facilitation of cardiac 
norepinephrine release by angiotensin II under basal conditions and during 
either physiological (ganglion stimulation) or pathophysiological (acute 
ischemia) sympathetic activation. Hence, angiotensin II is not a local mediator 
of cardiac sympathetic activity in the in vivo porcine heart. 
Lameris TW, de Zeeuw S, Duncker DJ, Alberts G, Boomsma F, 
V erdouw PD, van den Meiracker. Angiotensin II does not facilitate basal or 
stimulated norepinephrine release in the porcine heart. Submitted. 
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Introduction 
Activation of the sympathetic nervous system (SNS) simultaneously leads to 
activation of the renin-angiotensin-system (RAS) via stimulation of !3-
adrenergic receptors within the kidney resulting in an increased renin release. 
There is also, albeit conflicting, evidence that the SNS is activated by the 
RAS.1·13 This activation supposedly occurs through stimulation of angiotensin 
II receptors within the central nervous system and/ or stimulation of 
presynaptic angiotensin II receptors located at sympathetic nerve terminals. 
When inves~o-ating the SNS and its interaction with the RAS, the heart is of 
particular interest. First of all, the mammalian heart has a dense sympathetic 
innervation. Second, all components of the RAS are present in the heart and 
most angiotensin II in the heart is formed from locally synthesized angiotensin 
!.14 Third, in conditions like hypertension, ischemia and especially heart failure, 
the RAS and SNS are both activated and this activation likely contributes to 
the deterioration of cardiac function."·" 
Evidence that angiotensin II activates the cardiac SNS in vivo is scarce 4 
or indirect.'·" In a recent study, Teisman et al! have shown with the use of the 
microdialysis technique that pharmacological (fiM) concentrations of locally 
applied angiotensin II were associated with an increase in norepinephrine 
concentrations (NE) in the myocardial interstitial fluid (NE,nF) of the in vivo rat 
heart. In the present study, we determined whether physiological (pM) to 
pathophysiological (nM) concentrations of angiotensin II modulate NE,nF in 
the porcine heart, in which contrary to the rat heart the parasympathetic 
system is dominant over the sympathetic system and in this respect is more 
akin to the human heart. To exclude a masking effect of neuronal 
norepinephrine reuptake (uptake-1, Ul) and negative feedback through 
presynaptic a-adrenergic receptor stimulation on modulation of NB:.rrF by 
angiotensin II, we co-perfused some probes with the Ul-inhibitor desipramine 
(DMI) and the a-adrenergic receptor antagonist phentolamine (PHA), without 
provoking systemic hemodynamic effects that also may modulate 
norepinephrine release."·" 
In those studies that demonstrated interaction between angiotensin II 
and the SNS, most evidence points towards direct facilitation mediated by 
presynaptic angiotensin II type 1 (AT1) receptors resulting in either a 'classic' 
calcium-dependent augmentation of exocytotic norepinephrine release,'·' or in 
enhanced nonexocytotic release via activation of the Na" /H+ exchanger.2223 
Therefore, we not only investigated the modulation of NEMIF by angiotensin II 
under basal conditions but also during enhanced exocytotic norepinephrine 
release evoked by stimulation of the left stellate ganglion. In addition, we 
monitored norepinephrine release in MJF during reduction of left anterior 
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descending coronary artery (LAD) flow, resulting in both exocytotic and 
nonexocytotic norepinephrine release,20 while still allowing for intracoronary 
infusion of angiotensin II. 
Methods 
Animal care 
All <=-'-l'eriments were performed in accordance with the "Guiding Principles 
for Research Involving Animals and Human Beings" as approved by the 
Council of the American Physiological Society and under the regulations of the 
Animal Care Committee of the Erasmus University Rotterdam. 
Surgical procedure 
Twenty-seven crossbred Landrace x Yorkshire pigs of either sex (30-35 kg) 
were sedated with ketamine (20-25 mg/kg i.m., Apharma BV), anesthetized 
with sodium pentobarbital (20 mg/kg i.v., Apharma BV), intubated and 
ventilated with a mL'<ture of m:ygen and nitrogen.1920 
Catheters were positioned in the superior vena cava for infusion of 
sodium pentobarbital (10-15 mg/kg per hour) and physiological saline drip. A 
fluid-filled catheter was placed in the descending aorta for monitoring blood 
pressure and for blood sampling. A micromanometer-tipped catheter (B. Braun 
Medical BV) was inserted into the left ventricle for measurement of left 
ventricular (LV) pressure and LV dP/dt.19 .20 After midsternal thoracotomy, an 
electromagnetic flow probe (Skalar) was placed around the ascending aorta and 
a Doppler flow probe (Triton) was placed on the proximal LAD segment, 
while a cannula (0: 1.3 mm) was inserted distal to this site into the LAD for 
infusion of angiotensin II. In animals subjected to LAD flow reduction, a 
fluid-filled balloon occluder (In Vivo Metric) was placed around the LAD 
distal to tbe Doppler flow probe and attached to a bi-directional roller pump 
(Ismatec). The voltage output from the Doppler equipment was directed 
through a custom-built electrical circuit, which steered the roller pump to 
maintain coronary flow at 30% of baseline values. In animals subjected to 
sympathetic stimulation, the left stellate ganglion was dissected and an 
electrode was inserted into the ganglion as described by Gootruan et al.,24 and 
connected to a nerve stimulator (Grass S9; pulses of 12 V, 10Hz and 5 msec). 
Microdialysis probes were implanted in the LV myocardium: one in the 
region perfused by the left circumflex coronary artery (LCx) and three in the 
area perfused by tbe LAD. To achieve local U1-inhibition, one of the LAD 
probes was co-perfused with DMI (100 fh\1, Sigma),21 while another LAD 
probe was co-perfused with DMI and PHA (100 f.ll\1, Dept of Pharmacy) to 
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block presynaptic e<-aclrenergic receptor-mediated inhibition of norepinephrine 
release. The microdialysis technique, probe characteristics, handling of the 
microdialysis and plasma samples for the measurement of norepinephrine 
concentrations, and probe recovery have been described previously.1925 Plasma 
samples for determination of angiotensin II concentrations (Angii) were 
rapidly drawn into chilled plastic syringes containing an "inhibitor mix".14 
Experimental protocol 
After a 120-min stabilization period, baseline measurements were obtained 
over a 30-min period. Probes were perfused with Ringer's solution (Baxter) at a 
flow of 2 f-LL/ min; dialysate was collected at 1 0-min intervals, in which period 
blood was collected from the aorta (Ao) and coronary vein (CV).1920 In group I 
(n=7), the effects of angiotensin II on basal sympathetic norepinephrine 
release were investigated by infusing angiotensin II (Dept of Pharmacy) into 
the LAD at consecutive infusion rates of 0.05, 0.5 and 5 ng- kg·'· min·' for 20 
min each. In group II (n=7), we assessed the effects of angiotensin II on 
enhanced exocytotic norepinephrine release by stimulating the left stellate 
ganglion prior to and during infusion of angiotensin II. To investigate the 
effect of angiotensin II on nonexocytotic norepinephrine release the LAD flow 
was reduced by 70% for 60 min without (group III, n=6) and during 
simultaneous infusion of angiotensin II into the LAD (group IV, n=7). 
Following 120 min of reperfusion, the LAD perfusion area (area at risk) and 
infarct size were determined.20 
Analytical procedures 
Norepinephrine concentrations in plasma and microdialysis samples were 
determined by HPLC with fluorimetric detection.25 Plasma angiotensin II 
concentrations were determined with HPLC after Sep-Pak extraction and 
radioimmunoassay.14 
Data analysis and statistics 
Dialysate norepinephrine concentrations were corrected for probe recovery to 
yield N~.1920 Lower limits of detection in dialysate and plasma were 0.2 and 
0.02 nmol/L, respectively.25 Baseline values were determined by averaging the 
three measurements over the 30-min period prior to intervention.19•20 
angiotensin II plasma concentrations in the LAD (AngiiwJ were calculated 
from angiotensin II infusion rate, coronary plasma flow and arterial 
angiotensin II concentrations. Results are expressed as mean ± SEM. For 
statistical analysis two-way analysis of variance, one-way analysis of variance 
for repeated measures with Dunnet's multiple comparison test as post-hoc test, 
and Student's t test were used as appropriate. 
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Results 
Table 1. Cardiovascular function during intracoronary infusion of angiotensin II. 
Baseline Angiotensin II, ng·lq(·min ~ 1 
0~05 0.5 5 
Mean arterial pressure, mmHg 83 ± 2 so ± 5 83 ± 3 85 ± 3 
Cardiac output, L/min 2.4 ± 0.1 2.2 ± 0.1 2.4 ± 0.1 2.3 ± 0.1 
Heart rate, bpm 134 ± 5 135 ± 6 135 ± 6 134 ± 6 
LV dP/dt=x.mmHg/s 1552 ± 76 1472 ± 111 1547 ± 87 1551 ± 87 
LV end diastolic pressure, mmHg 12 ± 1 11 ± 1 11 ± 1 12 ± 1 
LAD flow, mL/min 32 ± 5 31 ± 4 30 ± 3 28 ± 3 
Values are mean±SEM. n=7 
Intracoronary angiotensin II infusion and basal norepinephrine concentrations (Group I) 
Although angiotensin II caused a dose-dependent increase in angiotensin II 
concentrations in the coronary vein (Angiicv) from 13±2 pmol/L at baseline 
up to 4150±329 pmol/L during infusion of 5 ng· kg~t. min-1 (Figure 1) while 
angiotensin II in aortic plasma increased from 12±2 to 80±9 pmol/L, there 
were no significant changes in either hemodynamics (Table 1) or 
norepinephrine concentrations in MIF, coronary vein and aortic plasma (Table 
2 and Figure 1). 
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Figure 1. Effect of intracoronary Angll infusion ( ng- kg-1. min·1) on plasma Angii 
concentrations (left panel) in the interventricular coronary vein (hatched bars) and LAD (solid 
bars), and basal cardiac sympathetic tone (right panel); NE MIF.LAD (•), NE,aF.LAD + D:\11 (o), 
NE>tiF.LAD + DMI + PHA (A), NE,aF.LC" (x), NEAo (solid bars) and NEcv (hatched bars). Data 
are mean± SEM> n=7. 
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Table 2. Effect of intracoronaxy Angii infusion on circulatory and interstitial NE 
concentrations. 
Arterial Phsma CoronatyVcin MIF Lt\D MIF LC." 
Group I (n= 1) 
Baseline 
Angii 0.05 
Angii 0.5 
Angii 5 
Group II (n= 1) 
nmol/L 
0.4 ± 0.2 
0.5 ± 0.1 
0.4 ± 0.2 
0.3 ± 0.1 
Baseline 0.1 ± 0.0 
I.SG stim uhtion 1.0 ± 0.1 * 
Ang II 0.5 0.1 ± 0.0 
I.SGsrim+AngliO.S 1.3 ± 0.1* 
Group m (n=6) 
Baseline 
Ischemia 
Reperfusion 
Group IV (n=1) 
B;c;eline 
Ischemia+ Ang II 0.5 
Reperfusion 
0.2 ± 0.1 
0.2 ± 0.0 
0.4 ± 0.2 
0.1 ± 0.1 
0.2 ± 0.1 
0.4 :: 0.2 
control D:MJ D:MI + PHA 
nmol/L 
0.4 ± 0.1 
0.3 ± 0.1 
0.4 ± 0.1 
0.3 ± 0.1 
nmol/L 
0.6 ± 0.1 
0.6 ± 0.1 
0.5 ± 0.1 
0.6 ± 0.2 
nmol/L 
1.4 ± 0.2 tt§ 
1.3 ± 0.2 tj:§ 
L2 ± 0.2tt§ 
1.3 ± 0.2t!:§ 
0.2 ± 0.1 0.5 ± 0.1tl: 1.7 ± 0.4t:J:§ 
1.7 ± 0.7* 1.3 ± 0.2"' 3.1 ± 0.6*t§ 
0.3 ± 0.1 0.7 ± 0.1 tl: 1.6:: 0.2tl:§ 
1.7 ± 0.6 * 0.9 ± 0.1 t 2.8 ± 0.6t§ 
0.3 = 0.1 
1.4 ± 0.6 
0.4 ± 0.1 
0.2 ± 0.3 
0.9 ± 0.2 
0.3 ± 0.1 
0.9 ± 0.1 ii 4.4 ± O.Stt§ 
16.2 ± 5.7t:j:* 12.3 ± 4.0ii"' 
0.5 ± 0.1 * 1.4 ± 0.2*t+§ 
0.9 ± 0.3t:j: 5.2 ± 0.6tj:§ 
10.9 ± 3.Stt* 11.2 ± 3.5t:j:* 
1.0 ± 0.5 1.7 ± 0.3 *tt 
nmol/L 
2.3 ± 0.4t:l:§l' 
2.1 ± 0.2 rt§'.l 
2.1 ± 0.4-ttlll 
2.2 ± O.SJtlll 
nmol/L 
0.5 ± 0.2 
0.4 ± 0.1 
0.6 ± 0.1 
0.6 ± 0.1 
2.7 ± 0.3 t+§ 0.6 = 0.1 t+ 
7.3 ± 1.2 *tJ:§ 1.4 ± 0.5 
2.3 ± 0.4tl:§ 0.5 ± 0.2 t 
6.9 ± 1.3 *tt§ll 1.2 ± 0.6 
5.0 ± 0.7ii§ 
14.3 ± 5.4t:J:* 
2.3 ± 0.4 'ii§ll 
5.8 ± O.itl:§ 
14.1 ± 3.Stt* 
2.2 ± 0.4 *t!:§ll 
O.i±0.2t 
0.5 ± 0.1 t§ 
0.5 ± 0.1 
0.6 ± o.q 
0.6 ± 0.\t§ 
0.7 ± 0.2 
Angii: angiotensin II (ng- kg·'- ntin·1); LSG: left stellate ganglion. Intracoronaxy infusion of 
.A.ngii had no effect on circulatory or interstitial NE in any of the e..'-"Perirnental protocols. 
Values are mean±SEM. * P < 0.05 vs. Baseline; t P < 0.05 vs. Arterial plasma; :j: P < 0.05 vs. 
Coronary vein;§ P < 0.05 vs. MIF LAD (control); II P < 0.05 DMI vs. DMI+PHA. 
Intracoronary angiotensin II infUsion and norepinephrine release during sympathetic 
activation (Group II) 
Stellate ganglion stimulation caused marked increases in blood pressure (19%), 
LAD flow (25%) and in particulru: LV dP/dt,_, (190%, Table 3 and Figure 2), 
and caused a rise in NEw,., particularly in the presence of Uc and IX-adrenergic 
receptor blockade where NE,.m..LAD increased from 2.7±0.4 to 7.3±1.2 nmol/L 
(fable 2 and Figure 2). Concomitant intracoronary infusion of angiotensin II 
did not affect hemodynamic responses to stimulation nor did it modify the 
stimulation-induced increase in NEwF.LAD (from 2.3±0.3 to 6.9±1.3 nmol/L). 
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Figure 2. Effect of angiotensin II on LV dP / dt m•' (left panel) and NEMIF.LAD + desipramine 
+ phentolamine (right panel) during left stellate ganglion (LSG) stimulation. Angii: 
intracoronary infusion of angiotensin II (0.5 ng- kg-1. min·1). Data are mean ± SEM, n=7. 
*** P < 0.001 vs. pre-stimulation values. 
Table 3. Intracoronary Angii infusion and cardiovascular function during 
sympathetic activation. 
Angll Baseline I.SG stimulation 
Mean arterial pressure, mmHg 77 ± 5 95 ± 7* 
+ 75 ± 4 93 ± 6* 
Cardiacoutput, L/min 2.5 ± 0.2 2.8 ± 0.2* 
+ 2.4 ± 0.1 2.7 ± 0.1 * 
Heart rate, bpm 114 ± 4 115 ± 4 
+ 111 ± 5 114 ± 4 
LV dP/dtrrm:<,mmHg/s 1197 ± 103 3445 ± 340 * 
+ 1172 ± 102 3383 ± 233 * 
LV end diastolic pressure, mmHg 11 ± 2 9±2 
+ 11 ± 2 9±2 
LAD flow, mL/min 27 ± 4 36 ± 4* 
+ 27 ± 4 35 ± 4* 
Angii: angiotensin II, 0.5 ng- kg·l.ntin-1; LSG: left stellate ganglion. Values 
are mean±SEM, n=7; * P < 0.05 vs. Baseline. 
Intracoronary angiotensin II infusion and norepinephrine release during ischemia (Groups III 
andJT/) 
Cardiovascular Function. The 70% LAD flow reduction resulted in 10% 
reductions of mean arterial pressure and cardiac output, while LV end-diastolic 
pressure slightly increased (fable 4). Following reperfusion, mean arterial 
pressure and cardiac output remained depressed while LV end-diastolic 
pressure returned to baseline. In addition, heart rate increased and LV dP / d~, 
decreased. 
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Angiotensin II infusion during ischemia did not alter the hemodynamic 
response to ischemia and reperfusion. Because LAD flow was kept at 30% of 
baseline during ischemia any effect of angiotensin II on LAD flow was 
prevented. 
Norepinephrine Concentrations. At baseline NBwF.LAD and NEMIFJL, were similar 
and three times the NEAo (P < 0.05; Table 2). Under U1-blockade with DMI, 
NEMIF.LAD increased approximately five-fold, irrespective of the presence of rx-
adrenergic receptor blockade. NBwF.r.w tripled during the first 20 min of 
ischemia and continued to rise up to 15-fold at 60 minutes of ischemia (Table 
2, Figure 3). Under U1-inhibition, the rate of rise of N~F.LAD was attenuated 
so that from 40 min of ischemia, N~F.LAD in the presence of DMI was similar 
to NEMIF.LAD without DMI. Upon reperfusion N~.LAD' NEMIF.LAD in the 
presence of DMI and NEcv declined rapidly, with the early rate of decline 
being most pronounced for NEMIF.LAD without DMI (Figure 3). 
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Figure 3. Effect of angiotensin IT on the time course of changes in norepinephrine 
concentrations during 70% LAD flow reduction (70% FR) and reperfusion. Data are 
shown for NEMIF.LAD (•), NE;np.un + desipramine (o), NEMIF.LAD + desipramine + 
phentolamine (.II.), NE:-nF.r.c., (x), arterial (solid bars) and coronary venous (hatched 
bars) norepinephrine concentrations. Angii: intracoronary infusion of angiotensin II 
(0.5 ng kg-'· min·'). Data are mean± SEM, n=6 Oeft panel) and n=7 (right panel). 
During ischemia, intracoronary infusion of angiotensin II raised 
AngiiCA from 9±1 to 2323±231 pmol/L while Angiicv increased from 13±3 to 
408±46 pmol/L, indicating that 80±5% of angiotensin II was extracted over 
the coronary bed. However, m:L~um NEMIF.LAD during the 60-min of 
ischemia was not modified by concomitant angiotensin II infusion (Table 2 
and Figure 3). Within 120 min of reperfusion, NEMIF.r.AD and NEcv had 
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returned to baseline and were similar for groups III and IV. NEMIF.I.Cx and 
NEAo remained unchanged during the course of the experiment in both 
groups. 
Table 4. Intracoronary infusion of angiotensin II and cardiovascular function during 
ischemia. 
Baseline Ischemia Reperfusion 
An gil 
60 min 120 min 
Mean arterial pressure, mmHg 95 ± 2 89 ± 1 85 ± 3 * 
+ 93 ± 3 86 ± 6 79 ± 4* 
Cardiac output, L/min 2.7 ± 0.2 2.4 ± 0.2 * 2.3 ± 0.1* 
+ 2.7 ± 0.1 2.3±0.1* 2.0 ± 0.2 * 
Heart rate, bpm 121 ± 4 127 ± 6 136 ± 6 * 
+ 117 ± 6 124 ± 6 138±10* 
LVdP/dtrc:~x, mmHg/s 1994 ± 141 1833 ± 85 1615 ± 104 * 
+ 1668 ± 111 1554 ± 115 1458 ± 181 
LV end diastolic pressure, mmHg 12 ± 2 14 ± 2 12 ± 1 
+ 6 ± 2 9 ± 2* 8±2 
LAD Flow, mL/ min 27 ± 4 8 ± 1"' 35 ± 6 
+ 35 ± 3 10 ± 1 * 44 ± 5 * 
Angii: angiotensin II, 0.5 ng-kg·1·min·1• Values are mean±SEM (Angii -, n=6; Angii +, n=7) 
* P < 0.05 vs. Baseline 
Infarct size. The 70% LAD flow reduction resulted in an ischemic area (area at 
risk) that comprised 32±4% of the LV mass in both groups. Infarct size was 
37±7% and 37±4% of the area at risk in group III and IV, respectively. 
Discussion 
This study provides no evidence for facilitation of cardiac norepinephrine 
release by angiotensin II under various experimental conditions in the intact 
porcine heart, as intracoronary infusion of angiotensin II did not modulate (i) 
basal sympathetic tone, (J.i) exocytotic norepinephrine release during 
sympathetic activation produced by left stellate ganglion stimulation, and (ill) 
exocytotic and nonexocytotic norepinephrine release during myocardial 
ischemia. 
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Intracoronary angiotensin II infusion and basal cardiac sympathetic tone 
While the intracoronary angiotensin II infusions in our experiments caused 
large increments in Angiicv, no increments in N~,LAD or NEcv 
concentrations were observed (Table 2). Inhibition of norepinephrine neuronal 
reuptake by co-perfusion of microdialysis probes with DMI and inhibition of 
the presynaptic ()(2-adrenergic receptor-mediated negative feedback of 
norepinephrine release with PHA did not unmask an angiotensin II-mediated 
increase in N~u.n· 
Although our findings agree with studies that also failed to 
demonstrate an effect of angiotensin II on basal norepinephrine concentration 
and norepinephrine spillover,9.11 they are at variance with other studies that 
have shown angiotensin II to increase basal sympathetic tone.3·4 It could be 
argued that in anesthetized animals, facilitation of norepinephrine release by 
angiotensin II is difficult to demonstrate because of low basal norepinephrine 
as compared to awake swine. However, Dendorfer and co-workers 3 have 
stated that facilitation of norepinephrine release by angiotensin II is in fact 
easier to demonstrate when background sympathetic tone is low. 
Angiotensin II may not only facilitate the neuronal release of 
norepinephrine, but may also inhibit its neuronal reuptake.1826 As neuronal 
reuptake is an important determinant of NE,.,:,F under baseline conditions as 
well as during increased sympathetic tone,1921 an increase in N~ 
concentration through inhibiting neuronal reuptake by angiotensin II would 
almost certainly have been detected in this study. 
We can also exclude that a putative facilitating effect of angiotensin II 
on norepinephrine release was masked by a hemodynamically mediated 
increase in norepinephrine clearance. First, we used intracoronary angiotensin 
II infusions to prevent significant systemic hemodynamic effects. Second, the 
tendency of LAD flow to decrease would have favored an increase in NE,.aF by 
blunting norepinephrine clearance. In fact, the angiotensin II-associated 
increase in norepinephrine observed in some studies might be e>--plained by a 
decrease in clearance caused by angiotensin II-induced vasoconstriction." 
Intracoronary angiotensin II infusion and norepinephrine release during sympathetic 
activation 
In the present study, sympathetic stimulation was induced by electrical 
stimulation of the left stellate ganglion, resulting in marked increases in LV 
dP / dt"'"" blood pressure and LAD flow. These hemodynamic effects were not 
enhanced by an intracoronary infusion of angiotensin II (Table 3 and Figure 2). 
Similarly, ganglion stimulation increased NE,.m, up to five-fold. In the presence 
of U1- and ()(-adrenergic receptor blockade, the absolute increase inN~ was 
the most substantial, suggesting an important negative feedback mechanism 
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through pre-synaptic ct-adrenergic receptors, most likely of the ct2-subtype. 
Again, infusion of angiotensin II did not au,oment this increase, irrespective of 
the presence ofU1- and ct-adrenergic receptor blockade (Table 2 and Figure 2). 
These results are in agreement with other studies that also failed to 
demonstrate enhanced norepinephrine release by angiotensin II during 
sympathetic activation in humans with and without CHF,10. 12 and in particular 
Rundqvist et al.8, who demonstrated that intracoronary administration of the 
angiotensin-converting-enzyme (ACE) inhibitor enalaprilat failed to attenuate 
the increase in cardiac norepinephrine spillover following sympathetic 
activation. In contrast, other studies using electrical stimulation in vitro 12~ as 
well as studies in humans '·' did demonstrate an angiotensin II-induced 
au,omentation of sympathetic activation, three of which in the heart.z.5•7 Of the 
latter only the study by Saino and colle"e,aues investigated augmentation of 
sympathoneural activation by angiotensin II in the intact (human) heart. 
However, since they did not measure norepinephrine spillover or 
norepinephrine concentrations directly but estimated differences in 
sympathetic activity by comparing responses of coronary blood flow and 
coronary vascular resistance to the diving and cold pressure tests with and 
without simultaneous intracoronaty angiotensin II infusion, it can not be 
excluded that other vasomotor mechanisms than ct-adrenergic receptor-
mediated vasoconstriction as a result of facilitated norepinephrine release are 
responsible for the observed hemodynamic responses. 
Intracoronary angiotensin II infusion and norepinephrine release during ischemia 
As angiotensin II has been reported to enhance either nonexocytotic 
norepinephrine release via activation of the Na + /H+ exchanger = or 
exocytotic release via 'classic' calcium-dependent facilitation,13 we monitored 
norepinephrine release in MIF during myocardial ischemia produced by LAD 
flow reduction which leads to both exocytotic and nonexocytotic 
norepinephrine release while still permitting intracoronaty infusion of 
angiotensin II during ischemia. The N~ increase during 70% flow reduction 
(15-fold) was much less than previously described during total occlusion (500-
fold),20 not only because ischemia was less severe but also because washout of 
released norepinephrine is partially preserved during 70% flow reduction. We 
kept LAD flow constant at 30% of baseline, thereby preventing any potential 
effects of angiotensin II on flow-induced changes in norepinephrine clearance 
(Table 4). During flow reduction, concomitant infusion of angiotensin II did 
neither augment the ischemia-induced increase in NBwF, nor did it alter its 
time course (Table 2, Figure 3). 
Our findings are at variance with the attenuation of ischemia-induced 
norepinephrine release,23·2728 as well as the decrease in sympathetic activity in 
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heart failw:e,1829·30 by ACE-inhibitors or ATcreceptor blockers (ARB's) that 
have been reported earlier. Several factors may contribute to these apparent 
conflicting results. (i) Diffusion limitations for angiotensin II from the 
bloodstream to the perivascular or myocardial sympathetic nerve terminals 
could have prevented the infused angiotensin II from reaching the interstitial 
space and occupying AT1-receptors.8 However, this is unlikely, as we have 
previously shown that the cardiac tissue concentration of radiolabeled 1251-
angiotensin II during 1251 -angiotensin II infusion was 7 5% of its arterial 
concentration and that most of this angiotensin II is bound to ATcreceptors.14 
(ii) Although RAS-inhibition may exert a direct effect on norepinephrine 
release in chronic heart failure (CHF),1829·30 the decrease in plasma 
norepinephrine concentrations during CHF treatment with ACE inhibitors or 
ARB's might also be due to an improvement of cardiac function. (ill) The 
decrease in sympathetic tone with ACE-inhibitors and ARB's 182327.30 might not 
be mediated through peripheral presynaptic AT1 receptors but by other 
mechanisms. For instance, ACE-inhibitors do not only inhibit Angl to 
angiotensin II conversion, but also limit bradykinin degradation and stimulate 
prostaglandin formation. Both bradykinin and prostaglandins have been shown 
to inhibit norepinephrine release.2n 1 In addition, the interaction between the 
RAS and SNS might be mediated through central AT1-receptors in the brain.32-
34 (iv) Facilitation of norepinephrine release by presynaptic ATcreceptor 
activation might be counteracted by presynaptic AT2-receptors, which can 
inhibit norepinephrine release and are down-regulated in cardiomyocytes of 
CHF patients.2223~5 
In conclusion, we found no evidence to suggest any facilitation of 
cardiac norepinephrine release by angiotensin II under basal conditions and 
during sympathetic activation either by ganglion stimulation or acute ischemia. 
Hence, angiotensin II is not a local mediator of cardiac sympathetic activity in 
the porcine heart. 
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Chapter 7 
Cardiac ischemia and local catecholamine 
release 
Background - Elevated concentrations of norepinephrine (NE) have been 
observed in ischemic myocardium. We investigated magnitude and mechanism 
of catecholamine release in the myocardial interstitial fluid (MIF) during 
ischemia and reperfusion in vivo, using the microdialysis technique. 
Methods and Results - In nine anesthetized pigs, interstitial catecholamine 
concentrations were measured in the perfusion areas of the left anterior 
descending coronary artery (LAD) and the left circumflex coronary artery 
(LCx). After stabilization, the LAD was occluded for 60 min and reperfused 
for 150 min. During the final 30 min, tyramine (154 nmol.kg.1.min-1) was 
infused into the LAD. During LAD occlusion, NEwe concentrations in the 
ischemic region increased progressively from 1.0±0.1 to 524±125 nmol/L. MIF 
concentrations of dopamine (DA>~1F) and epinephrine (EPiwF) rose from 
0.4±0.1 to 43.9±9.5 nmol/L, and from less than 0.2 (detection limit) to 4.7±0.7 
nmol/L, respectively. Local U1-blockade attenuated release of all three 
catecholamines by more than 50%. During reperfusion, MIF catecholamine 
concentrations returned to baseline within 120 min. At that time, the tyramine-
induced NE release was similar to that seen in non-ischemic controls despite 
massive infarction. Arterial and MIF catecholamine concentrations in the LCx 
region remained unchanged. 
Conclusions - Myocardial ischemia is associated with a pronounced increase of 
MIF catecholamines, which is at least in part mediated by a reversed neuronal 
reuptake mechanism. The increase of EPIMIF implies a (probably neuronal) 
cardiac source, while the preserved catecholamine response to tyramine in 
post-ischemic necrotic myocardium indicates functional integrity of 
sympathetic nerve tetrninals. 
Lameris TW, de Zeeuw S, Alberts G, Boomsma F, Duncker DJ, 
Verdouw PD, Man in 't Veld AJ, van den Meiracker AH. Time course and 
mechanism of myocardial catecholamine release during transient ischemia in 
vivo. Circulation. 2000;101:2645-2650. 
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Introduction 
Myocardial ischemia is associated with a marked accumulation of 
norepinephrine (NE) in ischemic tissue.14 In vitro studies suggest that this is 
caused by non-exocytotic release of NE from cardiac sympathetic nerves. 5-7 In 
contrast to the normally occurring exocytotic NE release, this non-exocytotic 
NE release is (z) calcium independent, (jz) not under influence of local or 
central sympathetic stimulation, and (iiz) not affected by presynaptic inhibition.' 
Interestingly, these in vitro studies in the sympathetically dominant rat heart also 
suggest that the ischemia-induced non-exocytotic NE release can be attenuated 
by neuronal uptake-1 (Ul) blockade, indicating that under ischemic conditions 
the Ul-mechanism is reversed, and can operate as a carrier for outward instead 
of inward NE transport. 5·6 However, this has not been investigated in 
parasympathetically dominant human and porcine hearts in vivo. Furthermore, 
little is known about myocardial release of epinephrine (EPI) and dopamine 
(DA) in the ischemic heart in vivo. This is of particular interest since cardiac E 
release has been reported in in vitro studies, and in healthy elderly men and 
patients with severe congestive heart failure at rest and during exercise.'-" 
Microdialysis allows measurement of catecholamine concentrations in 
the myocardial interstitial fluid (MJF) in vivo, and investigation of the 
mechanisms underlying their local release and clearance.12 Using an in vivo 
porcine model, we investigated time course and ma,onitude of changes in MIF 
concentrations of catecholamines during severe myocardial ischemia and 
reperfusion. To determine the contribution of reversal of the Ul-mechanism 
to ischemia-induced NE release, one of the microdialysis probes in the 
ischemic myocardium was co-perfused with the Ul-inhibitor desipramine 
(DMI).'2.13 
Finally, we determined whether sympathetic nerve endings are 
functionally impaired following reperfusion after severe myocardial ischemia, 
as has been suggested for the isolated rat hearts.2 For this purpose, local NE 
response to an intracoronary infusion of tyramine in the post-ischemic 
myocardium was compared to the response observed in the non-ischemic 
porcine myocardium of control animals previously studied under similar 
experimental conditions.12 Tyramine is taken up via Ul into the sympathetic 
nerve endings where it releases NE. Tyramine thus gives information on the 
NE content as well as Ul-function of sympathetic nerve endings12 
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Methods 
Animal care 
All experiments were performed in accordance with the "Guiding Principles 
for Research Involving Animals and Human Beings" as approved by the 
Council of the American Physiological Society and under the regulations of the 
Animal Care Committee of the Erasmus University Rotterdam. 
S urgica! procedure 
After an overnight fast, crossbred Landrace x Yorkshire pigs of either sex (30-
35 kg, n=9) were sedated with ketamine (20-25 mg/kg i.m.), anesthetized with 
sodium pentobarbital (20 mg/kg i.v.), intubated and connected to a respirator 
for intermittent positive pressure ventilation with a mixture of oxygen and 
nitrogen. Respiratory rate and tidal volume were set to keep arterial blood 
"thin th al 1' 14 gases W1 e norm range. -
Catheters were positioned in the superior caval vein for continuous 
administration of sodium pentobarbital (10-15 mg.kg·'.h-1) and saline for 
replacing blood withdrawn during sampling. In the descending aorta, a fluid-
filled catheter was placed to monitor aortic blood pressure and blood sampling. 
Through a carotid artery a micromanometer-tipped catheter (B. Braun Medical 
BV, Uden, The Netherlands) was inserted into the left ventricle for 
measurement of left ventricular (LV) pressure and its first derivative LV dP / dt. 
After administration of pancuronium bromide ( 4 mg), a midsternal 
thoracotomy was performed and the heart was suspended in a pericardia! 
cradle. An electromagnetic flow probe (Skalar, Delft, The Netherlands) was 
then placed around the ascending aorta for measurement of cardiac output. 
After a Doppler flow probe was placed on a proximal segment of the left 
anterior descending coronary artery (LAD), a cannula (0: 1.3 rnm) was 
inserted distal to this site into the LAD for administration of tyramine. 
Microdialysis probes were implanted in left ventricular myocardium 
using a steel guiding needle and split plastic tubing: one in the region perfused 
by the left circumflex coronary artery (LCx) and two in the area perfused by 
the LAD. In order to achieve local U1-inhibition, one of the LAD probes was 
co-perfused with DMI (100 fL!\1).13 Additionally, a microdialysis probe was 
placed in the interventricular coronary vein that drains the LAD region.15 
Dialysis methodology 
The polycarbonate dialysis membrane of the microdialysis probes (CMA/20, 
Carnegie Medicine AB, Sweden) has a cut-off value of 20 kD, a len,ath of 10 
mm and a diameter of 0.5 rnm. Probes were perfused with an isotonic Ringer's 
solution at a rate of 2 J.!L/rnin using a CMA/100 microinjection pump. 
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Dialysate volumes of 20 IlL (sampling time 10 min) were collected in 
microvials containing 20 IlL of a solution of 2 % (' lv) EDTA and 30 n1\1 1-
erythro-alpha-methyl-NE (AL\1N) as internal standard in 0.08 N acetic acid. 
Sampling started immediately after inserting the probes. Plasma samples were 
drawn into chilled heparinized tubes containing 12 mg glutathione. 
J\ficrodialysis and plasma samples were stored at -80 °C, until analysis within 
1?16 the next five days. -· 
In vivo probe recovery of NE (52±1 %) has been determined by 
retrodialysis using AJ\.1N as a calibrator and direct comparison of hemo-
microdialysis and plasma samples.12.17 In vivo probe recovery for EPI (68±3%) 
was determined by comparing EPI concentrations in arterial plasma with EPI 
concentrations in the dialysate obtained from the carotid artery probe. The in 
vivo probe recovery for DA was not determined directly but was assumed 
similar to probe recovery of NE because of the similarities of NE and DA in 
size and charge distribution. 
Experimental protocol 
After a 120-min stabilization period,12 baseline measurements were obtained 
over a 30-min period before the LAD was occluded distal to the first diagonal 
branch for 60 min, using an atraumatic clip, and thereafter, reperfused for 150 
min. During the last 30 min of reperfusion, tyramine (154 nmol.kg1.min.1) was 
infused directly into the LAD. At the end of the experiment, the perfusion area 
of the LAD was determined by an intra-atrial infusion of 30 ml of a 5% (' / w) 
solution of fluorescein sodium during reocclusion of the LAD. During 
occlusion, ventricular arrhythmias were counted and distinguished as 
premature ventricular contractions (PVC), ventricular tachycardia (VT), and 
ventricular fibrillation (VF).18 After inducing ventricular fibrillation with a 9 V 
battery, the heart was excised and infarct size was determined using para-
nitrobluetetrazolium.14 
Analytical procedures 
Plasma catecholamines were determined by HPLC with fluorimetric detection 
after liquid-liquid extraction and derivatization with the fluorogenic agent 1,2-
diphenyl-ethylenediamine (DPE).19 For microdialysis samples, the 
catecholamines are not extracted prior to fluorimetric detection with HPLC, 
but directly derivatized according to the procedure described by Alberts et al.17 
This method suppresses the interference of sulfhydryl compounds on 
derivatization, thus improving sensitivity. 
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Reagents and pharmaceuticals 
Ketamine and sodium pentobarbital were obtained from Apharmo BV 
(Arnhem, The Netherlands), pancuronium bromide from Organon Teknica 
BV (Boxtel, The Netherlands), Ringer's solution from B~xter (Uden, The 
Netherlands). Tyramine was obtained from the department of pharmacy of the 
University Hospital Rotterdam. Fluorescein sodium, para-nitrobluetetrazolium, 
DMI, NE, EPI, DA and AM:N were purchased from Sigma (St. Louis, MO), 
EDTA from Merck (Darmstadt, Germany), L-glutathione from Fluka (Buchs, 
Switzerland), and acetic acid from Baker (Deventer, The Netherlands). DPE 
was prepared as reported previously.19 
S tatistica! anafysis 
Five out of the 9 animals encountered ventricular fibrillation during LAD 
occlusion (between 10 and 30 min of ischemia), but were successfully 
defibrillated within 1 min using 20-30 W counter shocks and therefore 
included in the analysis. Since there were no differences in the hemodynamic 
and catecholamine responses between animals that fibrillated and animals that 
maintained sinus rhythm, data of all 9 animals were pooled. Catecholamine 
concentrations obtained with microdialysis were corrected for probe recovery. 
Lower limits of detection for catecholamines measured with microdialysis and 
those measured in arterial plasma were 0.2 and 0.02 nmol/L, respectively. 
Baseline values were determined by averaging the three measurements over the 
30-min period prior to occlusion.12 Results are expressed as mean ± SEM. For 
statistical analysis two-way analysis of variance, one-way analysis of variance 
for repeated measures with Dunnet's multiple comparison test as post-hoc test 
and Student's t test were used as appropriate. 
Results 
Systemic hemorfynamics during ischemia and repetfusion 
Baseline hemodynamic data and the changes produced by 60-min LAD 
occlusion and 120 min of reperfusion (Table 1) are in accordance with 
previously published data from our laboratory. 14 
Infarct size 
The LAD occlusion resulted in an ischemic area (area at risk) that comprised 
29±2% of the left ventricular mass. Infarct size determined at the end of 
reperfusion was 84±4% of the area at risk 
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Table 1. Cardiac and systemic hemodynamics at baseline, at 60 min of ischemia and 
120 min of reperfusion. 
Isffiemia Reperfusion 
Baseline 
60min 120 min 
Mean arterial pressure, mmHg 97 ± 2 82 ± 2* 79 ± 5 
Cardiac output, L/ min 2.4 ± 0.2 2.1 ± 0.1 1.8±0.1* 
Heart rate, bpm 114 ± 4 118 ± 7 137 ± 11 * 
Systemicvasrolar resistance, mmHg.min ·1.L 42 ± 4 41 ± 4 43 ± 5 
Stroke volume., mL 22 ± 2 18 ± 1 * 15 ± 2* 
LV dP/dtm~,_,mmHg/s 1680 ± 100 1460 ± 110 1380 ± 150 
LV end diastolic pressure, mmHg 6.6 ± 0.8 9.3 ± 1.4 10 ± 1.9 * 
LAD flow, mL/min 34 ± 3 0 46 ± 8 
Values are given as mean±SEM, n=9. * = P < 0.05, vs. Baseline 
Catecholamine concentrations during ischemia and reperfusion 
At baseline, NE concentrations in MIF (N~F) in the LAD and LCx regions 
were similar to concentrations in the coronary vein (NEcv), but three times the 
concentrations in arterial plasma (NE,J (P<O.OS; Table 2). Dopamine 
concentrations followed a similar pattern, while EPI was only detectable in 
arterial plasma. Under U1-blockade, NE:.rrF increased five-fold, while DAMIF 
did not change and EPiwF remained undetectable. 
ischerria 
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Figure 1. Time course of changes in catecholamine concentrations during ischemia and 
reperfusion. Data axe shown for MIF in the LAD region ,_,.;thout (G) and mth DMI (0), MIF 
in the LCx region (x), and concentrations in arterial plasma (hatched bars) and in the coronary 
vein (n:). Data are presented as mean± SE}J, n=9 
During the first 10 min of ischemia, N~F in the LAD region tripled 
and continued to rise progressively so that N~F had increased 500-fold at the 
end of ischemia (Table 2, Figure 1). In the presence ofU1-blockade, the rate of 
rise of N~ was attenuated so that after 20 min of ischemia, NBwF under 
U1-blockade was similar and at 60 min only one-fifth of N~ in the absence 
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of U1-blockade. NEcv increased progressively to 100-fold its baseline value. 
Upon reperfusion NEMIF• NEw. under U1-blockade and NEcv declined 
rapidly, witb tbe early rate of decline being most pronounced for NEMIF in tbe 
absence of U1-blockade (Figure 1). Witbin 120 min of reperfusion, 
catecholamine concentrations in MIF and coronary vein had returned to 
baseline values. NEMIF in tbe LCx perfused area and NE= remained unchanged 
during tbe course of tbe e>.'J'eriment. 
Table 2. Circulatory and interstitial catecholamine concentrations at baseline, at 60 min of 
ischemia and 120 min of reperfusion. 
'uterial plasm' Coronary vein MIFLAD 11IF LAD + DMI MIFLCX 
nmol/L nmol/L nmol/L nmol/L nmol/L 
Norepinephrine 
Baseline 0.30 ± 0.08 0.86 ± 0.22 t 0.97 ± 0.11t 5.76 ± 0.77tl:§ 0.96 ± 0.13t 
Ischemia 0.32 ± 0.07 90 ± 36*t 524 ± 125 *t+ 198 ± 46 *t+§ 0. 79 ± 0.27 t+§ 
Reperfusion 0.54 ± 0.23 0.62 ± 0.30 0.54 ± 0.11 1.99 ± 0.28 *t+§ 0.62 ± 0.16 
Epinephrine 
Baseline 0.04 ± 0.01 < 0.20 < 0.20 < 0.20 < 0.20 
Isd1emia 0.03 ± 0.01 2.55 ± 1.07 *t 4.74 ± 0.71 *t 2.09 ± 0.43 *t§ < 0.20 t§ 
Reperfusion 0.07 ± 0.02 < 0.20 < 0.20 < 0.20 < 0.20 
Dopamine 
Baseline 0.06 ± 0.01 0.71 ± 0.45 t 0.40 ± 0.12t 0.57 ± 0.16t 0.59 ± 0.27t 
Ischemia 0.06 ± 0.01 11.6±4.3*t 43.9 ± 9.5 *t+ 16.5 ± 5.6 *t§ 0.47 ± 0.04t+§ 
Reperfusion 0.15 ± 0.07 0.27 ± 0.11 0.30 ± 0.10t 0.34 ± 0.13 t 0.21 ± 0.03 
Values are given as mean±SEM, n=9. * P < 0.05 vs Baseline; t P < 0.05 vs Arterial plasma; :f 
P < 0.05 vs Coronary vein; § P < 0.05 vs MlF LAD 
In tbe LAD region, EPIMIF and DA,IIF in tbe absence and presence of 
U1-blockade as well as EPicv and DAcv followed qualitatively similar patterns, 
but absolute increments during ischemia were substantially less pronounced 
(Table 2, Figure 1). Again, BPI= D~ and DAMIF in tbe LCx region did not 
change over tbe course of tbe experiment, while EPIMIF in tbe LCx region 
remained undetectable. 
Ventricular arrhythmias during ischemia 
Most of tbe ventricular atrhytbmias occurred witbin tbe first half-hour of 
ischemia. The incidence of PVC's was particularly high between 20 to 30 min 
of ischemia, 661 in total and an average of 73±19 per animal. Five animals 
suffered from ventricular fibrillation, but were defibrillated successfully witbin 
1 minute. There was no correlation between MIF NE concentrations and tbe 
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occurrence of ventricuhr arrhythmias in general or with ventricular fibrillation 
in particular. 
Post-ischemic catecholamine release by tyramine 
Figure 2 shows that infusion of tyramine directly into the LAD after 120 min 
of reperfusion caused an increase in NE,uF in the post-ischemic myocardium 
from 0.6±0.1 to 11.5±1.9 nmol/L (P < 0.05). This increment was not different 
from the increase from 0.9±0.2 to 13.4±3.2 nmol/L in the LAD region of the 
normal (non-ischemic) swine heart.12 Furthermore, compared to the increment 
seen in the absence of U1-blockade, the increase in the presence of U1-
blockade was minimal. 
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Figure 2. Tyramine induced NE 
release in the perfusion area of the 
LAD with and without Ul-inbibition. 
Data are shown for post-ischemic 
myocardium (n =4, hatched bars) and 
for historic non-ischemic controls 
(n=4, solid bars). DMI: desipramine, 
"C1-.inhibitor. Data presented as mean 
± SEM, n=4, ns: not significant, *: P 
< 0.05 
This study demonstrates that myocardial ischemia is associated with a rapid 
and massive increase of the concentration of all three endogenous 
catecholarnines NE, EPI and DA in the myocardial interstitial fluid as 
measured with the microdialysis technique in vivo. As suggested for NE in in 
vitro studies,'·' the reversed U1-mechanism plays an important role in the 
release of all three catecholarnines during ischemia in vivo. Furthermore, our 
study shows that after 60 min of ischemia, which results in massive infarction 
of the jeopardized myocardium, the functional integrity of sympathetic nerve 
terminals remains intact. Finally, our results suggest that cardiac interstitial EPI 
has a neuronal o%oin. 
Interstitial catecholamine concentrations during basal conditions 
The present study confirms that, at baseline, N4rrF is about 3 times the NE=, 
and increases about 6-fold in response to U1-blockade,u2.2o while EPI:.rrF was 
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below the detection limit irrespective of the presence of U1-inhibition. DA>rrF 
did not rise under U1-blockade, suggesting that U1 does not play a 
predominant role in the clearance of DA from the interstitial compartment 
under baseline conditions in the heart. Little is known about the affinity of 
dopamine (DA) for U1 and its relevance to DA clearance in the heart. As the 
main purpose of the U1 mechanism is to modulate synaptic transmission, it is 
hard to envisage a substantial role for U1 in the clearance ofDA in the absence 
of any cardiac doparninergic synaptic transmission. Furthermore, in tissues 
with known doparninergic transmission, like brain and kidney DA is taken up 
by a specific DA neuronal uptake mechanism, which does not take up NE and 
which is poorly inhibited by DMI.2122 
Interstitial catecholamine concentrations during ischemia and reperfusion 
In in vitro experiments in isolated rat hearts, three phases of ischemia-induced 
release of NE, each with a different mechanism, have been recognized.25•6·23 
During the early phase of ischemia (0-10 min), release of NE, if present, is 
exocytotic and depends on the activation of efferent sympathetic neurons. 
Accumulation of catecholarnines in the extracellular space in this early phase is 
prevented by the highly efficient U1 mechanism and by presynaptic inhibition 
by adenosine, which accumulates in cardiac tissue during this phase of 
ischemia. The latter has shown to be of particular importance in the rat, as 
adenosine concentrations are considerably higher than in other species. 24 
During the second phase of ischemia (10-40 min), the release of NE becomes 
non-exocytotic and is thought to involve the U1-mechanism in the carrier-
mediated efflu.x of NE in reverse of its normal transport direction5 ·6 During 
the third phase (> 40 min ischemia) the release of NE is no longer attenuated 
by U1-inhibitors, which is explained by the occurrence of structural changes in 
the neuronal membrane of the myocardial neurons.2 
In the present smdy, a rapid and pronounced increase of MIF 
concentrations of all three catecholarnines was observed shortly after occlusion 
of the LAD. As released NE is avidly taken up by the cardiac U1-mechanism, 
we expected a larger rise of NE,nF in the presence of the U1-inhibitor DMI 
than without U1-inhibition. However, during this first 10 minutes of ischemia, 
the increment of NEMIF with U1-blockade (5.8 to 8.5 nmol/L) was similar to 
the increment without U1-blockade (0.9-2.7 nmol/L). Possibly, in the 
parasympathetically dominant porcine heart, U1-carrier mediated non-
exocytotic NE efflu.x already occurred in the iritial 10 minutes of ischemia, so 
that in the presence of DMI any decrease in U1-mediated clearance was 
compensated for by a decrease in the ischemia-induced U1-carrier-mediated 
NE-efflu.x. As mentioned, myocardial release of NE in first 10 minutes of 
ischemia is not an invariable finding. For example, stimulation-evoked NE 
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release has shown to be suppressed in rat hearts and human atrial tissue, but to 
be facilitated in guinea pig hearts.25 
Throughout the ischemic period, MIF catecholamine concentrations 
rose progressively in the ischemic area. Concentrations of catecholamines 
changed neither in the non-ischemic LCx area nor in the systemic circulation. 
Reversal of U1-mechanism continued to contribute to the catecholamine 
release during the entire period of ischemia. Thus, U1-blockade attenuated the 
release of all catecholamines by more than 50%, indicating that despite 
infarction of 83% of the area at risk, U1 was operative after 60 min of 
ischemia. Our findings vary from those obtained in the ischemic myocardium 
of the isolated rat heart where the reversed U1-mechanism no longer 
contributes to release of catecholamines 40 min after induction of ischemia. 
This difference may be explained by the differences in experimental conditions, 
e.g. in vivo versus in vitro studies, and the species investigated.' 
Upon reperfusion, MIF catecholamine concentrations rapidly declined 
in the post-ischemic myocardium. Washout was probably the predominant 
factor in the clearance of catecholamines in this early phase of reperfusion. 
However, the decline in the first 10 min of reperfusion was substantially 
greater without inhibition of the U1-mechanism, indicating that the U1-
mechanism also contributed significantly to the clearance of catecholamine 
during early reperfusion. Although it should be noted that in contrast to 
techniques used in in vitro studies,225 the time resolution of the :MD technique 
as presently used does not allow making conclusions about minute-to-minute 
changes of catecholamine concentrations. Compatible with previous findings 
that EPI is less avidly taken up by U1 than NE,26 the decline of the EPIMIF 
during reperfusion was not affected by Ul-blockade. 
Origjn of myocardial interstitial epinephrine 
An interesting finding was the ischemia-induced increase of the EPI""F' albeit 
small as compared to the increase in NEwF· Since the concentration of EPI"' 
and EPIMIF in the non-ischemic LCx region did not change during ischemia, 
this increase must have ori,oinated from the heart. It is currently unclear 
whether this source is neuronal or extra-neuronal. Evidence favoring extra-
neuronal synthesis and release of EPI is the presence of the enzyme 
phenylethanolamine N-methyltransferase in extra-neuronal myocardial 
tissue.1027 Furthermore, an intrinsic cardiac adrenergic cell type outside the 
sympathetic nervous system, capable of releasing EPI and NE, has been 
identified in the human heart.10 Finally, enhanced cardiac EPI spill-over into 
the coronary circulation of heart failure patients during sympathetic stimulation 
was disproportionate to the spillover of NE, suggesting that EPI may, in part, 
be derived from sources other than chromaffin cells or sympathetic nerves.9.1 1 
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On the other hand, it is known that sympathetic neurons can take up EPI from 
the circulation and release it upon stimulation.28 In our study, the pattern of 
release and clearance of EPI during ischemia and reperfusion was similar to 
that of NE and DA. Furthermore, inhibition of the neuronal Ul-mechanism 
attenuated the ischemia-induced release of all catecholamines to a similar 
degree, suggesting a common source, thus favoring a neuronal origin. 
Functional integrity of sympathetic nerve endings 
The effects of Ul blockade on the NEwF responses to ischemia and 
reperfusion suggested that Ul-mechanism of the sympathetic nerves was still 
functioning during and after the 60 min LAD occlusion. Thls is further 
substantiated by the NE:.rr, response to tyramine at the end of reperfusion. 
Similar toNE, tyramine is taken up by neurons through Ul, where it displaces 
NE from the nerve terminals because of its higher affinity for the neuronal 
storage proteins. Consequently, the tyramine-induced NE release reflects both 
neuronal NE content and the efficacy of U1.1229 The increase of NE.wc in the 
post-ischemic LAD region was very similar to that in the non-ischemic control 
hearts (Figure 2).12 These findings are in line with those reported by Shindo et 
al.' who studied the tyramine-induced NE release in non- and post-ischemic 
areas in cat hearts after 40 min of reperfusion following 40 min of ischemia. 
Additionally, in the present study, the attenuation of the tyramine-induced NE 
release by Ul-inhibition in both post-ischemic and non-ischemic groups was 
also similar (Figure 2). Although the present e>.-perimental setup does not allow 
for any predictions concerning long-term survival of sympathetic nerves, these 
present findings indicate that sympathetic nerve terminals remained 
functionally intact at least during the first few hours after reperfusion. 
However, functional alterations of the somata of the sympathetic nerves 
cannot be entirely excluded. Thus, in a canine model of tachycardia-induced 
heart failure, impairment of the myocardial contractile response to electrical or 
chemical stimulation of sympathetic somata was observed at a time when the 
contractile response to tyramine was completely preserved.30 
Implications 
Although the pathophysiological significance of the massive accumulation of 
catecholamines in the ischemic myocardial tissue was not investigated in the 
present study, there is evidence ftom e>.-perimental as well as clinical studies 
that high catecholamine concentrations are deleterious to the heart.31 "34 Several 
studies have demonstrated NE-dependent anti-arrhythmic effects of Ul-
inhibition during ischemia either by tricyclic anti-depressant agents like 
desipramine and imipramine or by structurally unrelated Ul-inhibitors like 
cocaine and nisoxetine.'-'5 This study provides a possible explanation for this 
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beneficial effect by demonstrating that the reversed Ul-mechanism contributes 
substantially to the release of catecholamines during ischemia. 
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Chapter 8 
Cardioprotection in pigs by exogenous 
norepinephrine 
Background - Endogenous norepinephrine release induced by cerebral ischemia 
may lead to small areas of necrosis in normal hearts. Conversely, 
norepinephrine may be one of the mediators that limit myocardial infarct size 
(IS) by ischemic preconditioning. Because brief ischemia in kidneys or skeletal 
muscle limits IS produced by coronary artery occlusion, we investigated 
whether cardiac norepinephrine release during transient cerebral ischemia also 
elicits remote myocardial preconditioning. 
Methods and Results - In 10 anesthetized control pigs, IS after a 60-min coronary 
occlusion and 120 min of reperfusion was 84±3% (mean±SEM) of the area at 
risk. Intracoronary infusion of 0.03 nmol·kg·1·min·1 norepinephrine for 10 min 
before coronary occlusion did not affect IS (80±3%, n=6), whereas infusion of 
0.12 nmol·kg·1·min·1 limited IS (65±2%, n=7, P<O.OS). Neither 10-min (n=S) 
nor 30-min (n=6) cerebral ischemia produced by elevation of intracranial 
pressure before coronary occlusion affected IS (83±4% and 82±3%, 
respectively). Myocardial interstitial norepinephrine levels tripled during 
cerebral ischemia and during low dose norepinephrine, but increased ten-fold 
during high dose norepinephrine. Norepinephrine levels increased 
progressively up to 500-fold in the area at risk during the 60-min coronary 
occlusion, independent of the pretreatment, while norepinephrine levels 
remained unchanged in adjacent non-ischemic myocardium and arterial 
plasma. 
Conclusions - Cerebral ischemia preceding a coronary occlusion did not modifY 
IS, which is likely related to the modest increase in myocardial norepinephrine 
levels during cerebral ischemia. The IS limitation by high dose exogenous 
norepinephrine is not associated with blunting of the ischemia-induced 
increase in myocardial interstitial norepinephrine levels. 
de Zeeuw S, Lameris TW, Duncker DJ, Hasan D, Boomsma F, van den 
Meiracker AH, Verdouw PD. Cardioprotection in pigs by exogenous 
norepinephrine but not by cerebral ischemia-induced release of endogenous 
norepinephrine. Stroke. 2001;32:767-774. 
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Introduction 
Ischemic preconditioning, originally described for the myocardium,1 also 
occurs in kidney,' skeletal muscle,' lung4 and brain.' Przyklenk et al' showed 
that brief regional myocardial ischemia protects not only the jeopardized 
myocardium during a subsequent coronary artery occlusion, but also the 
adjacent "virgin" myocardium. Furthermore, it has been shown that brief 
ischemia in remote organs such as kidney,' small intestine' and skeletal muscle,' 
is also capable of limiting myocardial infarct size produced by a prolonged 
coronary artery occlusion. 
Norepinephrine (NE) is one of the mediators involved in the signaling 
pathway leading to ischemic preconditioning,9·10 and because cerebral ischemia 
causes a profound release of norepinephrine from sympathetic nerve endings 
in normal myocardium,11 this raises the question whether transient cerebral 
ischemia prior to a coronary artery occlusion may also be cardioprotective. In 
addition, exogenous admioistration of norepinephrine before a coronary artery 
occlusion elicits cardioprotection in rabbits12 and rats13 
The major aim of this study was therefore to investigate the effect of 
cerebral ischemia on myocardial infarct size produced by a coronary artery 
occlusion in pigs. Because the cardioprotective effect of norepinephrine has 
not been established in pigs, we first studied whether intracoronary infusions 
of norepinephrine are capable of limiting myocardial infarct size. A further aim 
was, using microdialysis,11J 4 to quantitate the myocardial norepinephrine 
concentrations during cerebral ischemia and exogenous norepinephrine 
infusions, and to determine whether limitation of infarct size is mediated by 
attenuation of myocardial interstitial norepinephrine levels during the infarct-
producing coronary artery occlusion 15 
Methods 
Animal care 
The present experiments were performed conform with the "Guide for Care and 
Use of Laboratory Animals" published by the US National Institutes of Health 
(NIH publication No. 85-23, revised 1996) and under the regulations of the 
Erasmus University Rotterdam. 
Experimental protocol 
Forty-one crossbred Landrace x Yorkshire pigs of either sex (34±1 kg) were 
assigned to one of 7 experimental groups of which in 6 groups myocardial 
infarct size was determined at the end of the protocol (Figure 1). Ten animals 
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(Control) underwent a 60-min left anterior descending coronary artery (LAD) 
occlusion followed by 120-min reperfusion, while in 13 animals the 60-min 
LAD occlusion-reperfusion was preceded by a 10-min norepinephrine infusion 
into the LAD at a rate of either 0.03 nmol·kg·'·min·' (NE1,., n=6) or 0.12 
nmol·kg·1·min·1 (NErugh> n=7). In 3 animals, the effects of the 10-min high dose 
norepinephrine infusion (NErug~;,,h,J on myocardial function and metabolism 
were evaluated to assess whether this dose produced myocardial ischemia and 
asynchrony of contraction. Infarct size was not determined in these animals. In 
5 animals a 1 0-min period of global cerebral ischemia (CI10) preceded the 60-
min LAD-occlusion by 20 min, while in 6 animals the LAD-occlusion was 
preceded by a 30-min period of cerebral ischemia (CI30) and 30 min of 
reperfusion. Finally, in 4 animals, we studied whether 30 min of global cerebral 
LAO-occlusion Reperfus.ion Figure 1. Diagram of the 7 
Control n=10 e.'\."Perimental groups. NE was 
infused at a rate of either 0.03 
NE~ow n=6 (:'i"EJow) 0.12 nmol/kg·min·' or 
NEI<IIGM n=7 (t'Erugh and NErugh.>h=) into the left 
arterial descending coronary artery 
NEHIGHSKAM n=3 (LAD). Global cerebral ischemia 
(CI), produced by elevating 
Ct,l) n=5 intracranial pressure (ICP), was 
Cl» n=6 
maintained for either 10 min (CI 10) 
or 30 min (CI,o and Ciso.,h=)- Infarct 
Ct::'QS>W.< o=4 size was determined at the end of 
120 min of reperfusion in all groups 
-60 -30 0 60 Tlme (mln) 180 e.'(cept in NErugh,sh=l· 
ischemia per se (CI30_,ruom) damaged normal myocardium. Cerebral ischemia was 
achieved by infusion of artificial cerebrospinal fluid,17 such that intracranial 
pressure increased to approximately 250 mmHg (invariably above the systolic 
arterial pressure). 
In all groups, a 120-min stabilization period followed the surgical 
procedures, after which baseline measurements were made. Microdialysis was 
performed in Control, NE1,w, NEhigh> and CI30• Dialysate samples were 
collected over 1 0-min periods for determination of myocardial interstitial 
norepinephrine concentrations starting 90 min into the stabilization period, 
when norepinephrine concentrations had reached stable levels.'4·13 During the 
subsequent 30 min, baseline dialysate samples were collected. Plasma samples 
were obtained halfway through each 10-min dialysate collection period. 
Animals encountering ventricular fibrillation during the protocol were allowed 
to complete the experiment when sinus rhythm could be restored by De-
countershock within 2 min. 
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At the end of the 120-min reperfusion period, the area at risk was 
determined by intra-atrial infusion of 20 ml of 5% ("' / wl fluorescein sodium.18 
After the heart was excised, the left ventricle was isolated and cut parallel to 
the atrioventricular groove into five slices of equal thickness. After the area at 
risk of each slice was demarcated on an acetate sheet under ultraviolet light, the 
slices were incubated in 0.125 g para-nitrobluetetrazolium (Sigma Chemicals 
Co., StLouis) per liter of phosphatebuffer (pH 7.4) at 3TC for 30 min, and the 
non-stained pale infarcted area was also traced onto the sheet. Myocardial 
infarct size was defined as the ratio of the summated infarct areas and 
summated areas at risk 18 
S urgica! procedure 
Overnight fasted pigs were sedated with ketamine (20-25 mg/kg i.m., 
Apharmo BV, Amhem, The Netherlands), anesthetized with sodium 
pentobarbital (20 mg/kg i.v., Apharmo) and intubated for ventilation with 30% 
oxygenated room air, while arterial blood gases were kept within the normal 
range. Catheters were inserted into the superior caval vein for infusion of 
sodium pentobarbital (10-15 mg·kg·1·h.1) and saline. A fluid-filled catheter was 
placed in the descending aorta for measurement of aortic blood pressure and 
collection of blood samples, while a micromanometer-tipped catheter was 
inserted in the carotid artery and advanced into the left ventricle for 
measurement of left ventricular pressure (L VP) and its first derivative (LV 
dP/dt). After administration of pancuronium bromide (4 mg, Organon 
Teknika BV, Boxtel, The Netherlands) and a midstemal thoracotomy, the heart 
was suspended in a pericardial cradle. An electromagnetic flow probe (Skalar, 
Delft, The Netherlands) was placed around the ascending aorta for 
measurement of cardiac output, while the segment of the LAD between the 
first and the second diagonal branch was dissected free for placement of a 
Doppler flow probe (Triton Technology Inc., San Diego, CA) and a 
microvascular clamp. In N~ow> NEhigh> and N~gh.,h.=> a small cannula was 
inserted into the LAD distal to the flow probe. 
One microdialysis probe was implanted in the LAD-area and one in the 
left circumflex coronary artery (LCx)-area. In CI30, a third probe was placed in 
the cortex of the brain. Perfusion of the probes started immediately after 
insertion. 14.1 5 
In CI30_,h= and NEhi,h.>h= pairs of ultrasound crystals were implanted in 
the midmyocardial layer of the LAD- and LCx-areas to assess regional 
myocardial wall function (Triton Technology Inc., San Diego, CA), while the 
great cardiac vein accompanying the LAD was cannulated for collection of 
blood samples. Finally, in N~ghAum also the left atrium was cannulated for 
injection of radioactive microspheres (' 13Sn or 141Ce, 15±1 (SD) ttm) to 
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determine the effect of norepinephrine on the distribution of myocardial blood 
flow.' 
Two catheters were inserted into the left and right cerebral lateral 
ventricles through bore holes to produce cerebral ischemia." A fluid-filled 
catheter was used for infusion of the artificial cerebrospinal fluid to elevate 
intracranial pressure, which was monitored with a micromanometer-tipped 
catheter 
Microdiafysis 
The polycarbonate dialysis membrane of the microdialysis probes (CMA/20, 
Carnegie Medicine AB, Sweden) has a cut-off value of 20 kD, a length of 10 
mm and a diameter of 0.5 mm. Cardiac probes were perfused with an isotonic 
Ringer's solution and the cerebral probe with the artificial cerebrospinal fluid, 
at a rate of 2 f.t]/min using a CMA/100 microinjection pump. Dialysate 
volumes of 20 f.ll (sampling time 10 min) were collected in microvials 
containing 20 f.t] of a solution of 2% \I J EDTA and 30 n..\11-erythro-alpha-
methyl-norepinephrine (AMJ'-.') as internal standard in 0.08 N acetic acid. 
Plasma samples were drawn into chilled heparinized tubes containing 12 mg 
glutathione. All samples were stored at -80°C, until analysis within the ne1."1: 
five days.14·15 In vivo probe recovery of norepinephrine, determined by 
retrodialysis and by direct comparison of hemo-microdialysis and plasma 
samples is 52±1 %.14·15•19 
Data analysis and statistics 
Percent systolic shortening (SS) was calculated as the difference in segment 
length at end-diastole and the minimal segment length during systole divided 
by the segment le!\,ath at end-diastole. Asynchrony during norepinephrine 
infusion was assessed by determining the time interval between the occurrence 
of minimal segment length (Lmm) in the LAD- and LCx-areas. 
Myocardial 0 2-extraction (%) was calculated as the ratio of the arteria 
- coronary venous 0 2-content difference and the arterial 0 2-content. At the 
end of the experiment, the heart was excised, the LAD- and LCx-areas were 
separated and divided into three layers of equal thickness to determine the 
subendocardial (1nner layer) and subepicardial (outer layer) blood flows and 
their ratios, using standard techniques.' 
All results have been expressed as mean±SEM. Statistical significance 
(P<0.05) for changes in hemodynamics and norepinephrine concentrations 
was determined by two-way ANOVA and one-way ANOVA for repeated 
measures, followed by Dunnett's multiple comparison test. Statistical 
significance (P<0.05) for differences in infarct size was determined using one-
way AN OVA followed by Student's t test. 
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Results 
Hemodynamics 
Norepinephrine infusions. lntracoronary norepinephrine infusion in NEww 
produced an increase in LV dP I dt,~_, reflecting an increase in regional 
contractility as the other cardiovascular variables remained unaffected (fable 
1). During the 10-min washout period LV dPidt,~, returned to baseline. 
During norepinephrine infusion in NEru,h and NErugh..,Jum mean arterial pressure 
decreased rapidly from 91±2 to 74±6 nllnHg followed by a gradual recovery 
(fable 1). The decrease in cardiac output was responsible for the hypotension, 
as systemic vascular resistance remained unchanged. Cardiac output decreased, 
because the increase in heart rate was insufficient to compensate for the 
decrease in stroke volume. The latter occurred despite the increase in LV 
dP I dt,,_, and was likely due to asynchrony of contraction (see below). All 
parameters recovered during the 1 0-min washout period that preceded the 60-
min LAD-occlusion. 
During norepinephrine infusion in NErugh.,h=, SS in the LAD-area 
increased from 27±2% at baseline to 34±4%, while SS in the LCx-area 
decreased from 18±1% to 13±1% (both P<O.OS). These changes were 
accompanied by asynchrony of contraction between the LAD- and LCx-areas. 
Thus, whereas under baseline conditions Lmin of both areas occurred at the end 
of global left ventricular systole, during norepinephrine the occurrence of Lmm 
in the LAD-area preceded Lmin in the LCx-area by 119±2 ms (P<O.OS). The 
latter was due to Lmin in the LAD-area occurring 56±15 ms before and Lmin in 
the LCx-area occurring 63±7 ms after closure of the aortic valves (both 
P<O.OS vs their respective baseline values). During washout all wall function 
parameters returned to baseline values. 
In the LAD-area of NEhig,,J=n, 0 2-extraction decreased from 64 ±7% at 
baseline to 54 ±7% during norepinephrine infusion, indicating that 0 2-delivery 
increased slightly in excess of the increase in myocardial 0 2-demand. In 
addition the arterio - coronary venous pH difference remained unchanged 
(0.06±0.01 at baseline and at the end of infusion). Moreover, the 
subendocardial to subepicardial blood flow ratio remained unchanged in both 
the LAD-area (1.14±0.25 at baseline and 1.30±0.17 at the end of infusion) and 
the LCx-area (1.21±0.07 and 1.24±0.05, respectively). Finally, SS in the LAD-
and LCx-areas returned to baseline values immediately during the recovery 
period (24±3% and 17±1 %, respectively), indicating that the norepinephrine 
infusion did not produce myocardial ischemia and stunning. 
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Table 1. Cardiovascular function during norepinephrine infusion or cerebral ischemia. 
Ch:mge from B:c;clinc 
Groups Baseline 2min Smin 10min 30min reoovcry 
::Vlean anctiul pre;sutc. mmHg A 93 ± 3 0±3 2 ± 2 3 ± 3 -1 ::2 
B+C 91 ± 2 -15 ::: 6 M -17 ± 5 * -8 = 4 -2 ± 2 
D 92::: 5 so= 10* 53= 13' -11::!: 5 -16 ± 12 
E+F 90 = 4 83 ± 6 * 67 ± 8. -19 ± 4* -17 ± SM -20±4• 
G.rdia.coutput, L/min A 2.8 ± 0.2 0.0 ± 0.1 o.o ± 0.1 0.0 ± 0.1 -0.1 :::0.1 
B+C 2.5 ± 0.2 -0.4 = 0.2 .. -0.5 ± 0.2 * -0.2 = 0.1 -0.1 ± 0.1 
D 3.8 ± 0.5 0.7 ± 0.2* 2.1 ± 0.4* 0.7 ± 0.3 -03 ± 0.6 
E+F 3.1 ± 0.2 0.7±0.2~ 2.2± 0.3~ 0.4±0.1M 0.9 ± 0.2 t -0.2 ± 0.4 
Syst=.icv:~>ruhr rcs.ist:mce_ A 33 ± 3 0.2 ± 0.8 0.4 ± 0.7 1.1 ± 0.7 1.1 = 1.1 
mmHg--L"1·min-1 B+C 37 ± 3 -0.6 = 1.4 0.7 = 0.9 0.6 = 1.0 1.2 ± 0.9 
D 26 ± 3 15.9 ± 4.6 .. 1.4 ± 4.4 -7.4 ± 1.9 t -3.6 ± 1.0 t 
E+F 30 ± 2 18.8 ± 4.2. 1.8 ± 3.2 -8.8 ± 1.3. -11.0 ± 1.5 .. -9.0 ± 2.1 .. 
H=r:l.re.bpm A lOi ± 7 1 ± 1 1 ± 2 1 ± 2 1 = 3 
B+C 117 ± 7 13 = 4 ~ 15 = 5. 12 = 5 2±2 
D 112 = 5 37 ± 8 68 ± 12. 19 ± 13 17 ± 10 
E+F 101 ± 3 -M±P 79 ± 6' 22 ± 4* 2± 3 9 ± 7 
S=kevolume. mL A 27 ± 4 1.1 ± 1.5 1.5 ± 1.4 1.2 ± 12 0.5 ::': 1.1 
B+C 22 ± 2 -5.4 ± 1.9 * -6.4 ± 1.6 .. -3.8:: 1.7 -1.1 ± 0.7 
D 33 ± 3 -2.6 ::: 2.2 0.2::: 3.8 1.4 ::!: 3.0 -5.8 ± 3.0 
E+F 30 ± 2 -4.4 ± 1.8 * -0.8 ± 1.5 -1.8 ± 1.2 8.0 ± 1.6 * -4.2 ± 
LV dP/dt=~· mmHg/s A 1560 ::!: 110 760±100* 790±90* 850 ± 60. -60 ± 70 
B•C 2030 ± 200 860±210• 890 ± 160. 1270 ± 120M -150 ± 70 
D 1790 ± 170 2810 :: 660 * 4650 ± 910 * -310 = 410 410 ::!: 560 
E+F 1640 :!:: 120 2570 ± 440 * 5010 = 34D. 160 = 230 -90 ± 170 so ± 220 
l.efr; veutrirul:ll: eud-diasrolic A 8:::2 1.2 ± o.s 1.3 ± 0.6 1.9 ± 0.8 1.1 ± 0.6 
pre;sure.mmHg B+C 8 ± 1 -1.7 ± 0.8 -2.0 ± 0.8. -1.4 ± 0.6 0.7 ± 0.6 
D 9 ± 1 8.5 ± 1.7* 15 ± 12. 0.2 ± 2.4 -2.5 = 1.8 
E+F 7 ± 1 10.6 ± 2.5 * 0.9 ± 1.7 -1.2 = 12 1.8 ± 1.5 0.0 ::!: 0.9 
LAD flow, mL·min 
., ., 
A 1.7 ± 0.2 0.3 ± 0.2 0.3 = 0.2 0.3 ± 0.1 .. 0.0 ± 0.2 ·g 
B+C 1.0 = 0.1 0.0 ± 0.1 0.1 ± 0.1 0.3 ± o.-, 0.0 ± 0.1 
D 1.0 ± 0.2 1.0±0.2* 0.7 ± 0.1. 0.0 ± 0.1 -0.1 ± 0.1 
E+F 1.3 ± 0.1 1.3±0.2* 1.4 ± 0.3 * -0.1 ± 0.1 0.2 ± 0.2 -0.1 = 0.1 
Values are mean±SEM; n=6 (r'Elow, group A), n=!O \c'JEiugh+:\iEhigh.>h=, groups B+q, 
n=S (CI10, group D), n=!O (CI;o+Cbo .• h=, groups E+F). * P < 0.05 vs. Baseline 
Cerebral ischemia. Increasing intracranial pressure (12±2 mmHg at baseline) to 
250 mmHg produced an immediate increase in mean aortic pressure in CI10, 
CI30 and CI30_,~um, which was initially tbe consequence of increases in both 
cardiac output and systemic vascular resistance (fable 1). However, after 5 min 
tbe tachycardia-mediated increase in cardiac output was exclusively responsible 
for tbe hypertension. Despite tbe increase in afterload, stroke volume was 
maintained most likely due to enhanced myocardial contractility as LV dP / dt;,"' 
increased up to four times its baseline value. The increase in coronary blood 
flow paralleled tbe increase in myocardial 0 2-demand, reflected by tbe 150% 
increase in double product (heart rate · systolic arterial pressure). 
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Table 2. Cardiovascular function dw::IDg coronary occlusion and :reperfusion. 
Preocdusion End~Oo:lusion End-Reperfusion 
Treatment Values Values Values 
Mean ::uteria.l pressure. mmHg Control 90 ± 2 75 ± 2 * 76 ± 6* 
NE1<>,_. 93 ± 4 72 ± 6 ... 70 ± 5* 
:SEhi<>h 87 ± 4 77 ± 5 77 ± 4 
010 75 ± 9 74 ± 5 65 ± 5 
O;o 65 ± 4 61 ± 5 66 ± 4 
Cardiac output. L/ min Control 2.6 ::':: 0.2 2.1±0.1* 2.1±0.2* 
KE1mv 2.8 ± 0.2 2.3 ± 0.2* 1.9±0.1* 
NEhi<>h 2.2 ± 0.2 1.9±0.2* 1.8 :::': 0.2 * 
Ow 3.5:!: 0.4 2.9 :::': 0.3 2.5 ± 0.4 
a, 2.9 ± 0.3 2.2 ± 0.2* 2.0 ± 0.1 .. 
Syst=icvascu.ln.r resist= a:.. Control 38 ± 3 37 ± 3 38 ± 4 
mmH~L-1-min-1 NE1,.,w 34± 4 32 ± 3 38 ± 4 
::S"Ehi<>h 41 ± 4 43 ± 4 45 ± 5 
010 22 ± 3 27 ± 4 28 ± 4* 
o_,n 24± 2 28 ± 2 * 33 ± 2 * 
He:rrt r:l.te., bpm Control 115 ± 4 123 ± 7 139 ± 8 ~ 
NE1nw 108 ± 9 112 ± 9 119 ± 13 
NEhi"h 124 ± 6 133 ± 11 136 ± 11 
CIHI 129 ± 7 119 ± 9 120 ± 7 
O;o 112 ± 6 112 ± 5 115 ± 6 
Stroke volume, mL Control 22 ± 2 18 ± 1 * 16 ± 1 * 
NElov.· 27 ± 4 22 ± 3 17 ± 2 
XEhi<>h 18± 2 14± 2"' 13 ± 1 * 
Ow 28 ± 4 25 ± 4 21 ± 3 
O;c 25 ± 2 20 ± 2* 18 ± 1 * 
LV dP/dtm.c~. mmHg/s Control 1610 ± 100 1480 = 100 1640 ± 260 
)\£low 1500 = 110 1350±110 1250 ± 100 
NEhi<>h 1980 ± 280 2060 ± 350 2050 ± 340 
a, 2200 ± 410 1630 ± 140 1350 ± 140 
CI_,n 1710 ± 320 1250 ± 160 1170 ± 100 
Left ventrirul:tr end--dbstolic: Control 7 ± 1 9 ± 1 10 ± 1 * 
pressure, mmHg NE1"''' 9±2 10 ± 1 10 = 1
NEhi<>h 8±2 10 ± 2 12 ± 1 
a, 7±3 13 ± 3 13 ± 1 
a, 6 ± 1 9 ± 2* 12 ± 1 * 
Values are mean±SEM; n=1 0 (Control), n=6 (NEJow), n=7 (NErugb), n=S 
(CI10), n=6 (Cl,o). Pre-occlusion values of the NE and CI groups correspond 
to the recovery values of Table 1. * P < 0.05 vs. pre-occlusion values. 
Similar to earlier observations in dogs20 and pigs,11 the transient 
hyperdynamic phase was followed by a fall in mean arterial pressure below 
baseline levels at 10 min of cerebral ischemia, which was the result of systemic 
vasodilatation. Except heart rate, which remained slightly elevated, all other 
variables had recovered at 10 min. In Cl30 and CI30_,~=n, mean arterial pressure, 
cardiac output and systemic vascular resistance did not change further during 
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the remainder of the 30-min period of cerebral ischemia, while heart rate 
returned to baseline levels and stroke volume increased. Except for mean 
arterial pressure and systemic vascular resistance, all other hemodynamic 
variables and intracranial pressure returned to baseline values during recovery 
(Table 1). 
The increase in intracranial pressure decreased myocardial 0 2-
extraction from 64±5% at baseline to 58±6% at 5 min, but did not change the 
arterio- coronary venous pH difference (0.04±0.01 at baseline and at 5 min), 
indicating the absence of myocardial ischemia. The elevation of the intracranial 
pressure decreased SS from 24±1% to 16±2% at 2 min, but at 5 min SS had 
already recovered to 23±1% and to 26±1% at 10 min, with no evidence of 
depressed regional wall function during the remainder of the 30-min period 
(27±1 %) or the subsequent recovery phase (23±3%). 
LAD-occlusion and reperfosion. In Control, mean arterial pressure decreased 
secondary to the decrease in cardiac output during the 60-min LAD-occlusion 
and did not change further during reperfusion (Table 2). Heart rate increased 
slightly, but insufficiently to compensate for the decrease in stroke volume. 
Pretreatment with norepinephrine had no effect on the hemodynamic 
responses during the subsequent LAD-occlusion and reperfusion in either 
NE10w or NEhigh· In CI10 and CI30, mean arterial pressure did not further 
decrease during the LAD-occlusion most likely because systemic vascular 
resistance, which was still below baseline levels at the onset of the LAD-
occlusion, recovered. 
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Infarct Size Figure 2. Area at risk and 
infarct size for the 5 groups in 
which the LAD was occluded. 
Global cerebral ischemia alone 
(CI30.>h=) did not cause 
irreversible myocardial damage 
(not shown). * P<O.OS vs. 
Control. For further details 
see Figure 1. 
The area at risk was identical in all experimental groups (Figure 2). Infarct size 
was 84±3%, in Control and 80±3% in N~ow> but only 65±2% in NEhigh 
(P<0.05). Cerebral ischemia had no effect on infarct size development during 
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the 60-min LAD occlusion as in CI10 and Cl30 infarct size was 83±4% and 
82±3%, respectively. Cerebral ischemia per se did not cause irreversible damage 
as in none of the Cl30,,,= animals infarct tissue was detected. 
Myocardial interstitial norepinephrine concentrations 
The myocardial interstitial norepinephrine levels in the LAD-area increased 
from 0.8±0.2 nmol/L to 2.2±0.5 nmol/L in NE,ow, and to 12.2±5.9 nmol/L in 
NE"'' during norepinephrine infusion (both P<0.05, Figure 3). Despite the 
intracoronary route, there was some spillover in NErugh as evidenced by small 
transient increments of norepinephrine in plasma from 0.2±0.1 to 1.0±0.2 
nmol/L and in the interstitium of the LCx-area from 1.1±0.3 to 2.4±1.2 
nmol/L (both P<0.05, Figure 3). 
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Figure 3. Norepinephrine levels in plasma (hatched bars) and in the interstitium of the LAD -
area (ED) and the LCx-area (0) during the 10-min norepinephrine infusions and during 30 min 
of cerebral ischemia. * P < 0.05 vs Baseline. For further details see Figure 1. 
In Cl30, cerebral interstitial norepinephrine levels increased from 
0.9±0.4 nmol/L at baseline to 6.1±1.9 nmol/L at 10 min of intracranial 
pressure elevation and up to 8.3±1.8 nmol/L at 30 min (not shown in Figure 
3). Upon cerebral reperfusion, interstitial levels initially increased further to 
12.3±2.3 nmol/L, but returned to baseline during the remainder of the 30-min 
recovery period. Cerebral iscbemia resulted in a transient rripling of interstitial 
norepinephrine levels in both the LAD- and LCx-areas, and a 20-fold increase 
in plasma norepinephrine levels (Figure 3). 
In Control, NE,ow, NEhigh' and Cl30, norepinephrine levels increased 
progressively during the LAD-occlusion by up to approximately 500-fold and 
recovered during reperfusion, independent of the preceding intervention 
(Figure 4). There was no correlation (r=0.03) between the maximum interstitial 
norepinephrine levels during the LAD-occlusion and myocardial infarct size. 
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Figure. 4. Norepinephrine levels in plasma (hatched bars), in the interstitium of the LAD -area 
(OJ and the LCx-area (OJ during 60-min LAD-occlusion and 120-min reperfusion. Notice that 
in the LAD-area levels increased 500-fold during LAD-occlusion independent of the 
preceding interv-ention. Levels in the LCx -area and plasma remained unchanged. 
Discussion 
The major findings of the present study are: (z) global cerebral ischemia, 
produced by either a 1 0-rnin or a 30-rnin elevation of intracranial pressure, 
which by itself produced no irreversible myocardial damage, had no effect on 
myocardial infarct size produced by a 60-rnin coronary artery occlusion; (iz) 
intracoronary infusion of 0.03 nmol· kg·1·rnin·1 norepinephrine produced similar 
increases in myocardial interstitial levels as cerebral ischemia, and did also not 
limit myocardial infarct size; (iiz) conversely, intracoronary infusion of 0.12 
nmol·kg-1·rnin·1 of norepinephrine that resulted in five times higher myocardial 
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interstitial norepinephrine levels than cerebral ischemia and low dose 
norepinephrine was capable of limiting myocatdial infatct size; (iv) the 
catdioprotection by exogenous norepinephrine was not caused by ischemic 
preconditioning and (v) this protection was not associated with a blunting of 
the progressive increase in myocardial interstitial norepinephrine levels during 
the coronary artery occlusion. 
Catecholamines and myocardial injury 
The relation between catecholatnines and myocatdial injury was first 
established by Rona and co-workers,21 .22 who showed some 40 yeats ago that 
administration of high systemic doses of isoproterenol produced focal necrotic 
lesions in normal rat hearts. Elevation of intracranial pressure is well 
recognized as a cause for myocatdial dysfunction and injury. Brain death 
caused by increased intracranial pressure produces echocatdiographic 
alterations, hemodynamic instability, and contraction band necrosis, all of 
which have been suggested to be the result of massive neuronal depolatization 
and release of catecholatnines.23.25 These clinical observations initiated a latge 
number of experimental investigations in which deleterious effects of brain 
death on function and integrity of normal myocatdium were found, but 
generally no or only minimal focal myocatdial necrosis could be 
demonstrated.26'27 
In view of the massive myocatdial norepinephrine release during 
coronary artery occlusion, 15•28 it could be hypothesized that catecholatnines may 
contribute to the development of irreversible injury during a coronary artery 
occlusion. Several,29'30 though certainly not all,31 "32 studies have reported that ~­
adrenergic receptor blockade slows the development of myocatdial infatction. 
In contrast, depletion of catdiac norepinephrine stores by reserpination, did 
not limit myocardial infatct size in rabbits9 and dogs,10 suggesting that 
endogenous catecholatnines do not contribute to irreversible damage. 
In contrast to the potentially deleterious effects of norepinephrine on 
normal and ischemic myocatdium, this catecholamine has also been implicated 
in mediating catdioprotection by ischemic preconditioning. Thus, Toombs et 
al.9 showed that in rabbits the protection by ischemic preconditioning was 
abolished when catecholatnine stores in sympathetic nerve endings were 
depleted by reserpine. Furthermore, Thornton et al.12 demonstrated in the 
same species that tyramine-induced norepinephrine release 10 min before a 30-
min coronary artery occlusion also protected the myocatdium. This 
catdioprotective action of catecholatnines has been confirmed in other species 
r 10 such as the rat' and the dog. We now show that a high dose of 
norepinephrine can also protect the porcine myocatdium. 
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Our data on wall function, myocardial blood flow, 0 2-extraction and 
proton release indicate that the high dose of norepinephrine did not produce 
myocardial ischemia and did therefore not protect the myocardium by ischemic 
preconditioning. The degree of protection afforded by norepinephrine is less 
than reported for ischemic preconditioning, but similar to that produced by 
other non-ischemic stimuli, like ventricular pacing33 and pharmacological 
agents such as the K+ ATP channel openers.34 Since all these stimuli have in 
common that they ultimately activate K+ ATP channels, it is tempting to 
speculate that norepinephrine also protected via IX1-adrenergic receptor-
mediated protein kinase C activation and subsequent opening of 
(mitochondrial) K+ ATP channels.35 Another mechanism by which 
norepinephrine might protect the myocardium is via a blunted release in 
catecholamines during the sustained ischemic episode.36 However, 
pretreatment with norepinephrine did not modify the release of cardiac 
norepinephrine during sustained myocardial ischemia in the present study, 
implying that the norepinephrine-mediated cardioprotection is not related to a 
blunting of the ischemia-induced increase in norepinephrine levels. 
Finally, the present study clarifies another issue on the role of 
norepinephrine in cardioprotection. Przyklenk et a!. 6 demonstrated that 
myocardial ischemia also elicited cardioprotection in adjacent virgin 
myocardium and speculated that this might have been triggered by a substantial 
catecholamine release in that adjacent region. However, we now show that 
norepinephrine levels in the normal (LCx-perfused) myocardium remained 
unaltered during and after the 60-min LAD-occlusion (Figure 4), even though 
the interstitial norepinephrine levels in the LAD-area were 100-fold higher 
than the value observed after 10 min of ischemia, corresponding to the period 
used by Przyklenk et al.6 to precondition the adjacent virgin myocardium. 
Cerebral ischemia as a stimulus for cardioprotection 
Transient ischemia in small intestines, kidneys and skeletal muscle prior to a 
coronary artery occlusion can also be cardioprotective. '·' We therefore 
hypothesized that cerebral ischemia might similarly protect the myocardium, 
especially because cerebral ischemia is associated with substantial 
norepinephrine release, one of the mediators involved in cardioprotection by 
ischemic preconditioning. However, transient cerebral ischemia did not reduce 
myocardial infarct size in the present study. The explanation for the lack of 
protection might be two-fold. Firstly, 30 min of cerebral ischemia did not 
produce myocardial ischemia and could therefore not protect the myocardium 
via ischemic preconditioning. Secondly, although myocardial interstitial 
norepinephrine levels increased during cerebral ischemia, the rise was much 
less than during infusion of the high dose of norepinephrine, which elicited 
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cardioprotection. Tbis is further corroborated by the findings with the low 
dose of norepinephrine, which produced similar interstitial myocardial 
norepinephrine levels as cerebral ischemia, and was also ineffective in 
protecting the heart. 
It could be argued that even the 30-min global cerebral ischemia (CI30) 
was too short to elicit cardioprotection. However, there is ample evidence that 
the intensity of the preconditioning stimulus is more important than its 
duration.37 Moreover, because the elevation of myocardial interstitial 
norepinephrine levels occurred exclusively during the first 10 min of cerebral 
ischemia, it is unlikely that extending the period of cerebral ischemia would 
produce cardioprotection. On the contraty, it might be argued that the 
duration of the intracranial pressure elevation and recovery phase lasted too long 
as the maximum myocardial interstitial norepinephrine levels reached their 
peak during the first 10 min, so that a potential effect of that stimulus was lost 
by the time (50 min later) the LAD was occluded. Tbis is supported by 
observations that the memory for cardioprotection is shorter when stimuli are 
used that do not cause myocardial ischemia.33~4 However, when cerebral 
ischemia was maintained for only 10 min, and the cerebral reperfusion was 
shortened to 20 min (CI10), infarct size after the 60-rnin coronaty artery 
occlusion was also not different from control. 
Finally, it can be excluded that a protective effect of transient global 
cerebral ischemia during the LAD-occlusion was masked by irreversible 
myocardial damage produced by transient global cerebral ischemia prior to the 
LAD-occlusion, as in the animals subjected to only 30 min of cerebral ischemia 
(CI30.,h,J, irreversible damage could not be detected. Tbis observation is in 
agreement with most experimental studies that have generally reported minimal 
or no focal myocardial necrosis following cerebral ischemia.26~7 
Conclusions 
In conclusion, global cerebral ischemia preceding a coronaty artery occlusion 
did not modify myocardial infarct size, which is likely related to the modest 
increase in myocardial norepinephrine levels during cerebral ischemia. The 
infarct size limitation by the high dose of norepinephrine is not associated with 
a blunting of the increase in myocardial interstitial norepinephrine levels during 
the coronaty occlusion. 
Chapter 8 Cerebral ischemia, norepinephrine and cardioprotection 119 
References 
1. Murry CE, Jennings RB, Rcimer KA. Preconditioning with ischemia: a delay of lethal 
cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136. 
2. Toosy N, McMorris EL, Grace PA, Mathie RT. Ischaemic preconditioning protects 
the rat kidney from reperfusion injury. BJU Int. 1999;84:489-494. 
3. Pang CY, Neligan P, Zhong A, HeW, Xu H, Forrest CR. Effector mechartism of 
adenosine in acute ischemic preconditioning of skeletal muscle against infarction. Am J 
PhysioL 1997;273:R887-895. 
4. I..i G, Chen S, Lu E, Hu T. Protective effects of ischemic preconditioning on lung 
ischemia reperfusion injury: an .in-vi.vo rabbit study. Thorac Cardiovasc Surg. 1999;47:38-41. 
5. Stagliano NE, Perez-Pinzon MA, Moskowitz MA, Huang PL. Focal ischemic 
preconditioning induces rapid tolerance to middle cerebral artery occlusion in mice. J 
Cereb Blood Flow Metab. 1999;19: 757-7 61. 
6. Ptzyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 
'preconditioning' protects remote virgin myocardium from subsequent sustained 
coronary occlusion. Circulation. 1993;87:893-899. 
7. Gho BC, Schoemaker RG, Van den Doe! MA, Duncker DJ, Verdouw PD. 
Myocardial protection by brief ischemia in noncardiac tissue. Circulation. 1996;94:2193-
2200. 
8. Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of 
myocardial infarct size by partial reduction of blood supply combined with rapid 
stimulation of the gastrocnemius muscle in the rabbit. Circulation. 1997;96:1641-1646. 
9. Toombs CF, Wiltse AL, Shebuski RJ. Ischemic preconditioning fails to limit infarct 
size in reserpinized rabbit myocardium. Implication of norepinephrine release in the 
preconditioning effect Circulation. 1993;88:2351-2358. 
10. Vander Heide RS, Schwartz LM, Jennings RB, Rcimer KA. Effect of catecholamine 
depletion on myocardial infarct size in dogs: role of catecholamines in ischemic 
preconditioning. Cardiovasc Res. 1995;30:656-662. 
11. Mettes PM, Buttin P, Carteaux JP, Jaboin Y, Dopff C, Pinelli G, Villemot JP, 
Burlet C, Boulange M. Brain death and myocardial injury: role of cardiac sympathetic 
innervation evaluated by in vivo interstitial microdialysis. Transplant Proc. 1994;26:231-232. 
12. Thornton JD, Daly JF, Cohen MV, Yang XM, Downey JM. Catecholamines can 
induce adenosine receptor-mediated protection of the myocardium but do not participate 
in ischemic preconditioning in the rabbit. Circ Res. 1993;73:649-655. 
13. Asimakis GK, Inners-McBride K, Conti VR, Yang CJ. Transient beta adrenergic 
stimulation can precondition the rat heart ~o-ainst postischaemic contractile dysfunction. 
Cardiovasc Res. 1994;28:1726-1734. 
14. Lameris TW, van den Meiracker AH, Boomsma F, Alberts G, de Zeeuw S, 
Duncker DJ, Verdouw PD, Veld AJ. Catecholamine handling in the porcine heart: a 
microdialysis approach. Am J PhysioL 1999;277:H1562-1569. 
15. Lameris T, de Zeeuw S, Alberts G, Boomsma F, Duncker D, Verdouw P, Man in 
't Veld A, van den Meiracker A. Time course and mechanism of myocardial 
catecholamine release during transient ischemia in vivo. Circulation. 2000;101:2645-2650. 
16. Ulatowski JA, Kirsch JR, Traystman RJ. Hypoxic reperfusion after ischemia in swine 
does not improve acute brain recovery. Am J PhysioL 1994;267:H1880-1887. 
17. Davson H. Physiology of thecerebrospinaf fluid. London: Churchill, A; 1967. 
120 
18. Koning :MJ\.1, Simonis LA, De Zeeuw S, Nieukoop S, Post S, Verdouw PD. 
Ischaemic preconditioning by partial occlusion without intermittent reperfusion. 
Cardiovasc Res. 1994;28:1146-1151. 
19. Alberts G, Lameris T, van den Meiracker AH, Man in 't Veld AJ, Boomsma F. 
Sensitive and specific method for the simultaneous determination of natural and synthetic 
catecholamines and 3,4-dihydroxyphenylglycol in microdialysis samples. ] Chromatogr B 
Biomed SciAppl. 1999;730:213-219. 
20. Seberring C, Hag! C, Szabo G, Tochtermann U, Strobel G, Schnabel P, Amann K, 
Vahl CF, Hagl S. Cardiocirculatory effects of acutely increased intracranial pressure and 
subsequent brain death. Eur J Cardiotborac Surg. 1995;9:360-372. 
21. Chappel CI, Rona G, Balazs T, Gaudry R. Comparison of cardiotoxic actions of 
certain sympathomimetic amines. Canad J Biochem. 1959;37:35-42. 
22. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol. 1985;17:291-306. 
23. Hugenholtz PG. Electrographic abnormalities in cerebral disorders: report of six cases 
and review of the literature. Am Heart]. 1962;63:451-461. 
24. DePasquale NP, Burch GE. How normal is the donor heart? Am Heart]. 1969;77:719-
720. 
25. Kolin A, Norris JW. Myocardial damage from acute cerebral lesions. Stroke. 1984;15:990-
993. 
26. Herijgers P, Borgers M, Flameng W. The effect of brain death on cardiovascular 
function in rats. Part I. Is the heart damaged? Cardiovasc Res. 1998;38:98-1 06. 
27. Shanlin RJ, Sole MJ, Rahi.m.ifar M, Tator CH, Factor SM. Increased intracranial 
pressure elicits hypertension, increased sympathetic activity, electrocardiographic 
abnormalities and myocardial damage in rats.] Am Col/ CardioL 1988;12: 727-736. 
28. SchOmig A. Catecholamines in myocardial ischemia. Systemic and cardiac release. 
Circulation. 1990;82:II13-22. 
29. Ku DD, Lucchesi BR Effects of dimethyl propranolol (UM-272; SC-27761) on 
myocardial ischemic injury in the canine heart after temporary coronary artery occlusion. 
Circulation. 1978;57:541-548. 
30. Jang IK, Van de Werf F, Vanhaecke J, De Geest H. Coronary reperfusion by 
thrombolysis and early beta-adrenergic blockade in acute experimental myocardial 
infarction.] Am CollCardioL 1989;14:1816-1823. 
31. TorrS, Drake-Holland AJ, Main M, Hynd J, Isted K, Noble MI. Effects on infarct 
size of reperfusion and pretreatment \Vith beta- blockade and calcium antagonists. Basic 
Res CardioL 1989;84:564-582. 
32. Genth K, Hofmann M, Schaper W. The effect of beta-adrenergic blockade on infarct 
size following experimental coronary occlusion. Basic Res Cardio/. 1981;76:144-151. 
33. Korring MM, Gho BC, Van K!aarwater E, Opstal RL, Duncker DJ, Verdouw PD. 
Rapid ventricular pacing produces myocardial protection by nonischemic activation of 
K+ ATP channels. Circulation. 1996;93:178-186. 
34. Duncker DJ, Verdouw PD. Role of K-ATP channels in ischemic preconditioning and 
cardioprotection. Cardiovasc Drugs Ther. 2000;14:7-16. 
35. Przyklenk K, Kloner RA. Ischemic preconditioning: e.'ploring the paradox. Frog 
Cardiovasc Dis. 1998;40:517-547. 
36. Feng J, Yamaguchi N, Foucart S, Chahine R, Lamont~one D, Nadeau R 
Transient ischemia inhibits nonexocytotic release of norepinephrine follo"ring sustained 
ischemia in rat heart: is bradykinin involved? Can] Physio! Pharmacal. 1997;75:665-670. 
Chapter 8 Cerebral ischemia, norepinephrine and cardioprotection 121 
37. Kotring MM, Gho BC, Van Klaarwater E, Duncker DJ, Verdouw PD. Endocardial 
and epicardial infarct size after preconditioning by a partial coronary artery occlusion 
without intervening reperfusion. Importance of the degree and duration of flow 
reduction. Cardiovasc fus. 1995;30:1017-1027. 

Chapter 9 
Discussion and Summary 
For years sympathetic act!Vlty in man and experimental animals has been 
assessed by measuring circulating catecholamines. As their concentration is not 
only a reflection of release but is also determined by clearance, other more 
precise methods for assessing sympathetic activity have been developed. The 
microdialysis technique allows for a semi-continuous measurement of 
interstitial concentrations in vivo, and is based on diffusion of the substance of 
interest from the intercellular space through a semi-permeable membrane into 
a suitable perfusion fluid like Ringer's or Ringer's lactate. Microdialysis can be 
particularly useful for monitoring sympathetic tone since it allows for the 
measurement of norepinephrine in the intercellular space, i.e. close to the sites 
of release and reuptake. In fact, interstitial norepinephrine levels are reported 
to correlate much more closely with regional sympathetic activity and its 
subsequent physiologic response than plasma norepinephrine concentrations.' 
Another advantage of this technique is the possibility of modification 
of local processes such as neuronal reuptake and presynaptic inhibition of 
norepinephrine without provoking an unwanted systemic response, by adding 
the appropriate agent to the perfusion fluid.24 In this thesis, we validated the 
microdialysis technique for measuring catecholamines (chapter 3) and used it 
to explore the pharmacokinetics (chapter 4), modulation (chapters 5 and 6) and 
pathophysiological role of norepinephrine (chapters 7 and 8) in the intact 
porcine heart. 
Chapter 3. Determination of catecho!amines in microdia!ysis samples 
This chapter describes the validation and technical aspects of the measurement 
of catecholamines in microdialysis samples. We devised a sensitive and 
selective method in which natural and synthetic catecholamines in 
microdialysate samples are simultaneously measured after direct derivatization, 
without an extraction step, with the fluorogenic agent DPE followed by HPLC 
separation and fluorimetric detection. When the thus established derivatization 
procedure was e.xecuted on real microdialysis samples, we noticed that the 
fluorescence of dopamine, 1-erythro-O<-methyl-norepinephrine, norepinephrine 
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and its neuronal metabolite 3,4-dibydrm:yphenylglycol was greatly inhibited, 
while the fluorescence of epinephrine, epinine and isoproterenol was 
unaffected. This phenomenon occurred in microdialysis samples from pigs and 
humans as well as in microdialysis samples from freshly obtained blood, albeit 
to different extents. Apparently, real microdialysis samples contain (an) 
unknown compound(s), which inhibit(s) the derivatization reaction. We found 
that the addition of the sulfhydryl reagent N-ethylmaleimide to the 
microdialysis samples was sufficient to overcome the inhibitory action of these 
unknown compound(s) on the derivatization reaction. 
As a compromise between high relative but low absolute recovery at a 
perfusion rate of 0.5 J.JL/min, and low relative but high absolute recovery at 8 
J.JL/ min, a perfusion rate of 2 J.!L/ min appeared satisfactory, and allowed for a 
sufficiently rapid sampling period of 10 min. At a perfusion rate of 2 J.!L/ min, 
in vitro and in vivo recoveries of norepinephrine were similar (50-60%) and 
compared favorably with the scarce results given in the literature with different, 
laboratory-made microdialysis probes (23-41 %r·7 
Chapter 4. Catecholamine handling in the porcine heart 
This chapter concentrates on the pharmacokinetics of norepinephrine in the 
heart and its modulation by the neuronal reuptake mechanism. Because the 
mechanism underlying the large norepinephrine concentration gradient 
between the interstitial and intra-vascular compartments in the heart was 
uncertain, we investigated to what extent the concentration of norepinephrine 
in the myocardial intercellular fluid relates to its concentration in the arterial 
and coronary venous circulation at baseline and after inducing increments in 
plasma or interstitial norepinephrine concentration either by systemic infusions 
of norepinephrine or by an intracoronary infusion of tyramine. In addition, the 
importance of neuronal reuptake to the interstitial norepinephrine 
concentration was assessed by perfusing one of the probes with the neuronal 
reuptake-inhibitor desipramine and by performing studies with isoproterenol, a 
synthetic catecholamine that is not handled by neuronal reuptake. Finally, 
adaptation of the method introduced by Kopin et al.8 provided an estimate of 
spillover, uptake and consequently, release of norepinephrine. 
The experiments largely confirmed the data about norepinephrine 
kinetics obtained by more indirect but established methods. We concluded 
that neuronal reuptake as well as extra-neuronal uptake and not an endothelial 
barrier are the principal mechanisms underlying the concentration gradient of 
norepinephrine between the interstitial and intra-vascular compartments in the 
porcine heart. 
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Chapter 5. Epinephrine in the heart 
This chapter describes to which extent epinephrine is taken up by and released 
from cardiac sympathetic nerves and whether it can increase myocardial 
interstitial norepinephrine concentrations under basal conditions and during 
sympathetic activation9 This study showed that epinephrine is readily taken up 
from the circulation by the heart, and that 70% is extracted over the cardiac 
vascular bed. In contrast to norepinephrine (chapter 4) most of the extracted 
epinephrine is cleared by other mechanisms than neuronal reuptake. In 
addition, we demonstrated that epinephrine is released during infusion of 
tyramine after loading the cardiac sympathetic nerve terminals with exogenous 
epinephrine, indicaring that cardiac epinephrine is derived from the storage 
vesicles of sympathetic nerves within the myocardium. This observation is in 
line with the results of the study described in chapter 7 demonstrating 
ischemia-induced epinephrine release, which was modulated by the neuronal 
reuptake mechanism. With respect to the function of cardiac epinephrine, we 
did not observe any au,omentation of myocardial norepinephrine release by 
epinephrine either under basal conditions or during activation of cardiac 
sympathetic tone induced by left stellate ganglion stimulation. 
Hence, we hypothesize that the uptake of epinephrine by the heart is 
principally a mechanism for rapid clearance of circulatory epinephrine, and that 
the small amount of locally released epinephrine does not modulate left 
ventricular function. 
Chapter 6. Angiotensin II and norepinephrine release 
In this chapter we investigate the interaction between the sympathetic nervous 
system and the renin-angiotensin-system. Activation of the sympathetic 
nervous system simultaneously leads to activation of the renin-angiotensin-
system via stimulation of f3-adrenergic receptors within the kidney resulting in 
an increased renin release. There is also, albeit conflicring, evidence that the 
sympathetic nervous system is activated by the renin-angiotensin-system.10.22 
This activation supposedly occurs through stimulation of angiotensin II 
receptors within the central nervous system and/ or stimulation of presynaptic 
angiotensin II receptors located at sympathetic nerve terminals. As evidence 
that the cardiac sympathetic nervous system is activated by angiotensin II in 
vivo is scarce 13 or indirect,1623 we determined whether physiological (pM) to 
pathophysiological (lli\1:) concentrations of angiotensin II modulated interstitial 
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norepinephrine concentrations in the intact porcme heart under vanous 
conditions. Our results provided no evidence for facilitation of cardiac 
norepinephrine release by angiotensin II, as intracoronary infusion of 
angiotensin II did not modulate (i) basal sympathetic tone, (ii) exocytotic 
norepinephrine release during sympathetic activation produced by left stellate 
ganglion stimulation, and (iii) exocytotic and nonexocytotic norepinephrine 
release during myocardial ischemia. 
Chapter 7. Cardiac ischemia and local catecholamine release 
In this chapter we explore the fate and potential role of catecholamines and in 
particular of norepinephrine in myocardial ischemia. This study demonstrated 
that myocardial ischemia is associated with a rapid and massive increase of the 
concentration of all three endogenous catecholamines norepinephrine, 
epinephrine and dopamine in the myocardial interstitial fluid as measured with 
the microdialysis technique in vivo. As suggested for norepinephrine in in vitro 
studies,2425 the reversed neuronal reuptake mechanism played an important role 
in the release of all three catecholamines during ischemia in vivo. 
Furthermore, this study showed that after 60 min of ischemia, which 
resulted in massive infarction of the jeopardized myocardium, the functional 
integrity of sympathetic nerve terminals remained intact. Finally, our results 
indicated that cardiac interstitial epinephrine has a neuronal or\,oin (see also 
chapter 5). 
Although the pathophysiological significance of the mass1ve 
accumulation of catecholamines in the ischemic myocardial tissue was not 
investigated in the present study, there is evidence from experimental as well as 
clinical studies that high catecholamine concentrations are deleterious to the 
heart.26.29 On the other hand, several studies have demonstrated 
norepinephrine-dependent anti-arrhythmic effects of neuronal reuptake-
inhibition during ischemia either by tricyclic anti-depressant agents like 
desipramine and imipramine or by structurally unrelated inhibitors of neuronal 
reuptake like cocaine and nisoxetine.30~1 Our study provided a possible 
e:>.-planation for this beneficial effect by demonstrating that the reversed 
neuronal reuptake mechanism contributes substantially to the release of 
catecholamines during ischemia. 
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Chapter 8. Cerebral ischemia, norepinephrine and cardioprotection 
This chapter describes the role of norepinephrine in local and remote 
preconditioning by cerebral ischemia. As norepinephrine is one of the 
mediators involved in the signaling pathway leading to ischemic 
preconditioning,32"33 and because cerebral ischemia causes a profound release of 
norepinephrine from sympathetic nerve endings in normal myocardium, 34 this 
raises the question whether transient cerebral ischemia prior to a coronary 
artery occlusion may also be cardioprotective. 
Global cerebral ischemia, induced by a substantial elevation of 
intracranial pressure, increased cardiac interstitial norepinephrine 
concentrations three-fold. Cerebral ischemia, which by itself caused no 
irreversible myocardial damage, had no effect on the myocardial infarct size 
produced by a 60-rnin coronary artery occlusion. Intracoronary infusion of 
0.03 nmol·kg·1·rnin·1 of norepinephrine induced similar increases in myocardial 
interstitial levels as cerebral ischemia and did not limit myocardial infarct size 
either. Conversely, 0.12 nmol·kg·1·rnin·1 of norepinephrine, which resulted in 
myocardial interstitial norepinephrine levels five times higher than cerebral 
ischemia, limited myocardial infarct size by more than 20%. The 
cardioprotection by exogenous norepinephrine was not caused by ischemic 
preconditioning nor was it associated with a blunting of the progressive 
increase in myocardial interstitial norepinephrine levels during coronary artery 
occlusion. 
Suggestions for future research 
The studies described in this thesis show that microdialysis is a valuable tool 
for measuring as well as for modifying local sympathetic activity. The 
application of this technique allowed a further extension of the knowledge 
concerning the kinetics, modulation and pathophysiological role of the cardiac 
sympathetic nervous system. Nevertheless, many questions remain, of which 
several will be addressed in this paragraph. 
Apart from using microdialysis in acute experiments, i.e. experiments 
within a timeframe of 6-12 hours, we have also tried to apply the technique in 
chronic experiments that can take up to 6 weeks. This would have allowed us 
to monitor cardiac sympathetic activity during the phases of remodeling and 
the development of heart failure after inducing myocardial infarction. This is of 
particular interest since it has been suggested that sympathetic activity increases 
during these two processes.23•3541 Unfortunately, up till now the application of 
microdialysis in these chronic experiments has been unsuccessful because of 
128 
two major problems; (z) the continuous friction of the beating of the heart for 
6 weeks on end (-6 million heartbeats) has proven to be too much for the 
delicate microdialysis probes; (iz) the insertion of a foreign body like a 
microdialysis probe in the myocardium results in an inflammatory reaction in 
the surrounding tissue. The subsequent fibrosis progressively hampers the 
diffusion of the catecholamines from the interstitial space into the perfusate, so 
that the interstitial norepinephrine concentration no longer reflects myocardial 
sympathetic activity. Fortifying the area where the in- and outlet tubes are 
glued to the microdialysis probes with silicone has solved the friction problem, 
but the problem of fibrosis is practically unsolvable. Hence, the solution lies in 
conducting acute microdialysis experiments both at the beginning and end of 
the chronic intervention. While this won't allow for continuous monitoring of 
sympathetic activity during remodeling and heart failure, it can provide insight 
into the changes in sympathetic activity associated with these processes. For 
instance, since some reports suggest that neuronal reuptake is affected in heart 
failure,42"44 it might be interesting to investigate this phenomenon in our 
porcine heart failure model using microdialysis with tyramine and desipramine 
(see also chapter 7). As there is evidence that the facilitation of norepinephrine 
release by angiotensin II is particularly apparent in heart failure, Z3.4S-4B it would 
also be interesting to verify our findings in chapter 6 during heart failure. 
Laser-induced-fluorescence, a new analytical technique that has 
recently been introduced in our laboratory, allows for an even more sensitive 
determination of catecholamines. In addition, it is probably also suitable for 
the determination of peptides like angiotensins and bradykinin. If this 
technique comes of age, it would open up a vast array of opportunities for 
future research. For instance, the microdialysis of angiotensins from the 
cardiac interstitium has proven to be troublesome, as the two studies on this 
subject report large differences in interstitial angiotensin II concentrations!9•50 
A more sensitive direct determination of angiotensin I and II might be able to 
resolve this matter and could provide important pharmacokinetic information 
on the distribution of these peptides over the circulatory, intercellular and 
intracellular compartments. Moreover, this could facilitate the investigation of 
the role and modulation of these peptides and their receptors. 
Last but not least, while the physiology and pathophysiology of the 
porcine heart are akin to that of the human heart, it would be very interesting 
to use the microdialysis technique to measure local sympathetic activity in 
humans. Obviously, it will not be feasible to monitor the cardiac sympathetic 
activity in humans with microdialysis, but a more sensitive determination of 
catecholamines would allow for measuring interstitial catecholamine 
concentrations in skin and muscle. Until now, we were only able to measure 
interstitial norepinephrine concentrations in subcutaneous fat of patients with 
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very high endogenous plasma norepinephrine concentrations (e.g. patients with 
a norepinephrine-producing pheochromocytoma, Figure 1). 
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Figure 1. Interstitial (subcutaneous fat) 
and arterial plaslllil norepinephrine 
concentrations of two patients with a 
norepinephrine-producing 
pheochromocytoma. Data are shown 
for patient 1 (solid bars) and patient 2 
(hatched bars) as mean±SD (6 samples 
per patient). 
The combination of microdialysis with strain-gauge plethysmography, a 
technique that is used in our laboratory to measure forearm blood flow, is 
particularly appealing as it would be possible to monitor and modulate forearm 
muscle sympathetic activity in a flow-controlled e>:perimental setup, which is 
essential to pharmacokinetic studies because of flow-induced changes in 
clearance of norepinephrine. 51 For instance, adding the measur=ent of muscle 
sympathetic nerve activity to this combination would allow for the 
investigation of the relationship between nerve-firing, interstitial 
norepinephrine concentrations and spillover. This would be of particular 
interest in patients with heart failure as the mechanism underlying the 
associated increase in sympathetic tone is still unclear!352 Such an approach 
could distinguish whether the activation of the sympathetic nervous system is 
due to a%omented sympathetic nerve traffic or to an increase in interstitial 
norepinephrine concentrations as a result of diminished clearance, e.g. due to a 
failing neuronal reuptake. 
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N ederlandse samenvatting 
Het hart is de drijvende kracht achter de bloedsomloop en daarmee essentieel 
voor de zuurstofvoorziening van het lichaam. Het hart klopt spontaan, maar de 
reactie op verandering in activiteit van het lichaam wordt gestuurd door twee 
tegengesteld werkende systemen die vanuit de hersenen de hartfunctie en 
bloeddruk regelen. Aan de ene kant is er het sympathische zenuwstelsel dat de 
bloedsomloop aanpast aan een verhoogde zuurstofbehoefte van het lichaam. 
Bijvoorbeeld tijdens hardlopen gaat het hart niet aileen sneller doch ook 
krachtiger pompen, de bloedvaten in de voor de activiteit benodigde spieren 
verwijden, terwijl de bloeddoorstroming in andere gebieden van het lichaam 
die niet bij de activiteit betrokken zijn zoals de ingewanden juist afueemt. Aan 
de andere kant 1s er het parasympathische zenuwstelsel dat de 
bloeddoorstroming aanpast aan inact!Vltelt en herstel. W anneer het 
parasympathische zenuwstelsel overheerst klopt het hart rustiger en verwijden 
de bloedvaten in organen als de darmen, nieren en lever zodat de bloedtoevoer 
daar toeneemt. 
Toename van de sympathische activiteit leidt tot een verhoogde afgifte 
van de neurotransmitter noradrenaline uit de sympathische zenuwuiteinden en 
van vooral adrenaline uit het bijniermerg. Noradrenaline en adrenaline binden 
zich aan receptoren in bijvoorbeeld hart en bloedvaten en oefenen zo hun 
werking uit. V anwege hun chemische structuur behoren heiden tot de 
catecholamines. Dopamine is een derde catecholamine, en is met name een 
belangtijke neurotransmitter in de hersenen en tevens de biochemische 
voorloper van noradrenaline en adrenaline. 
Over het algemeen wordt de activiteit van het sympathische 
zenuwstelsel gemeten door de concentratie van catecholamines in het bloed te 
meten. De concentratie van deze catecholamines in het bloed hangt echter niet 
aileen af van de mate waarin zij worden geproduceerd en worden vtijgemaakt, 
maar ook van de snelheid waarmee zij worden geklaard hetzij door heropname 
in de sympathische zenuwuiteinden (het neuronale opnamemechanisme) hetzij 
door afbraak. Ter bepaling van de sympathische activiteit zijn de afgelopen 
jaren zijn er dan ook methoden ontwikkeld die niet van de catecholamine-
concentratie in het bloed afhankelijk zijn, hetzij door specifiek de uitstoot van 
noradrenaline in het bloed te meten met behulp van radioactief gemerkt 
noradrenaline, hetzij door de elektrische impulsen van de sympathische 
zenuwen te registreren. 
Microdialyse is een nieuwe techniek waarmee via dunne kathetertjes de 
concentratie van stoffen in de vloeistof tussen de cellen (de zgn. interstitii'le 
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vloeistof) bijna onafgebroken kan meten. Deze techniek is gebaseerd op 
diffusie van stoffen vanuit de interstitiele vloeistof door een halfdoorlatende 
membraan dat alleen kleine moleculen doorlaat, naar een geschikte vloeistof 
die heel traag ( enkele microliters per minuut) door de katheter gepompt wordt 
(het zgn. perfusaat) zoals de Ringers-oplossing (zie figuur 1). 
Lengte membraan: 
L--~~='~:£J[ ____ ~~O~m~m~-------=~~~::~ Porie-grootte membraan: 
20 kD 
Figuur 1. De microdialyse katheter. IN: slange* waarlangs het perfusaat naar binnen gaat; 
UIT: slange* waarlangs het dialysaat naar buiten komt. Afgel eid van de intemetpagirut van 
Carnegie Medicine AB (http:/ /www.microdialysis.se). 
Microdialyse is bij uitstek geschikt om de regionale sympathische 
activiteit te meten, omdat met deze techniek de concentratie van noradrenaline 
dichtbij de plaatsen van uitstoot en opname kan worden gemeten (figuur 2). 
Dit wordt nog eens bevestigd door experimenten die hebben laten zien dat de 
interstitiele noradrenaline concentratie beter met de regionale sympathische 
activiteit en de daaraan verbonden fysiologische respons overeenkomt dan de 
noradrenaline concentratie in het bloed.1 
Een ander voordeel van deze techniek is dat niet alleen stoffen h.-unnen 
worde opgevangen in de dialysevloeistof, maar ook lokale processen als 
neuronale opname en presynaptische inhibitie (figuur 2) kunnen worden 
be!nvloed door toevoeging van pharmaca aan het perfusaat. De pharmaca in 
het perfusaat zullen op dezelfde wijze vanuit het perfusaat naar het interstitium 
diffunderen als de stoffen in de interstitiele vloeistof naar de dialysevloeistoE_14 
Dit proefschrift gaat in op de functie van het sympathische 
zenuwstelsel in het hart, en dan met name op die van de neurotransmitter 
noradrenaline. Na de inleiding (hoofdstnk 1), het uiteenzetten van de 
doelstellingen (hoofdstnk 2), en de bespreking van de techniek (hoofdstnk 3) 
wordt de rol van catecholamines bij de fysiologie van het hart besproken: 
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Figuur 2. Sympathische zenmvuiteinden in het hart: presynaptische facilitatie en inhibitie. 
Getoond zijn de uitstulpingen v--an de zenuwuiteinden met daari.n de blaasjes waarin 
noradrenaline (NA) opgeslagen is, het neuronale opname mechanisme (Ul), de 
presynaptische :recepto:ren die de afgifte van noradrenaline faciliteren (+), bijv. de ~z­
adrenergische receptor (~z), de thromboxa.an type 2 receptor (TXAz) en de angiotensine-II 
type 1 receptor (AT,), evenals de receptoren die de afgifte remmen ( -), bijv. de adenosine Al-
receptor (Al), de <X2-adrenerge receptor (r<2) en de prostaglandine PGE,-receptor (PGE,). 
hoeveel noradrenaline (hoofdstuk 4) en adrenaline (hoofdstuk 5) wordt er in 
het hart opgenomen, hoeveel wordt er door de zenuwuiteinden uitgestoten en 
welke stoffen kunnen deze opname en afgifte befuvloeden (hoofdstuk 6). In de 
laatste twee hoofdstukken wordt ook de rol van noradrenaline bij de 
pathofysiologie van het hart onderzocht: zowel de assoe1ane met 
zuurstoftekort en de daarmee gepaard gaande hartritmestoornissen (hoofdstuk 
7), als ook de betrokkenheid bij juist de bescherming van het hart tegen 
zuurstoftekort (hoofdstuk 8). De hoofdstukken 3 tot en met 8 hebben 
betrekking op de werkelijke studies die in het kader van dit proefschrift gedaan 
zijn en zullen hieronder per hoofdstuk kort behandeld worden. 
Hoofdstuk 3. De bepa!ing van catecho!amines in microdiafyse monsters 
Dit hoofdstuk beschrijft de technische aspecten en validatie van de bepaling 
van catecholamines in microdialyse-monsters. Wij ontwikkelden een gevoelige 
en selectieve methode waarmee natuurlijke en synthetische catecholamines 
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gelijktijdig gemeten konden worden in zeer kleine volumina van h.-unstmatige 
oplossingen na derivatisering met een fluorophoor gevolgd door HPLC 
scheicling en fluorimetrische detectie. Toen de methode werd toegepast op 
'echte' (in vivo) microdialyse-monsters, bleek dat de fluorescentie van 
dopamine, ()(-methylnoradrenaline, noradrenaline en 3,4-clihydroxyphenylglycol, 
de neuronale metaboliet van noradrenaline, sterk was geremd, terwijl de 
fluorescentie van adrenaline, epinine and isoprenaline onaangedaan was. Dit 
fenomeen trad op bij microdialyse monsters van zowel varkens als patienten. In 
vivo microdialyse monsters bevatten klaarblijkelijk een of meer onbekende 
stoffen die de derivatiseringsreactie kunnen remmen. De toevoeging van het 
sulfhydryl reagens N-ethylmaleimide bleek voldoende om de remmende 
werking op de derivatisering te niet te doen. 
Bij wijze van compromis mssen een hoge relatieve maar !age absolute 
opbrengst bij een perfusiesnelheid van 0.5 f.!}/ min, en een !age relatieve maar 
hoge absolute opbrengst bij 8 f.!.)/ min, bleek een perfusiesnelheid van 2 f.!.)/ min 
optimaal. Bij een perfusiesnelheid van 2 f.!}/ min waren de relatieve in vitro en in 
vivo opbrengsten voor noradrenaline nagenoeg gelijk (50-60%)en h.-wamen goed 
overeen met die zoals beschreven in de schaarse smdies waarin meestentijds 
gebruik gemaakt werd van zelfgemaakte microdialyse katheters (23-41 %).5·7 
Hoofdstuk 4. De farmacokinetiek van catecho!amines in het varkenshart 
Dit hoofdsmk concentreert zich op de farmacokinetiek van noradrenaline in 
het hatt en de beinvloecling daarvan door het neuronale opnamemechanisme. 
Tussen de interstitiele en de intravasculaire ruimten bestaat een grote gradient 
in noradrenalineconcentraties. Het mechanisme dat hieraan ten grondslag ligt is 
tot op heden nog onopgehelderd. Daarom onderzochten wij hoe de 
noradrenalineconcentratie in de interstitiele vloeistof van het hattspierweefsel 
zich verhoudt tot de concentratie in het arteriele en het veneuze bloed onder 
basale omstandigheden en na het verhogen van zowel de interstitiele 
noradrenalineconcentratie als de noradrenalineconcentratie in het bloed. De 
concentratie in het bloed werd verhoogd door noradrenaline intraveneus toe 
te dienen, terwijl de interstitiele noradrenalineconcentratie werd verhoogd door 
infusie van tyramine via een van de kransslagaders. Tyramine heeft een hogere 
affiniteit voor de opslageiwitten van noradrenaline en verdrijft zodoende na 
opname in het zenuwuiteinde via het neuronale opnamemechanisme 
noradrenaline uit de opslagblaasjes en vervolgens uit de zenuwuiteinden (f\,ouur 
2). Ook werd het belang van de neuronale opname voor de hoogte van de 
noradrenalineconcentratie onderzocht door een van de rnicrodialyse katheters 
te perfunderen met de neuronale opnameremmer desipramine, en middels 
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experimenten met isoprenaline, een synthetisch catecholamine dat niet door 
het neuronale opnamemechanisme opgenomen wordt. Tenslotte maakte 
aanpassing van de methode beschreven door Kopin et al. 8 het mogelijk 
spillover, opname en uitstoot van noradrenaline uit de zenuwuiteinden te 
berekenen. 
De experimenten bevestigden in belangrijke mate de data aangaande de 
farmacokinetiek: van noradrenaline zoals verkregen met indirecte benaderingen. 
Wij concluderen dat vooral neuronale en in minder mate extraneuronale 
opname en niet een endotheliale barriere verantwoordelijk zijn voor de 
genoemde concentratiegradient van noradrenaline tussen de interstitie!e en 
intravasculaire ruimten in het varkenshart. 
Hoofdstuk 5. Adrenaline in het hart 
Dit hoofdstuk beschrijft in welke mate adrenaline wordt opgenomen en 
uitgestoten door de sympathische zenuwuiteinden in het hart. Tevens werd 
onderzocht of de interstitie!e noradrenalineconcentratie onder invloed van 
adrenaline kan stijgen. Deze studie laat zien dat adrenaline gemakkelijk vanuit 
de bloedbaan wordt opgenomen door het hart. Van het via de kransslagader 
aangeboden adrenaline wordt 70% onttrokken. In tegenstelling tot wat we 
zagen voor noradrenaline (hoofdstuk 4), wordt het grootste dee! van dit 
onttrokken adrenaline geklaard door andere mechanismen dan neuronale 
opname. Ook kon worden aangetoond dat adrenaline uitgestoten wordt tijdens 
infusie met tyramine mits het hart tevoren was opgeladen met adrenaline, 
hetgeen suggereert dat het cardiale adrenaline afkomstig is uit de opslagblaasjes 
in de sympathische zenuwuiteinden van het hart. Deze waameming komt 
overeen met de resultaten van de studie beschreven in hoofdstuk 7, waarin 
aangetoond wordt dat de door zuurstoftekort gelo.duceerde uitstoot van 
adrenaline gemoduleerd kan worden door het neuronale opnamemechanisme. 
Alhoewel gesuggereerd is dat het cardiale adrenaline de uitstoot van 
noradrenaline uit sympathische zenuwuiteinden bevordert, konden wij dat in 
onze studies niet bevestigen; noch onder basale omstandigheden noch 
gedurende activatie van de sympathicus tonus door elektrische stimulatie van 
het linker ganglion stellatum (het laatste sympathische neuronale 'tussenstation' 
tussen de hersenen en het hart). Op grond van deze waarnemingen denken we 
dat de opname van adrenaline door het hart voomamelijk een mechanisme is 
voor de snelle !daring van circulerend adrenaline waardoor de werkingsduur 
van adrenaline zo kort mogelijk is. 
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Hoofdstuk 6. Angjotensine-II en de a£gifte van noradrenaline 
Dit hoofdstuk beschrijft de interactie tussen het sympathische zenuwstelsel en 
het renine-angiotensine-systeem in het hart. Activatie van het sympathische 
zenuwstelsel leidt gelijktijdig tot activatie van het renine-angiotensine-systeem 
via stimulatie van ~-adrenerge receptoren in de nier met als gevolg een 
toegenomen afgifte van renine aan het bloed. Er zijn echter ook aanwijzingen, 
hoewel niet eenduidig, dat het sympathische zenuwstelsel kan worden 
geactiveerd door het renine-angiotensine-systeem.9.21 Deze wijze van activatie 
zou bewerkstelligd worden via stimulatie van angiotensine-II receptoren in de 
hersenen en/ of presynaptische angiotensine-II receptoren op de sympathische 
zenuwuiteinden (figuur 2). Omdat aanwijzingen voor het bestaan van een 
dergelijke interactie in het hart in vivo schaars 12 en indirect 15,22 zijn, 
onderzochten wij of £Ysiologische (1 0"12 mol/1) tot patho£Ysiologische (1 o·' 
mol/1) angiotensine-II concentraties onder diverse omstandigheden de 
interstitiele noradrenaline concentratie in het intacte varkenshart bcinvloeden. 
In onze studie kon geen facilitatie van de noradrenalineafgifte door 
angiotensine-II worden aangetoond: toediening van angiotensine-II via een 
kransslagader veranderde noch de basale sympathicus tonus van het hart, noch 
de noradrenalineafgifte tijdens sympathische activatie, bewerkstelligd door 
respectievelijk ganglionstimulatie en acuut zuurstoftekort van het 
hartspierweefseL 
Hoofdstuk 7. Zuurstrjtekort van bet hart en !oka!e a£,uifte van catecho!amines 
In dit hoofdstuk worden het lot en de mogelijke rol van catecholamines en met 
name noradrenaline tijdens acuut zuurstoftekort van het hartspierweefsel 
behandeld. Onze resultaten Iaten zien dat dit zuurstoftekort is geassocieerd met 
een snelle massale stijging van de interstitiele concentratie van noradrenaline, 
adrenaline en dopamine. Zoals eerder gesuggereerd voor noradrenaline in in 
vitro studies,2324 wordt deze uitstoot in belangrijke mate veroorzaakt door 
omkering van het neuronale opnamemechanisme. Bovendien laat deze studie 
zien dat na een 60 minuten durende afsluiting van de kransslagader waarbij 
meer dan 80% van het bedreigde hartspierweefsel afsterft, de functie van de 
sympathische zenuwuiteinden behouden blijft. 
Hoewel de pathofYsiologische consequentie van de buitengewoon hoge 
noradrenalineconcentratie in het zuurstofarme hartspierweefsel in deze studie 
niet is onderzocht, zijn er aanwijzingen vanuit experimentele en klinische 
studies dat hoge catecholamineconcentraties toxisch zijn voor het hart25.28 Ook 
is uit onderzoek gebleken dat tricyclische antidepressiva zoals desipramine en 
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imipramine, als ook andere niet-verwante remmers van het neuronale 
opnamemechanisme zoals cocaine en nisoxetine, het ontstaan van 
noradrenaline-afhankelijke ritmestoornissen tijdens zuurstoftekort van het hart 
remmen.29~0 Onze studie geeft een mogelijke verklating voor dit gunstige effect 
door aan te tonen dat de omkering van het neuronale opnamemechanisme in 
belangtijke mate bijdraagt aan de uitstoot van catecholamines tijdens 
zuurstoftekort van het hart. 
Hoofdstuk 8. Zuurstoftekort van de hersenen, noradrenaline en bescherming van bet hart 
In dit hoofdstuk wordt de rol van noradrenaline bij lokale preconditionering en 
preconditionering op afstand door zuurstoftekort van de hersenen beschreven. 
Korte perioden van zuurstoftekort 1:unnen het hart beschermen tegen een 
daaropvolgende langere periode van zuurstoftekort, de zgn. ischemische 
preconditioneting. Deze bescherming is in meerdere organen zoals het hart en 
de hersenen aangetoond en kan ook op afstand plaatsvinden: kortdurende 
perioden van zuurstoftekort in een ander gebied binnen het betreffende orgaan 
of zelfs in een ander orgaan kunnen het orgaan beschermen tegen een 
volgende periode van zuurstoftekort. Omdat zuurstoftekort van de hersenen 
gepaard gaat met een forse uitstoot van noradrenaline vanuit de sympathische 
zenuwuiteinden in normaal hartspierweefsel 33 en omdat noradrenaline 
betrokken is bij de signaaloverdracht van preconditionering,31 •32 rijst de vraag of 
een korte periode van zuurstoftekort van de hersenen voorafgaand aan 
afsluiting van een kransslagader het hart tegen het daaropvolgende 
zuurstoftekort beschermt. 
Zuurstoftekort van de hersenen, bewerkstelligd door een sterke 
verhoging van de hersendruk, leidde tot een dtievoudige stijging van de 
interstitieJ.e noradrenalineconcentratie in het hart. Het zuurstoftekort van de 
hersenen had geen effect op de grootte van het hartinfarct veroorzaakt door 
afsluiting van een kransslagader. Het toedienen van een relatief !age 
hoeveelheid noradrenaline via de kranssla,o-ader met vergelijkbare interstitiele 
noradrenalinespiegels als tijdens zuurstoftekort van de hersenen verkleinde het 
hartinfarct evenmin. Echter, toediening van een grotere hoeveelheid 
noradrenaline, leidend tot vijftnaal hogere interstitiele noradrenalinespiegels 
dan de eerder genoemde interventies, verkleinde daarentegen het aangedane 
gebied met meer dan 20%. Deze bescherming door exogeen noradrenaline was 
niet te wijten aan ischemische preconditionering ten gevolge van 
noradrenaline-gemedieerd zuurstoftekort noch was deze geassocieerd met 
verminderde uitstoot van noradrenaline gedurende de afsluiting van de 
kransslagader. 
140 
Suggesties voor verder onderzoek 
De studies in dit proefschrift tonen aan dat microdialyse een waardevol 
instrument is om de lokale sympathische activiteit te meten en te moduleren. 
De toepassing van deze techniek heeft onze kennis over de rol van het cardiale 
sympathische zenuwstelsel verder verdiept. Desalniettemin blijven nog vee! 
vragen onbeantwoord, waarvan enkele in deze paragraaf behandeld zullen 
worden. 
Naast het gebruik van microdialyse bij kortdurende experimenten (6-12 
uur), hebben wij ook getracht de techniek aan te wenden bij chronische 
experimenten die wei 6 weken lmnnen duren. Dergelijke experimenten zouden 
het mogelijk gemaakt hebben de sympathische activiteit tijdens de 
verschillende fases van het remodelleringsproces en de ontwikkeling van 
hartfalen na een hartinfarct te volgen. Dit is met name van belang omdat er 
duidelijke aanwijzingen zijn dat de sympathische activiteit tijdens deze 
processen toegenomen is.22"3440 Helaas bleek chronische microdialyse in het 
hart tot op heden niet erg succesvol vanwege twee belangtijke problemen: (f) 
de microdialyse-kathetertjes waren niet hestand tegen de continue ftictie van 
het kloppen van het hart gedurende 6 weken (-6 miljoen hartslagen), metals 
gevolg lekkage of verstopping; (jz) de aanwezigheid van lichaamsvreemd 
materiaal zoals microdialyse-kathetertjes in het hartspierweefsel leidt tot een 
ontstekingsreactie in het omliggende weefsel. De daaropvolgende fibrose 
hindert de diffusie van de catecholamines vanuit de interstitie!e ruimte naar het 
perfusaat zodanig dat de interstitie!e noradrenaline concentratie niet Ianger de 
lokale sympathische activiteit vertegenwoorcligt. Het verstevigen van de plaats 
waar de slangetjes voor de in- en afvoer in het microdialyse-kathetertje 
samengelijmd zijn met siliconenkit heeft het frictieprobleem weliswaar 
opgelost, maar het fibroseprobleem is nagenoeg onoplosbaar. Zodoende ligt de 
oplossing in het doen van kortdurende experimenten aan het begin en einde 
van de chronische interventie. Hoewel dit niet een volledig beeld zal kunnen 
geven van de veranderingen in sympathische activiteit tijdens remodellering en 
hartfalen, verschaft een dergelijke opzet wei inzicht in de grove veranderingen 
in activiteit die met deze processen in verband gebracht worden. 
Aangezien er enige aanwijzingen zijn dat de neuronale opname van 
noradrenaline bij hartfalen gestoord is;143 kan het zeker waardevol zijn om dit 
fenomeen in ons hartfalenmode! bij varkens te onderzoeken met tyramine en 
desipramine (zie ook hoofdstuk 7). In het zelfde diermodel zou het ook 
interessant zijn onze resultaten in hoofdstuk 6 nog eens te verifieren omdat een 
aantal studies hebben aangetoond dat de facilitatie van noradrenaline door 
angiotensine-II bij hartfalen in het bijzonder een belangtijk mechanisme is.22·"'" 
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Recentelijk is in ons laboratorium een nieuwe analytische techniek, de 
laser-geinduceerde-fluorescentie, ge!ntroduceerd. Met deze techniek neemt de 
gevoeligheid van de bepaling van catecholarnines belangrijk toe. Daarenboven 
zou met deze techniek de bepaling van peptiden als bradykinine en 
angiotensines in rnicrodialyse-monsters wellicht eenvoudiger worden. De twee 
studies die met conventionele methoden de concentratie van angiotensine-II in 
rnicrodialyse-monsters hebben gemeten, rapporteren sterk uiteenlopende 
interstitiele angiotensine-II concentraties in het hart!8•49 Een gevoeliger en 
directere techniek om angiotensine-I en II te bepalen zou de werkelijke 
interstitiele angiotensine-II concentratie wellicht beter kunnen benaderen en 
bovendien belangrijke informatie kunnen verschaffen over de farrnacokinetiek 
van deze peptiden en hun verdeling over de circulatoire, inter- en intracellulaire 
compartirnenten. Hierdoor zou aan het onderzoek naar de rol en modulatie 
van deze peptiden en hun receptoren een krachtige nieuwe irnpuls gegeven 
l-unnen worden. 
Hoewel de fysiologie als ook de pathofysiologie van het varkenshart 
sterk overeenkomt met die van het hart van de mens, zou het zeer aantrekkelijk 
zijn de rnicrodialyse techniek aan te wenden om de lokale syrnpathische 
activiteit bij de mens te meten. Het is weliswaar niet mogelijk zonder meer de 
syrnpathische activiteit met rnicrodialyse bij de mens in het hart te meten, doch 
met een gevoeliger bepaling van catecholarnines zou het wel mogelijk zijn de 
syrnpathische activiteit in subcutaan vet en spier te meten. Tot op heden is het 
ons alleen gelukt de interstitiele noradrenaline concentratie in subcutaan vet te 
meten bij patienten met sterk verhoogde noradrenalinespiegels in het bloed, 
zoals bij patienten met een noradrenaline-producerende bijnierturnor (zie 
figuur 3). 
interstitiele ruimte arterieel plasma 
Figuur 3. Interstitiele ( subcutaan vet) en 
arteriele noradrenalineconcentraties van 
twee patiffiten met een noradrenaline-
producerende bijniertumor. 
Getoond worden de data van patient 1 
( dichte balk en) en patient 2 (gearceerde 
balken) als gentiddelde±SD (6 monsters 
per patient). 
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De combinatie van rnicrodialyse met "strain-gauge" -plethysmografie, 
een techniek die in ons laboratorium gebruikt wordt om de bloedstroom (flow) 
door de onderarm te meten, lijkt zeer aantrekkelijk aangezien het hierdoor 
mogelijk is de sympathische activiteit in de onderarm te meten en te moduleren 
onder flow-gecontroleerde omstandigheden. Dit laatste is bij farmacokinetische 
studies essentieel vanwege de invloed van flow op de klaring van 
noradrenaline. 50 Het uitbreiden van deze combinatie met het gelijktijdig meten 
van de (elektrische) zenuwactiviteit in de spieren van de onderarm biedt de 
mogelijkheid de relatie tussen de werkelijke zenuwactiviteit, de interstitiele 
noradrenaline concentratie en spillover te onderzoeken. Zulk onderzoek is met 
name waardevol bij patienten met hartfalen, aangezien het mechanisme achter 
de met hartfalen geassocieerde toename van sympathische activiteit nog altijd 
niet opgehelderd is.'2•51 Met deze benadering zou onderscheid gemaakt h."U111len 
worden of de activatie van het sympathische zenuwstelsel het gevolg is van een 
toename in elektrische activiteit in de sympathische zenuwen dan wel van 
verhoogde interstitiele noradrenalineconcentraties, bijvoorbeeld als gevolg van 
een falend neuronaal opnamemechanisme. 
N.B. De voertaal in dit proefschrift is het Amerikaans-Engels, de stofnamen 
noradrenaline, adrenaline en isoprenaline worden dan ook in de rest van dit 
proefschrift gespeld als respectievelijk norepinephrine, epinephrine en 
isoproterenol. 
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Dankwoord 
Vaak wordt op deze plaats geschreven hoe moeilijk het is een danb:woord te 
formuleren en hoe gevaarlijk bovendien, - men zou maar eens iemand kunnen 
vergeten - geenszins! Na vier jaar onderzoek en het schrijven van een 
proefschrift kan het oprecht bedanken van mensen voor hun steun en bijdrage 
toch geen opgave zijn. Ik heb er zin in en ga er dan ook de ruimte voor nemen 
(op een proefschrift van 150+ bladzijden mist men twee, drie kan*s niet ... ). 
In september 1993 b.-warn ik (strak in pak, maar met knikkende knieen) 
met Diederik de J ong voor het eerst op de afdeling Interne I bij Dr. Frans 
Derkx om hem om raad te vragen naar aanleiding van een onderzoek dat wij 
deden bij de gynaecologie in het St. Catherina ziekenhuis in Eindhoven. Hij 
kon ons niet helpen, maar bood ons na de vraag "hebbie spijtserum?" meteen 
een onderzoek aan. Wij hadden geen spijtserum, maar zijn gelijk gebleven om 
in mijn geval eigenlijk niet meer weg te gaan. Frans zijn enthousiasme, 
vriendelijkheid en innemende verstrooidheid (hij was de belichaming van de 
spreekwoordelijke verstrooide professor) hebben mijn eerste schreden in de 
wetenschap tot een hele pretrige herinnering gemaakt. Het is ook daarom dat 
het mij zwaar valt Frans nu na zijn zoveelste hersenbloeding in dit danb.-woord 
toe te spreken aangezien hij het wellicht niet meer zal b.-lmnen lezen c.q. horen. 
Ik wil hem en zijn vrouw Idje in ieder geval enorm veel sterkte wensen; 
parafraserend op de woorden van zijn broer J os bij een zeer geslaagde maaltijd 
tijdens een afdelingsui*: "Frans, nog efkes door klappen!". 
Na Frans Derkx wil ik heel graag mijn directe begeleider, baas en co-
promotor, Dr. A.H. van den Meiracker bedanken: Ton, vier jaar geleden heb ik 
jouw aanbod om mijzelf en de microdialyse techniek in een jaar te bewijzen na 
het afslaan van eerdere AIO-onderzoeken, hetgeen voor velen zeer 
ongebruikelijk (bijna onfatsoenlijk) was, met beide handen aangenomen en ik 
heb daar nooit spijt van gehad. De relatieve clandestiniteit waarin mijn 
onderzoek zich voltrok (niet iedereen was volledig op de hoogte van de aard 
van mijn aanstelling) heeft mij als wetenschappelijk broekie zeer veel vrijheid 
opgeleverd waarvan ik hoop dat ik die waard geweest ben. Door die vrijheid en 
aangezien jij niet een man van veel woorden bent, had ik de eerste tijd geen 
idee of ik het wetenschappelijk bij het juiste eind had. Ik heb naderhand maar 
stiekem aangenomen dat het in mij gestelde vertrouwen en het feit dat ik een 
aantal malen met je heb mogen samenwerken aan een aantal andere 
onderzoeken en een boekje, betekenden dat het we] in orde was. Enfin, ik heb 
onze samenwerking altijd zeer op prijs gesteld en hoop dat we die in de 
toekomst ook voort kunnen zetten. Er zijn ondanks alle ellende nog genoeg 
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leuke dingen te doen! Zo lijkt de ontwikkeling van het vakgebied 
( cardio )vasculaire geneeskunde me veelbelovend en is deze voor de eigen 
afdeling wellicht een goede gelegenheid om de gedachten weer op een lijn te 
krijgen; om met Frans Derkx te spreken: "Kop houden, pipetteren!". 
De e":perimenten voor dit proefschrift heb ik mogen doen op de 
afdeling e::-..1'erimentele cardiologie die geleid wordt door mijn promotor 
Prof.dr. P.D. Verdouw en Dr. D.]. Duncker. Piet, ik weet dat jij en Dirk-Jan 
met name in het begin nogal vreemd opkeken van mijn manier van doen: 
terwijl jullie meer vat op mijn onderzoek wilden krijgen probeerde ik juist 
heftig mijn zojuist verkregen vrijheid niet prijs te geven. In tegenstelling tot het 
'hands-on' beleid jegens jullie eigen jonge onderzoekers was ik gewend aan 
(verwend door) het bij ons heersende "geen nieuws, goed nieuws" principe. 
Achteraf denk ik dat ik in de afgelopen jaren "the best of both worlds" gehad 
heb: aan de ene kant de vrijheid en het vertrouwen van de Interne, aan de 
andere kant het enthousiasme en de drang tot presteren van de e::-..1'erimentele 
cardiologie. Hiervoor ben ik jou, c.q. jullie heiden, zeer dankbaar. Zo ook voor 
jou hulp en persoonlijke aandacht bij mijn sollicitatie voor de opleiding 
cardiologie; die wedstrijd hebben we grotendeels samen gewonnen, denk ik. 
Niet alleen de Ieiding van deze afdeling moet ik bedanken, doch zeker 
ook Dr. P.A. de Zeeuw met wie ik alle dierexperimenten in dit proefschrift heb 
gedaan. Sandra, ik weet het, de experimenten waren vaak lang en zeker niet 
altijd even spannend en dat laatste gold met nadruk voor de analyses die je 
voor me gedaan hebt. Ik wil je dan ook ontzettend bedanken voor je 
gezelligheid en je enorme inzet die vanwege de MKZ-crisis zelfs je verblijf op 
de afdeling oversteeg. Ik wens jou en John alle goeds (tot op de bruiloft?). 
Naast Sandra waren er nog een aantal mensen bij 'de e::-..1'erimentele' die 
absoluut een woord van dank verdienen vanwege hun bijdrage en/ of 
gezelligheid (bijna net zo belangrijk): Serge (onze paden zullen elkaar zeker nog 
een keer kruisen, hopelijk met veel wijn en goede muziek), Elza (is er nog 
nieuws?), Monique (ga je nou nog s doorbreken bij de Kernploeg? de winter 
komt erweer aan!), Rob van Bremen, Wouter, Tessa,Joris, David en Carla. 
Ik wil Prof.dr. Lamers en Dr. Lenders graag bedanken voor hun 
bereidheid in de kleine commissie plaats te nemen en het concept-proefschrift 
aan hun kritische blik te onderwerpen, evenals de overige )eden van de 
promotiecommissie. 
Terug bij mijn eigen afdeling, voorheen de Interne I, wil ik graag het 
hoofd van het lab, Dr. F. Boomsma bedanken voor zijn vertrouwen, 
spitsvondigheid, en frisse kijk op de (mijn) materie. Frans, niet iedereen heeft 
klaarblijkelijk even vee! baat bij jouw zachte hand van regeren of weet met deze 
lu..xe om te gaan, maar ik heb mij persoonlijk altijd bijzonder goed gevoeld bij 
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de relaxte atmosfeer die jij op het lab wist te scheppen (of was dat de 
uitstekende whish:y?). 
En dan de man die alles met LC/CE kan en met wie ik vier jaar aan 
een bureau~e met drie beeldschermen, een telefoon, twee muismatten en drie 
muizen in "de Mir'' gezeten heb, onze LC-analist Gooitzen Alberts. Gooitzen 
zat naast mij ingesnoerd in het wagen~e op de achtbaan van mijn humeur: 
donderend, zingend, briesend, juichend, doosjes schoppend/ stompend, 
keiharde muziek, absolute st:ilte; Gooitzen is een echte Drent en gaf geen 
(S)kik. Gooitzen, zonder jou was de microdialyse op onze afdeling uiet van de 
grond gekomen, had ik mij wat dat betreft uiet kunnen bewijzen en was dit 
proefschrift er dus uiet geweest; dat zegt genoeg, denk ik. Maar uiet alles, u is 
nog uiet van mij af, ik hoop dan ook dat we elkaar zowel in de Mir als 
daarbuiten (we! zo fris) nog tegenkomen. 
Zoals op de experimentele cardiologie waren er op mijn eigen afdeling 
velen die hun bijdrage al dan niet bewust geleverd hebben. Het voormalig 
hoofd van de afdeling, Prof.dr. M.A.D.H. Schalekamp: Maarten, mijn dank 
voor het gedogen van mijn aanwezigheid en je waardevolle bijdrage aan mijn 
angiotensine- komt het er nu wei of uiet- probleem. Mijn gewezen promotor 
en initiator van de microdialyse op onze afdeling, Prof.dr. A.J. Man in 't Veld: 
Arie, mijn hartelijke dank voor mijn aanstelling; je enthousiasme en creatieve 
geest worden mijns inziens node gemist. Dr. J. (het geweten) Deinum: J aap, 
mijn hartelijke dank voor al onze vurige discussies, weet je zeker dat je geen 
familie van mijn vader bent? Richard: goede keuze, maar ons onderzoek naar 
de (explosieve) mogelijkbeden van droogijs is nog lang uiet afgerond! Marine!: 
september 2004: ik terug in Dijkzigt, jij Doctor met een uieuwe keuken? Sjors: 
jammer dat je er niet bent, maar aangezien je het pad volgt van Jose Marti en 
Che Guevara: Hasta la Victoria, Siempre! Nicole: mijn ongevraagd (zoals wel 
vaker) advies: maak het afl Een promotie is straks voor een opleiding wellicht 
niet meer noodzakelijk maar zal later zeker het onderscheid maken. Rene, 
Jeanette, U sha, Angeli que (Uhh, ik durf het bijna uiet te vragen maar er staan 
nog wat monsters in de vriezer .. ), M~olein, Evelien, Edith, Martin en Jasper. 
Bijna op het eind van mijn danbroord wil ik natuurlijk ook mijn 
paranimfen, Drs. E. de Buijzer en Mr. P.A.M. Broers, bedanken. Heren, het zal 
uiet altijd even makkelijk geweest zijn orde te scheppen in mijn chaos; mijn 
hartelijke dank voor jullie grate inzet en geduld. We hebben in ieder geval goed 
gegeten, rijkelijk gedronken en bovenal veel gelachen. 
Sommigen zal het zeer verbazen, anderen wat minder, maar tenslotte 
wil ik graag het woord richten tot een dame die de laatste periode meer en 
meer voor mij is gaan betekenen en wie ik tot mijn grate geluk op 19 december 
aan mijn zijde weet; Bianca, ik ga je hier nu uiet bedanken, want ik hoop dat 
mijn hele !even nog te h:unnen doen, b:us. 

Curriculum Vitae 
Thomas werd op 5 augustus 1970 in Leiden geboren als Thomas Wiebe 
Lameris. In 1988 behaalde hij het Gymnasium B diploma op het St. 
Stanislascollege in Delft, waarna hij geneeskunde ging studeren aan de Erasmus 
Universiteit Rotterdam. In juni 1993 legde hij tijdens zijn doctoraalstudie de 
basis voor zijn interesse voor de wetenschap op de afdeling obstetrie en 
gynaecologie van het St. Catharina ziekenhuis in Eindhoven bij Dr. P.A. de 
J ong. Kort daarna deed hij zijn keuzeonderzoek ''W aarde van de aldosteron-
renine-ratio bij diagnostiek primair hyperaldosteronisme" op de afdeling 
inwendige geneesh."U1lde I van het academisch ziekenhuis Dijkzigt onder 
begeleiding van Dr. F.H.M. Derh en Prof. dr. M.A.D.H. Schalekamp. 
V ervolgens werkte hij op diezelfde afdeling gedurende 14 maanden mee aan 
het promotieonderzoek van Dr. M.A. van den Dorpel naar de rol van de 
endotheel-afhankelijke vasodilatatie in de etiologie van hypertensie bij 
cyclosporinegebruik door niettransplantatiepatienten onder begeleiding van 
Prof. dr. A.J. Man in 't Veld en Dr. A.B. van den Meiracker. Na zijn arts-
examen in februari 1997 keerde hij in september 1997 terug bij de afdeling 
inwendige geneeskunde I als arts-onderzoeker. Bet grootste dee! van het 
onderzoek dat hij daar de afgelopen vier jaar gedaan heeft, leidde uiteindelijk 
tot dit proefschrift. Daarnaast is hij betrokken bij het onderzoek van Lt-Kol. 
R.A. van Hulst van de Koninklijke Marine en de afdeling experimentele 
anaesthesiologie naar de pathofysiologie van luchtembolieen in de hersenen, en 
werkt hij sam en met Drs. J de J ong - van der Linden aan een studie naar de 
prognostische waarde van de flow-reserve van de onderarm voor het welslagen 
van de Brescia-Cimino shunt onder begeleiding van Dr. M.A. van den Dorpel 
van de afdeling neftologie van het Medisch Centrum Rijnmond-Zuid, locatie 
Clara en Dr. A.B. van den Meiracker. Op 1 oktober is hij begonnen aan de 
vooropleiding inwendige geneeskunde in het Medisch Centrum Rijnmond-
Zuid, locatie Clara in Rotterdam (opleider: Dr. A.F. Grootendorst) in het kader 
van de opleiding Cardiologie aan het Thora.xcentrum van de Erasmus 
Universiteit Rotterdam (opleider: Prof. dr. M.L. Simoons). 
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